Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 1557 articles:
HTML format



Single Articles


    July 2021
  1. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    PubMed     Abstract available


  2. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    PubMed     Abstract available


  3. GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
    Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
    PubMed     Abstract available


  4. ZONG L, Sun Z, Mo S, Lu Z, et al
    PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00539.
    PubMed     Abstract available


  5. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    PubMed     Abstract available


  6. BACKES FJ, Wei L, Chen M, Hill K, et al
    Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
    PubMed     Abstract available


  7. TRAVAGLINO A, Raffone A, Santoro A, Raimondo D, et al
    Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00537.
    PubMed     Abstract available


  8. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    PubMed     Abstract available


  9. POLI JG, Paiva G, Freitas F, Mora P, et al
    Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00551.
    PubMed     Abstract available


  10. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    PubMed     Abstract available


  11. KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
    The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
    PubMed     Abstract available


  12. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    PubMed     Abstract available


  13. HAESEN J, Salihi R, Van Gorp T, Van Nieuwenhuysen E, et al
    Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00522.
    PubMed     Abstract available


  14. VICTOOR J, Borght SV, Spans L, Lehnert S, et al
    Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00527.
    PubMed     Abstract available


  15. SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
    Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
    PubMed     Abstract available


  16. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    PubMed     Abstract available


  17. GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
    Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
    PubMed     Abstract available


  18. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    PubMed     Abstract available


  19. HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
    Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
    PubMed     Abstract available


  20. STRAUBHAR AM, Dalton L, Rolston A, McCool K, et al
    Optimization of postoperative opioid prescriptions in gynecologic oncology: Striking a balance between opioid reduction and pain control.
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00519.
    PubMed     Abstract available


  21. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
    Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial).
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00512.
    PubMed     Abstract available


    June 2021
  22. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00511.
    PubMed     Abstract available


  23. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    PubMed     Abstract available


  24. FEIGENBERG T, Cormier B, Gotlieb WH, Jegatheeswaran K, et al
    Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology (GOC) community of practice (CoP).
    Gynecol Oncol. 2021 Jun 25. pii: S0090-8258(21)00493.
    PubMed     Abstract available


  25. JIA N, Che X, Jiang Y, Zhu M, et al
    Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 25. pii: S0090-8258(21)00495.
    PubMed     Abstract available


  26. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    PubMed     Abstract available


  27. GRAY HJ, Secord AA
    Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care.
    Gynecol Oncol. 2021 Jun 21. pii: S0090-8258(21)00332.
    PubMed    


  28. WRIGHT JD, Huang Y, Melamed A, Albright BB, et al
    Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
    Gynecol Oncol. 2021 Jun 19. pii: S0090-8258(21)00496.
    PubMed     Abstract available


  29. BARRINGTON DA, Haight PJ, Calhoun C, Tubbs C, et al
    Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00494.
    PubMed     Abstract available


  30. ZHANG G, Zhang Y, He F, Wu H, et al
    Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors.
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00492.
    PubMed     Abstract available


  31. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
    Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
    PubMed     Abstract available


  32. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    PubMed     Abstract available


  33. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    PubMed     Abstract available


  34. YUAN R, Zhang C, Li Q, Ji M, et al
    The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis.
    Gynecol Oncol. 2021 Jun 14. pii: S0090-8258(21)00488.
    PubMed     Abstract available


  35. ZAMORANO AS, Wilson EM, Liu J, Leon A, et al
    Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial.
    Gynecol Oncol. 2021 Jun 14. pii: S0090-8258(21)00487.
    PubMed     Abstract available


  36. IMBODEN S, Nastic D, Ghaderi M, Rydberg F, et al
    Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
    Gynecol Oncol. 2021 Jun 11. pii: S0090-8258(21)00432.
    PubMed     Abstract available


  37. BENITO V, Lubrano A, Perez-Regadera JF, Torne A, et al
    Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00485.
    PubMed     Abstract available


  38. FAN Y, Zhang YF, Wang MY, Mu Y, et al
    Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
    PubMed     Abstract available


  39. MATANES E, Eisenberg N, Lau S, Salvador S, et al
    Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00446.
    PubMed     Abstract available


  40. RONSINI C, Anchora LP, Restaino S, Fedele C, et al
    The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00482.
    PubMed     Abstract available


  41. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
    PubMed     Abstract available


  42. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    PubMed     Abstract available


  43. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    PubMed     Abstract available


  44. ACKROYD SA, Huang ES, Kurnit KC, Lee NK, et al
    Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Gynecol Oncol. 2021 Jun 5. pii: S0090-8258(21)00444.
    PubMed     Abstract available


  45. DOSSUS L, Kouloura E, Biessy C, Viallon V, et al
    Prospective analysis of circulating metabolites and endometrial cancer risk.
    Gynecol Oncol. 2021 Jun 5. pii: S0090-8258(21)00447.
    PubMed     Abstract available


  46. JOU J, Brodsky A, Charo L, Binder P, et al
    Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials.
    Gynecol Oncol. 2021 Jun 4. pii: S0090-8258(21)00443.
    PubMed     Abstract available


  47. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    PubMed     Abstract available


  48. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    PubMed     Abstract available


  49. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    PubMed     Abstract available


  50. MILLS JM, Morgan JR, Dhaliwal A, Perkins RB, et al
    Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00441.
    PubMed     Abstract available


  51. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    PubMed     Abstract available


  52. MOUKARZEL LA, Braxton KF, Zhou QC, Pedra Nobre S, et al
    Non-exenterative surgical management of recurrent endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00426.
    PubMed     Abstract available


  53. RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
    Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00435.
    PubMed     Abstract available


  54. SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
    Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
    PubMed     Abstract available


  55. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    PubMed     Abstract available


    May 2021
  56. SERT BM, Kristensen GB, Kleppe A, Dorum A, et al
    Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.
    Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00434.
    PubMed     Abstract available


  57. CHAMBERS LM, Chalif J, Yao M, Chichura A, et al
    Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00409.
    PubMed     Abstract available


  58. BRODEUR MN, Dejean R, Beauchemin MC, Samouelian V, et al
    Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00429.
    PubMed     Abstract available


  59. SONG F, Belinson JL, Yan P, Huang X, et al
    Evaluation of p16(INK4a) immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00410.
    PubMed     Abstract available


  60. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    PubMed     Abstract available


  61. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    PubMed     Abstract available


  62. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    PubMed     Abstract available


  63. JANDA M, Robledo KP, Gebski V, Armes JE, et al
    Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151].
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00422.
    PubMed    


  64. MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
    Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
    PubMed     Abstract available


  65. TOBONI MD, Crane EK, Brown J, Shushkevich A, et al
    State of the science: Uterine carcinosarcomas: From pathology to practice.
    Gynecol Oncol. 2021 May 21. pii: S0090-8258(21)00362.
    PubMed     Abstract available


  66. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    PubMed     Abstract available


  67. WINER I, Kim C, Gehrig P
    Neuroendocrine tumors of the gynecologic tract update.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00359.
    PubMed    


  68. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    PubMed     Abstract available


  69. ISHIKAWA M, Shibata T, Iwata T, Nishio S, et al
    A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Prim
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00403.
    PubMed     Abstract available


  70. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    PubMed     Abstract available


  71. TRAN DT, Vo VK, Le MT, Chuang L, et al
    Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
    PubMed     Abstract available


  72. MATSUO K, Mandelbaum RS, Klar M, Ciesielski KM, et al
    Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00364.
    PubMed     Abstract available


  73. CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
    Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
    PubMed     Abstract available


  74. ZAMMARRELLI WA 3RD, Afonso AM, Broach V, Sonoda Y, et al
    Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00405.
    PubMed     Abstract available


  75. MCALARNEN LA, Tsaih SW, Aliani R, Simske NM, et al
    Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum.
    Gynecol Oncol. 2021 May 11. pii: S0090-8258(21)00357.
    PubMed     Abstract available


  76. GONZALEZ R, Kurtovic K, Habib AS, Ryan ES, et al
    A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service.
    Gynecol Oncol. 2021 May 11. pii: S0090-8258(21)00355.
    PubMed     Abstract available


  77. FUCINARI J, Elshaikh MA, Ruterbusch JJ, Khalil R, et al
    The impact of race, comorbid conditions and obesity on survival endpoints in women with high grade endometrial carcinoma.
    Gynecol Oncol. 2021 May 10. pii: S0090-8258(21)00356.
    PubMed     Abstract available


  78. HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
    What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
    PubMed     Abstract available


  79. JEONG SY, Cho YJ, Ryu JY, Choi JJ, et al
    Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00348.
    PubMed     Abstract available


  80. CAO L, Wei M, Liu Y, Fu J, et al
    Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
    PubMed     Abstract available


  81. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    PubMed     Abstract available


  82. BAGARIA M, Wentzensen N, Clarke M, Hopkins MR, et al
    Quantifying procedural pain associated with office gynecologic tract sampling methods.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00353.
    PubMed     Abstract available


  83. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    PubMed     Abstract available


  84. HOW JA, Patel S, Fellman B, Lu KH, et al
    Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00354.
    PubMed     Abstract available


  85. SIMS TT, Boruta DM
    Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
    Gynecol Oncol. 2021;161:331-332.
    PubMed    


  86. AIOB A, Naskovica K, Sharon A, Bornstein J, et al
    A possible association between hydatidiform mole and the COVID-19 pandemic: A retrospective cohort study.
    Gynecol Oncol. 2021;161:454-457.
    PubMed     Abstract available


    April 2021
  87. SUN Z, Wang S, Yang R, Li X, et al
    Gestational diabetes mellitus and risks of gynecologic cancers: Results from a nationwide Swedish twin study.
    Gynecol Oncol. 2021 Apr 29. pii: S0090-8258(21)00266.
    PubMed     Abstract available


  88. BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
    Uterine serous carcinoma.
    Gynecol Oncol. 2021 Apr 29. pii: S0090-8258(21)00349.
    PubMed     Abstract available


  89. PIEDIMONTE S, Li S, Laframboise S, Ferguson SE, et al
    Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center.
    Gynecol Oncol. 2021 Apr 28. pii: S0090-8258(21)00350.
    PubMed     Abstract available


  90. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    PubMed     Abstract available


  91. DILLEY S, Huh W, Blechter B, Rositch AF, et al
    It's time to re-evaluate cervical Cancer screening after age 65.
    Gynecol Oncol. 2021 Apr 26. pii: S0090-8258(21)00347.
    PubMed     Abstract available


  92. MARAMAI M, Achilarre MT, Aloisi A, Betella I, et al
    Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2021 Apr 24. pii: S0090-8258(21)00346.
    PubMed     Abstract available


  93. KASUGA Y, Ikenoue S, Tanaka M, Ochiai D, et al
    Management of pregnancy after radical trachelectomy.
    Gynecol Oncol. 2021 Apr 23. pii: S0090-8258(21)00343.
    PubMed     Abstract available


  94. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    PubMed     Abstract available


  95. RUBINSTEIN MM, Dickinson S, Narayan P, Zhou Q, et al
    Bevacizumab in advanced endometrial cancer.
    Gynecol Oncol. 2021 Apr 21. pii: S0090-8258(21)00326.
    PubMed     Abstract available


  96. LUCCHINI SM, Esteban A, Nigra MA, Palacios AT, et al
    Updates on conservative management of endometrial cancer in patients younger than 45 years.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00327.
    PubMed     Abstract available


  97. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    PubMed     Abstract available


  98. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    PubMed     Abstract available


  99. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    PubMed     Abstract available


  100. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    PubMed     Abstract available


  101. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    PubMed     Abstract available


  102. SHIM SH, Chae SH, So KA, Lee SJ, et al
    Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
    PubMed     Abstract available


  103. GONZALEZ-BOSQUET J, Bakkum-Gamez JN, Weaver AL, McGree ME, et al
    PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00318.
    PubMed     Abstract available


  104. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    PubMed     Abstract available


  105. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Erratum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00319.
    PubMed    


  106. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    PubMed     Abstract available


  107. HUTTEN RJ, Huang YJ, Gaffney DK
    Stereotactic body radiotherapy for the treatment of gynecologic malignancies: Passing fancy or here to stay?
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00320.
    PubMed    


  108. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    PubMed     Abstract available


  109. VREDE SW, van Weelden WJ, Visser NCM, Bulten J, et al
    Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00269.
    PubMed     Abstract available


  110. FANG C, Zhang P, Yu A, Yang Y, et al
    Different prognosis of stage IIIB cervical cancer patients with lower third of vaginal invasion and those without.
    Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00275.
    PubMed     Abstract available


  111. VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
    The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
    PubMed     Abstract available


  112. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: Results from an Australian record-linkage study.
    Gynecol Oncol. 2021 Apr 9. pii: S0090-8258(21)00271.
    PubMed     Abstract available


  113. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    PubMed     Abstract available


  114. JANDA M, Robledo KP, Gebski V, Armes JE, et al
    Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
    Gynecol Oncol. 2021;161:143-151.
    PubMed     Abstract available


  115. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    PubMed     Abstract available


    March 2021
  116. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    PubMed     Abstract available


  117. RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
    Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
    PubMed     Abstract available


  118. GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
    Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
    PubMed     Abstract available


  119. SIA TY, Huang Y, Gockley A, Melamed A, et al
    Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma.
    Gynecol Oncol. 2021 Mar 30. pii: S0090-8258(21)00265.
    PubMed     Abstract available


  120. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    PubMed     Abstract available


  121. HAN Y, Park IS, Kim SI, Wang W, et al
    Increasing serum gamma-glutamyltransferase level accompanies a rapid increase in the incidence of endometrial cancer in Korea: A nationwide cohort study.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00262.
    PubMed     Abstract available


  122. RAHIMIAN N, Razavi ZS, Aslanbeigi F, Mirkhabbaz AM, et al
    Non-coding RNAs related to angiogenesis in gynecological cancer.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00258.
    PubMed     Abstract available


  123. FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
    Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
    PubMed     Abstract available


  124. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    PubMed     Abstract available


  125. ZHANG X, Devins K, Ko EM, Reyes MC, et al
    Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
    PubMed     Abstract available


  126. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    PubMed     Abstract available


  127. WATSON CH, Puechl AM, Lim S, Monuszko K, et al
    Chemotherapy discontinuation processes in a gynecologic oncology population.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00196.
    PubMed     Abstract available


  128. NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
    Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
    PubMed     Abstract available


  129. MATSUO K, Huang Y, Matsuzaki S, Ragab OM, et al
    Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00171.
    PubMed     Abstract available


  130. CHANG CL, Ho SC, Su YF, Juan YC, et al
    DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
    Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00148.
    PubMed     Abstract available


  131. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Corrigendum to 'Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary' [Gynecologic Oncology 157 (2020) 85-88].
    Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00201.
    PubMed    


  132. KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
    Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
    PubMed     Abstract available


  133. ALHOLM Z, Monk BJ, Ting J, Pulgar S, et al
    Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
    Gynecol Oncol. 2021 Mar 16. pii: S0090-8258(21)00194.
    PubMed     Abstract available


  134. SOLSKY I, Chen J, Rebbeck TR
    Corrigendum to "Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations" [Gynecologic Oncology 156 (2020) 363-376].
    Gynecol Oncol. 2021 Mar 14. pii: S0090-8258(21)00200.
    PubMed    


  135. MATSUO K, Klar M, Harter P, Miller H, et al
    Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States.
    Gynecol Oncol. 2021 Mar 13. pii: S0090-8258(21)00232.
    PubMed     Abstract available


  136. MONK BJ, Coleman RL, Herzog TJ, Moore KN, et al
    The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00230.
    PubMed     Abstract available


  137. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    PubMed    


  138. ABEL MK, Liao CI, Chan C, Lee D, et al
    Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00197.
    PubMed     Abstract available


  139. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    PubMed     Abstract available


  140. RAFFONE A, Travaglino A, Raimondo D, Boccellino MP, et al
    Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00175.
    PubMed     Abstract available


  141. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    PubMed     Abstract available


  142. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    PubMed     Abstract available


  143. COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
    Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
    PubMed     Abstract available


  144. SANTORO A, Angelico G, Travaglino A, Raffone A, et al
    Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00174.
    PubMed     Abstract available


  145. POST CCB, Mens JWM, Haverkort MAD, Koppe F, et al
    Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00198.
    PubMed     Abstract available


  146. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    PubMed     Abstract available


  147. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    PubMed     Abstract available


  148. TEOH D, Hill EK, Goldsberry W, Levine L, et al
    Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.
    Gynecol Oncol. 2021 Mar 8. pii: S0090-8258(21)00083.
    PubMed    


  149. SCHNARR KL, Seow H, Elit LM, Pond GR, et al
    The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?
    Gynecol Oncol. 2021 Mar 6. pii: S0090-8258(21)00166.
    PubMed     Abstract available


  150. ULLRICH A, Gultekin M, Teguete I, Trimble EL, et al
    Gynecologic oncology on the global health agenda: A wake-up call.
    Gynecol Oncol. 2021 Mar 5. pii: S0090-8258(21)00178.
    PubMed    


  151. BACKES FJ, Felix AS, Plante M, Gregoire J, et al
    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
    PubMed     Abstract available


  152. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    PubMed     Abstract available


  153. FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
    Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
    PubMed     Abstract available


  154. FELIX AS, Sherman ME
    Implications of the obesity epidemic for endometrial cancer risk, mortality, and survivorship.
    Gynecol Oncol. 2021;160:643-645.
    PubMed    


  155. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    PubMed     Abstract available


    February 2021
  156. BERNARD L, Kwon JS, Simpson AN, Ferguson SE, et al
    The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study.
    Gynecol Oncol. 2021 Feb 26. pii: S0090-8258(21)00165.
    PubMed     Abstract available


  157. MULLEN MM, McKinnish TR, Fiala MA, Zamorano AS, et al
    A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Feb 26. pii: S0090-8258(21)00172.
    PubMed     Abstract available


  158. SIA TY, Wen T, Cham S, Friedman AM, et al
    The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial Cancer surgery.
    Gynecol Oncol. 2021 Feb 24. pii: S0090-8258(21)00167.
    PubMed     Abstract available


  159. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    PubMed     Abstract available


  160. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    PubMed     Abstract available


  161. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    PubMed     Abstract available


  162. DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
    Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
    PubMed     Abstract available


  163. SKORSTENGAARD M, Frederiksen ME, Baillet MV, Beau AB, et al
    Cervical cancer survivors and health care use: A Danish population-based register study.
    Gynecol Oncol. 2021 Feb 19. pii: S0090-8258(21)00139.
    PubMed     Abstract available


  164. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    PubMed     Abstract available


  165. FABER MT, Sperling CD, Bennetsen AKK, Aalborg GL, et al
    A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00147.
    PubMed     Abstract available


  166. FRIEDLANDER M, Benson C, O'Connell RL, Reed N, et al
    Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00153.
    PubMed     Abstract available


  167. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    PubMed     Abstract available


  168. LUO LY, Aviki EM, Lee A, Kollmeier MA, et al
    Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 14. pii: S0090-8258(21)00101.
    PubMed     Abstract available


  169. HICKEY M, Moss KM, Brand A, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
    PubMed     Abstract available


  170. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    PubMed     Abstract available


  171. BURG LC, Vermeulen RJ, Bekkers RLM, Wijn SRW, et al
    A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancer.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00095.
    PubMed     Abstract available


  172. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    PubMed     Abstract available


  173. HASHEMIPOUR M, Boroumand H, Mollazadeh S, Tajiknia V, et al
    Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00140.
    PubMed     Abstract available


  174. INSIN P, Vitoopinyoparb K, Thadanipon K, Charakorn C, et al
    Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: A systematic review and network meta-analysis.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00087.
    PubMed     Abstract available


  175. VARELA CAGETTI L, Gonzague-Casabianca L, Zemmour C, Lambaudie E, et al
    The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00094.
    PubMed     Abstract available


  176. SIEDEL JH, Ring KL, Hu W, Dood RL, et al
    Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(20)34181.
    PubMed     Abstract available


  177. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
    Gynecol Oncol. 2021 Feb 5. pii: S0090-8258(21)00092.
    PubMed    


  178. LATIF N, Oh J, Brensinger C, Morgan M, et al
    Lymphadenectomy is associated with an increased risk of postoperative venous thromboembolism in early stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00090.
    PubMed     Abstract available


  179. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    PubMed     Abstract available


  180. GU B, Shang X, Yan M, Li X, et al
    Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00096.
    PubMed     Abstract available


  181. RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
    Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
    PubMed     Abstract available


  182. ESSELEN KM, Stack-Dunnbier H, Gompers A, Hacker MR, et al
    Crowdsourcing to measure financial toxicity in gynecologic oncology.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00100.
    PubMed     Abstract available


  183. COLEMAN RL, Hu W, Soliman P, Nick A, et al
    Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00082.
    PubMed     Abstract available


  184. TAKENAKA M, Kamii M, Iida Y, Yanaihara N, et al
    Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00054.
    PubMed     Abstract available


  185. KUROKI LM, Morris DH, Greenwade M, Landon M, et al
    Impact of employment and insurance status on distress in gynecologic oncology patients.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00098.
    PubMed     Abstract available


  186. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    PubMed     Abstract available


  187. LESLIE KK, Filiaci VL, Mallen AR, Thiel KW, et al
    Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
    Gynecol Oncol. 2021 Feb 1. pii: S0090-8258(21)00085.
    PubMed     Abstract available


  188. BROOKS SE, Davis EC, Farley JH
    Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair.
    Gynecol Oncol. 2021;160:361-363.
    PubMed    


    January 2021
  189. WANG XS, Kamal M, Chen TH, Shi Q, et al
    Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00081.
    PubMed     Abstract available


  190. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    PubMed     Abstract available


  191. MCGINNIS JM, Jones R, Hillis C, Kokus H, et al
    A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre.
    Gynecol Oncol. 2021 Jan 29. pii: S0090-8258(21)00061.
    PubMed     Abstract available


  192. HAMILTON CA, Pothuri B, Arend RC, Backes FJ, et al
    Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(20)34224.
    PubMed     Abstract available


  193. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    PubMed     Abstract available


  194. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    PubMed     Abstract available


  195. EOH KJ, Han M, Kim EH, Jung I, et al
    Markedly increased risk of malignancies in women with endometriosis.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00079.
    PubMed     Abstract available


  196. CHAMBERS LM, Michener CM, Rose PG, Reizes O, et al
    Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
    Gynecol Oncol. 2021 Jan 24. pii: S0090-8258(21)00075.
    PubMed     Abstract available


  197. BOGANI G, Papadia A, Buda A, Casarin J, et al
    Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study.
    Gynecol Oncol. 2021 Jan 20. pii: S0090-8258(21)00055.
    PubMed     Abstract available


  198. CHASE DM, Salani R, Farley J, Torres T, et al
    Unwittingly biased: A note to gynecologic cancer providers.
    Gynecol Oncol. 2021 Jan 20. pii: S0090-8258(21)00056.
    PubMed    


  199. KIM SR, Tone A, Kim RH, Cesari M, et al
    Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
    PubMed     Abstract available


  200. CHICHURA A, Chambers LM, Costales AB, Yao M, et al
    Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.
    Gynecol Oncol. 2021 Jan 16. pii: S0090-8258(21)00053.
    PubMed     Abstract available


  201. NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
    Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
    PubMed     Abstract available


  202. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    PubMed     Abstract available


  203. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    PubMed     Abstract available


  204. KALJOUW S, Jansen EEL, Aitken CA, Harrijvan LM, et al
    Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
    Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34253.
    PubMed     Abstract available


  205. HAMILTON CA, Pothuri B, Arend RC, Backes FJ, et al
    Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
    Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34227.
    PubMed     Abstract available


  206. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    PubMed     Abstract available


  207. KO EM, Aviles D, Koelper NC, Morgan MA, et al
    Impact of past surgical history on perioperative outcomes in gynecologic surgery.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34241.
    PubMed     Abstract available


  208. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    PubMed     Abstract available


  209. KANAO H, Aoki Y, Omi M, Nomura H, et al
    Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: Technical feasibility and short-term oncologic outcome.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34249.
    PubMed     Abstract available


  210. LEES B, Hampton JM, Trentham-Dietz A, Newcomb P, et al
    A population-based study of causes of death after endometrial cancer according to major risk factors.
    Gynecol Oncol. 2021 Jan 6. pii: S0090-8258(20)34223.
    PubMed     Abstract available


  211. MATSUZAKI S, Matsuzaki S, Chang EJ, Yasukawa M, et al
    Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34247.
    PubMed     Abstract available


  212. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    PubMed    


  213. ZAPARDIEL I, Kocian R, Kohler C, Klat J, et al
    Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34221.
    PubMed     Abstract available


  214. TJALSMA AS, Wagner A, Dinjens WNM, Ewing-Graham PC, et al
    Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34242.
    PubMed     Abstract available


  215. DI DONATO V, Caruso G, Bogani G, Giannini A, et al
    Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: A systematic review.
    Gynecol Oncol. 2021 Jan 4. pii: S0090-8258(20)34245.
    PubMed     Abstract available


  216. MATSUO K, Matsuzaki S, Mandelbaum RS, Kanao H, et al
    Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States.
    Gynecol Oncol. 2021 Jan 2. pii: S0090-8258(20)34251.
    PubMed     Abstract available


  217. BATMAN S, Bohn J, Weisenberger MW, Hersh A, et al
    Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
    Gynecol Oncol. 2021;160:214-218.
    PubMed     Abstract available


  218. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    PubMed     Abstract available


  219. SPINOSA D, Acosta T, Wong J, Kurtovic K, et al
    Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative.
    Gynecol Oncol. 2021;160:169-174.
    PubMed     Abstract available


  220. HAMPEL H, Pearlman R, de la Chapelle A, Pritchard CC, et al
    Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Gynecol Oncol. 2021;160:161-168.
    PubMed     Abstract available


  221. SHALOWITZ DI
    Physician outreach and access to gynecologic cancer care.
    Gynecol Oncol. 2021;160:1-2.
    PubMed    


  222. GOODMAN CD, Mendez LC, Velker V, Weiss Y, et al
    3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience.
    Gynecol Oncol. 2021;160:134-139.
    PubMed     Abstract available


  223. ALIMENA S, Sullivan MW, Philp L, Dorney K, et al
    Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship.
    Gynecol Oncol. 2021;160:252-259.
    PubMed     Abstract available


  224. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    PubMed     Abstract available


  225. VAN DER VELDEN J, Pleunis N, Barlow E, Zijlmans H, et al
    Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis.
    Gynecol Oncol. 2021;160:128-133.
    PubMed     Abstract available


  226. INAYAMA Y, Yamanishi Y, Nakatani E, Aratake J, et al
    Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis.
    Gynecol Oncol. 2021;160:140-147.
    PubMed     Abstract available


  227. BOGANI G, Raspagliesi F, di Donato V, Brusadelli C, et al
    Spotlight on the role of human papillomavirus vaccines.
    Gynecol Oncol. 2021;160:346-350.
    PubMed     Abstract available


    December 2020
  228. DAHLMAN D, Li X, Magnusson H, Sundquist J, et al
    Cervical cancer among Swedish women with drug use disorders: A nationwide epidemiological study.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34214.
    PubMed     Abstract available


  229. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    PubMed     Abstract available


  230. MOYNAGH MR, Dowdy SC, Welch B, Glaser GE, et al
    Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program.
    Gynecol Oncol. 2020 Dec 30. pii: S0090-8258(20)34252.
    PubMed     Abstract available


  231. BISCH SP, Jago CA, Kalogera E, Ganshorn H, et al
    Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 30. pii: S0090-8258(20)34250.
    PubMed     Abstract available


  232. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    PubMed     Abstract available


  233. MATSUO K, Nishio S, Matsuzaki S, Iwase H, et al
    Surgical margin status and recurrence pattern in invasive vulvar Paget's disease: A Japanese Gynecologic Oncology Group study.
    Gynecol Oncol. 2020 Dec 28. pii: S0090-8258(20)34226.
    PubMed     Abstract available


  234. MESSELT A, Thomaier L, Jewett PI, Lee H, et al
    Comparisons of emotional health by diagnosis among women with early stage gynecological cancers.
    Gynecol Oncol. 2020 Dec 28. pii: S0090-8258(20)34222.
    PubMed     Abstract available


  235. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    PubMed     Abstract available


  236. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    PubMed     Abstract available


  237. BERGER AA, Dao F, Levine DA
    Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34219.
    PubMed     Abstract available


  238. AYHAN A, Toptas T, Oz M, Vardar MA, et al
    Low-grade endometrial stromal sarcoma: A Turkish uterine sarcoma group study analyzing prognostic factors and disease outcomes.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34220.
    PubMed     Abstract available


  239. CASTELLANO T, John Maxwell IV, Adam Walter J, Thompson S, et al
    Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34217.
    PubMed     Abstract available


  240. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    PubMed     Abstract available


  241. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    PubMed     Abstract available


  242. JOU J, Coulter E, Roberts T, Binder P, et al
    Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34180.
    PubMed     Abstract available


  243. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    PubMed     Abstract available


  244. FACHINI AMD, Zuliani AC, Sarian LO, Teixeira JC, et al
    Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.
    Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34157.
    PubMed     Abstract available


  245. LEUNG E, Pervaiz Z, Lowe-Zinola J, Cree S, et al
    Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre.
    Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34216.
    PubMed     Abstract available


  246. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    PubMed     Abstract available


  247. FORD S, Tarraf W, Williams KP, Roman LA, et al
    Differences in cervical cancer screening and follow-up for black and white women in the United States.
    Gynecol Oncol. 2020 Dec 12. pii: S0090-8258(20)34155.
    PubMed     Abstract available


  248. FORSSE D, Berg HF, Bozickovic O, Engerud H, et al
    Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34173.
    PubMed     Abstract available


  249. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    PubMed     Abstract available


  250. COLLINS A, Miles GJ, Powley IR, Hew R, et al
    Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.
    Gynecol Oncol. 2020 Dec 10. pii: S0090-8258(20)34161.
    PubMed     Abstract available


  251. SOBECKI JN, Rice LW, Hartenbach EM
    Bone health and osteoporosis screening in gynecologic cancer survivors.
    Gynecol Oncol. 2020 Dec 10. pii: S0090-8258(20)34156.
    PubMed     Abstract available


  252. NAHSHON C, Segev Y, Gemer O, Bar Noy T, et al
    Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 9. pii: S0090-8258(20)34162.
    PubMed     Abstract available


  253. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    PubMed     Abstract available


  254. CAIN KE, Iniesta MD, Fellman BM, Suki TS, et al
    Effect of preoperative intravenous vs oral acetaminophen on postoperative opioid consumption in an enhanced recovery after surgery (ERAS) program in patients undergoing open gynecologic oncology surgery.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34152.
    PubMed     Abstract available


  255. PAREEK V, Barthwal M, Giridhar P, Patil PA, et al
    A phase III randomised trial of trans-abdominal ultrasound in improving application quality and dosimetry of intra-cavitary brachytherapy in locally advanced cervical cancer.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34160.
    PubMed     Abstract available


  256. APPIAH D, Farias RM, Olokede OA, Nwabuo CC, et al
    The influence of individual and neighborhood-level characteristics on rural-urban disparities in cardiovascular disease mortality among U.S. women diagnosed with breast and gynecologic cancers.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34151.
    PubMed     Abstract available


  257. NGO NT, Aniagolu N, Lang J, Mcdougale A, et al
    Underrepresented minority representation trends in gynecologic oncology fellowships in the United States.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34130.
    PubMed     Abstract available


  258. TRAVAGLINO A, Raffone A, Gencarelli A, Saracinelli S, et al
    Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34126.
    PubMed     Abstract available


  259. ISLAM JY, Deveaux A, Previs RA, Akinyemiju T, et al
    Racial and ethnic disparities in palliative care utilization among gynecological cancer patients.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34159.
    PubMed     Abstract available


  260. COHEN JG, Chang AJ
    Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications.
    Gynecol Oncol. 2020;159:599-600.
    PubMed    


  261. DEKEN MM, van Doorn HC, Verver D, Boogerd LSF, et al
    Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer - a randomized controlled trial.
    Gynecol Oncol. 2020;159:672-680.
    PubMed     Abstract available


  262. SPINILLO A, Dominoni M, Boschi AC, Cesari S, et al
    The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
    Gynecol Oncol. 2020;159:630-635.
    PubMed     Abstract available


  263. COHEN PA, Leung Y, Anderson L, van der Griend R, et al
    Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and
    Gynecol Oncol. 2020;159:623-629.
    PubMed     Abstract available


  264. HELLMAN K, Holmberg E, Bjurberg M, Borgfeldt C, et al
    Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study.
    Gynecol Oncol. 2020;159:663-671.
    PubMed     Abstract available


  265. RICHMAN AH, Vargo JA, Ling DC, Sukumvanich P, et al
    Dose-escalated intensity modulated radiation therapy in patients with locally-advanced vulvar cancer - does it increase response rate?
    Gynecol Oncol. 2020;159:657-662.
    PubMed     Abstract available


  266. BOGANI G, DI Donato V, Sopracordevole F, Ciavattini A, et al
    Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.
    Gynecol Oncol. 2020;159:636-641.
    PubMed     Abstract available


  267. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    PubMed     Abstract available


  268. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    PubMed     Abstract available


  269. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    PubMed     Abstract available


  270. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    PubMed     Abstract available


    November 2020
  271. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    PubMed     Abstract available


  272. SUGRUE R, Foley O, Elias KM, Growdon WB, et al
    Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34150.
    PubMed     Abstract available


  273. GRESSEL GM, Marcus JZ, Mullen MM, Sinno AK, et al
    Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement.
    Gynecol Oncol. 2020 Nov 28. pii: S0090-8258(20)34131.
    PubMed     Abstract available


  274. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    PubMed     Abstract available


  275. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    PubMed     Abstract available


  276. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    PubMed     Abstract available


  277. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    PubMed     Abstract available


  278. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    PubMed     Abstract available


  279. HICKS-COURANT K, Kanter GP, Giuntoli RL 2nd, Schapira MM, et al
    An increase in multi-site practices: The shifting paradigm for gynecologic cancer care delivery.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34052.
    PubMed     Abstract available


  280. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    PubMed     Abstract available


  281. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    PubMed     Abstract available


  282. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    PubMed     Abstract available


  283. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    PubMed     Abstract available


  284. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    PubMed     Abstract available


  285. RODRIGUEZ AM, Polychronopoulou E, Hsu E, Shah R, et al
    Factors associated with endometrial cancer and hyperplasia among middle-aged and older Hispanics.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34055.
    PubMed     Abstract available


  286. CHAMBERS LM, Jia X, Rose PG, AlHilli M, et al
    Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34123.
    PubMed     Abstract available


  287. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    PubMed     Abstract available


  288. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    PubMed     Abstract available


  289. AYHAN A, Oz M, Topfedaisi Ozkan N, Aslan K, et al
    Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34125.
    PubMed     Abstract available


  290. STALEY SA, Tucker KR, Gehrig PA, Clark LH, et al
    Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34067.
    PubMed     Abstract available


  291. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    PubMed     Abstract available


  292. HOEIJMAKERS YM, Gorris MAJ, Sweep FCGJ, Bulten J, et al
    Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34113.
    PubMed     Abstract available


  293. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    PubMed     Abstract available


  294. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    PubMed     Abstract available


  295. JANSEN EEL, Ivanus U, Jerman T, de Koning HJ, et al
    The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
    Gynecol Oncol. 2020 Nov 13. pii: S0090-8258(20)34058.
    PubMed     Abstract available


  296. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    PubMed     Abstract available


  297. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    PubMed     Abstract available


  298. GUO XM, Cowan M, Folsom S, Ehimiaghe E, et al
    Discrepancies between author- and industry-reported disclosures of financial relationships at an annual gynecologic oncology research meeting.
    Gynecol Oncol. 2020 Nov 10. pii: S0090-8258(20)34061.
    PubMed     Abstract available


  299. NITECKI R, Fu S, Lefkowits C, Smith BD, et al
    Employment disruption following the diagnosis of endometrial cancer.
    Gynecol Oncol. 2020 Nov 9. pii: S0090-8258(20)34063.
    PubMed     Abstract available


  300. MATSUZAKI S, Klar M, Matsuzaki S, Roman LD, et al
    Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
    Gynecol Oncol. 2020 Nov 9. pii: S0090-8258(20)34065.
    PubMed     Abstract available


  301. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    PubMed     Abstract available


  302. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    PubMed     Abstract available


  303. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    PubMed     Abstract available


  304. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    PubMed     Abstract available


  305. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    PubMed     Abstract available


  306. LEE EK, Fader AN, Santin AD, Liu JF, et al
    Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34039.
    PubMed     Abstract available


  307. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    PubMed     Abstract available


  308. RUSSO S, Walker JL, Carlson JW, Carter J, et al
    Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34048.
    PubMed     Abstract available


  309. PEDRA NOBRE S, Hensley ML, So M, Zhou QC, et al
    The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34042.
    PubMed     Abstract available


  310. DE LA MOTTE ROUGE T, Touboul C, Lhomel C, Roupret M, et al
    Factors associated with compliance to cervical cancer screening in France: The EDIFICE 6 survey.
    Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34054.
    PubMed     Abstract available


  311. BREWSTER WR
    Insurance and adherence to guideline concordant cervical cancer therapy do not reduce mortality?
    Gynecol Oncol. 2020;159:297-298.
    PubMed    


  312. YANG J, Delara R, Magrina J, Magtibay P, et al
    Management and outcomes of primary vaginal Cancer.
    Gynecol Oncol. 2020;159:456-463.
    PubMed     Abstract available


  313. BRZEZINSKA BN, Shepherd JP, Rath KS, Clements AE, et al
    A cost-effectiveness analysis of sentinel lymph node detection in vulvar cancer by preoperative lymphoscintigraphy versus intraoperative detection alone.
    Gynecol Oncol. 2020;159:498-502.
    PubMed     Abstract available


    October 2020
  314. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    PubMed     Abstract available


  315. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    PubMed     Abstract available


  316. JOU J, Binder P, Saenz C, Eskander R, et al
    Charting a professional course for academic gynecologic oncology mentors.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34046.
    PubMed     Abstract available


  317. CARTER J, Huang HQ, Armer J, Carlson JW, et al
    GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.
    Gynecol Oncol. 2020 Oct 24. pii: S0090-8258(20)34045.
    PubMed     Abstract available


  318. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    PubMed     Abstract available


  319. STINTON C, Fraser H, Al-Khudairy L, Court R, et al
    Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34011.
    PubMed     Abstract available


  320. HAN X, Liu S, Yang G, Hosseinifard H, et al
    Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
    Gynecol Oncol. 2020 Oct 19. pii: S0090-8258(20)34019.
    PubMed     Abstract available


  321. HUNG P, Zahnd WE, Brandt HM, Adams SA, et al
    Cervical cancer treatment initiation and survival: The role of residential proximity to cancer care.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34014.
    PubMed     Abstract available


  322. LI Q, Cong R, Wang Y, Kong F, et al
    Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34021.
    PubMed     Abstract available


  323. FERRISS JS, Rose S, Rungruang B, Urban R, et al
    Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34017.
    PubMed     Abstract available


  324. SAMOIL D, Abdelmutti N, Gallagher LO, Jivraj N, et al
    Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34015.
    PubMed     Abstract available


  325. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    PubMed     Abstract available


  326. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    PubMed     Abstract available


  327. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    PubMed     Abstract available


  328. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    PubMed     Abstract available


  329. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    PubMed     Abstract available


  330. RESHKO LB, Baliga S, Crandley EF, Harry Lomas IV, et al
    Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33967.
    PubMed     Abstract available


  331. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    PubMed     Abstract available


  332. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    PubMed     Abstract available


  333. KWON BS, Roh HJ, Lee S, Yang J, et al
    Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.
    Gynecol Oncol. 2020 Oct 8. pii: S0090-8258(20)33945.
    PubMed     Abstract available


  334. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    PubMed     Abstract available


  335. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    PubMed     Abstract available


  336. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    PubMed     Abstract available


  337. JAREEMIT N, Horowitz NS, Goldstein DP, Berkowitz RS, et al
    Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
    Gynecol Oncol. 2020 Oct 3. pii: S0090-8258(20)33956.
    PubMed     Abstract available


  338. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    PubMed    


  339. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    Using machine learning to create prognostic systems for endometrial cancer.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33957.
    PubMed     Abstract available


  340. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    PubMed     Abstract available


  341. ROSSI EC
    Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.
    Gynecol Oncol. 2020;159:1-2.
    PubMed    


  342. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    PubMed     Abstract available


  343. HUH WK
    51st Annual Meeting of the Society of Gynecologic Oncology.
    Gynecol Oncol. 2020;159 Suppl 1:1.
    PubMed    


  344. BAO H, Bi H, Zhang X, Zhao Y, et al
    Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study.
    Gynecol Oncol. 2020;159:171-178.
    PubMed     Abstract available


  345. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    PubMed     Abstract available


  346. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    PubMed    


  347. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    PubMed     Abstract available


    September 2020
  348. CYR MP, Dumoulin C, Bessette P, Pina A, et al
    Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33856.
    PubMed     Abstract available


  349. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    PubMed     Abstract available


  350. CHEN LC, Huang Y, Hou JY, Khoury-Collado F, et al
    Toxicity after adjuvant therapy for stage III uterine cancer.
    Gynecol Oncol. 2020 Sep 29. pii: S0090-8258(20)33943.
    PubMed     Abstract available


  351. STENZEL AE, Moysich KB, Ferrando CA, Starbuck KD, et al
    Clinical needs for transgender men in the gynecologic oncology setting.
    Gynecol Oncol. 2020 Sep 29. pii: S0090-8258(20)33948.
    PubMed     Abstract available


  352. NASIOUDIS D, Albright BB, Roy A, Ko EM, et al
    Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer.
    Gynecol Oncol. 2020 Sep 28. pii: S0090-8258(20)33916.
    PubMed    


  353. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    PubMed    


  354. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    PubMed     Abstract available


  355. ROMERO I, Rubio MJ, Medina M, Matias-Guiu X, et al
    An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Gynecol Oncol. 2020 Sep 25. pii: S0090-8258(20)33906.
    PubMed     Abstract available


  356. SMITH M, Lara OD, O'Cearbhaill R, Knisely A, et al
    Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection.
    Gynecol Oncol. 2020 Sep 25. pii: S0090-8258(20)33946.
    PubMed     Abstract available


  357. ALBRIGHT BB, Nasioudis D, Byrne ME, Latif NA, et al
    Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33942.
    PubMed     Abstract available


  358. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    PubMed     Abstract available


  359. FREY MK, Fowlkes RK, Badiner NM, Fishman D, et al
    Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33898.
    PubMed     Abstract available


  360. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    PubMed     Abstract available


  361. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    PubMed     Abstract available


  362. PERRONE AM, Dondi G, Giunchi S, De Crescenzo E, et al
    COVID-19 free oncologic surgical hub: The experience of reallocation of a gynecologic oncology unit during pandemic outbreak.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33940.
    PubMed     Abstract available


  363. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    PubMed     Abstract available


  364. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    PubMed     Abstract available


  365. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33850.
    PubMed     Abstract available


  366. CHINO J, Annunziata CM, Beriwal S, Bradfield L, et al
    The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33908.
    PubMed    


  367. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    PubMed     Abstract available


  368. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    PubMed     Abstract available


  369. KORTEKAAS KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, et al
    Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33917.
    PubMed     Abstract available


  370. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
    PubMed     Abstract available


  371. GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
    The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
    PubMed     Abstract available


  372. RIEDINGER CJ, Kimball KJ, Kilgore LC, Bell CW, et al
    Water only fasting and its effect on chemotherapy administration in gynecologic malignancies.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33901.
    PubMed     Abstract available


  373. MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
    Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
    PubMed     Abstract available


  374. KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
    Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
    PubMed     Abstract available


  375. JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
    mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
    PubMed     Abstract available


  376. BOITANO TKL, Sanders LJ, Gentry ZL, Smith HJ, et al
    Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33907.
    PubMed     Abstract available


  377. YOSHIMOTO Y, Sasaki Y, Murata K, Noda SE, et al
    Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33821.
    PubMed     Abstract available


  378. CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
    Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
    PubMed     Abstract available


  379. PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
    Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
    PubMed     Abstract available


  380. LI C, Li X, You J, Liang B, et al
    Impact of radiation source activity on short- and long-term outcomes of cervical carcinoma patients treated with high-dose-rate brachytherapy: A retrospective cohort study.
    Gynecol Oncol. 2020 Sep 12. pii: S0090-8258(20)33854.
    PubMed     Abstract available


  381. ALHILLI MM, Bae-Jump V
    Diet and gut microbiome interactions in gynecologic cancer.
    Gynecol Oncol. 2020 Sep 12. pii: S0090-8258(20)33828.
    PubMed     Abstract available


  382. HELPMAN L, Pond GR, Elit L, Anderson LN, et al
    Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity.
    Gynecol Oncol. 2020 Sep 11. pii: S0090-8258(20)33830.
    PubMed     Abstract available


  383. ADAM JA, van Diepen PR, Mom CH, Stoker J, et al
    [(18)F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature.
    Gynecol Oncol. 2020 Sep 10. pii: S0090-8258(20)33822.
    PubMed     Abstract available


  384. HURWITZ LM, Pinsky PF, Huang WY, Freedman ND, et al
    Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
    Gynecol Oncol. 2020 Sep 10. pii: S0090-8258(20)33855.
    PubMed     Abstract available


  385. PLETT H, Filippova OT, Garbi A, Kommoss S, et al
    Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Gynecol Oncol. 2020 Sep 9. pii: S0090-8258(20)33829.
    PubMed     Abstract available


  386. YEGYA-RAMAN N, Cao CD, Hathout L, Girda E, et al
    Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review.
    Gynecol Oncol. 2020 Sep 8. pii: S0090-8258(20)33808.
    PubMed     Abstract available


  387. JIANG F, Yang K, Wan XR, Xiang Y, et al
    Reproductive outcomes after floxuridine-based regimens for gestational trophoblastic neoplasia: A retrospective cohort study in a national referral center in China.
    Gynecol Oncol. 2020 Sep 8. pii: S0090-8258(20)33819.
    PubMed     Abstract available


  388. RISCHIN D, Gil-Martin M, Gonzalez-Martin A, Brana I, et al
    PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
    Gynecol Oncol. 2020 Sep 8. pii: S0090-8258(20)33827.
    PubMed     Abstract available


  389. MADARIAGA A, Garg S, Bruce JP, Thiryayi S, et al
    Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 7. pii: S0090-8258(20)33849.
    PubMed     Abstract available


  390. AMIT A, Beck D, Lowenstein L, Lavie O, et al
    Corrigendum to 'The role of hybrid PET/CT in the evaluation of patients with cervical cancer' [Gynecologic Oncology 100 (2005) 65-69].
    Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)32338.
    PubMed    


  391. WALLBILLICH JJ, Morris RT, Ali-Fehmi R
    Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
    PubMed     Abstract available


  392. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    PubMed     Abstract available


  393. YANG J, Mead-Harvey C, Polen-De C, Magtibay P, et al
    Survival outcomes in patients with cervical cancer treated with open versus robotic radical hysterectomy: Our surgical pathology interrogation.
    Gynecol Oncol. 2020 Sep 3. pii: S0090-8258(20)33832.
    PubMed     Abstract available


  394. VETTER MH, Smrz S, Gehrig PA, Peng K, et al
    Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter?
    Gynecol Oncol. 2020 Sep 2. pii: S0090-8258(20)33760.
    PubMed     Abstract available


  395. ZEIMET AG
    Molecular characterization of vulvar squamous cell cancer: High time to gain ground.
    Gynecol Oncol. 2020;158:519-520.
    PubMed    


  396. YANG J, Delara R, Ghaith S, Newman H, et al
    Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2020;158:555-561.
    PubMed     Abstract available


  397. PRIESKE K, Alawi M, Oliveira-Ferrer L, Jaeger A, et al
    Genomic characterization of vulvar squamous cell carcinoma.
    Gynecol Oncol. 2020;158:547-554.
    PubMed     Abstract available


  398. CAO D, Shen K, Chen Y, Xu Y, et al
    Value of endocervical curettage in follow-up for patients with cervical intraepithelial neoplasia stage 2+ after loop electrosurgical excision.
    Gynecol Oncol. 2020;158:584-589.
    PubMed     Abstract available


  399. BERTOLI HK, Baandrup L, Aalborg GL, Kjaer AK, et al
    Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study.
    Gynecol Oncol. 2020;158:734-739.
    PubMed     Abstract available


  400. FRUMOVITZ M, Westin SN, Salvo G, Zarifa A, et al
    Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
    Gynecol Oncol. 2020;158:570-575.
    PubMed     Abstract available


    August 2020
  401. SIA TY, Wen T, Cham S, Friedman AM, et al
    Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
    Gynecol Oncol. 2020 Aug 28. pii: S0090-8258(20)33825.
    PubMed     Abstract available


  402. GONZALEZ R, Havrilesky LJ, Myers ER, Secord AA, et al
    Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33759.
    PubMed     Abstract available


  403. LEE JT, Kuo HY, Huang KG, Lin JR, et al
    Diversity of sexual activity and correlates among women with gynecological cancer.
    Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33761.
    PubMed     Abstract available


  404. DE JAEGHERE EA, Laloo F, Lippens L, Van Bockstal M, et al
    Splenic (18)F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer.
    Gynecol Oncol. 2020 Aug 25. pii: S0090-8258(20)33757.
    PubMed     Abstract available


  405. NISHIO S, Murotani K, Nakao S, Takenaka M, et al
    Investigation of clinicopathological features of vulvar cancer in 1068 patients: A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study.
    Gynecol Oncol. 2020 Aug 24. pii: S0090-8258(20)33820.
    PubMed     Abstract available


  406. GLICKMAN A, Brennecke A, Tayebnejad A, Matsuo K, et al
    Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
    Gynecol Oncol. 2020 Aug 24. pii: S0090-8258(20)33746.
    PubMed     Abstract available


  407. SHEN L, Xie L, Li R, Shan B, et al
    A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
    PubMed     Abstract available


  408. BELL SG, Dalton L, McNeish BL, Fang F, et al
    Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
    PubMed     Abstract available


  409. STASENKO M, Tarney C, Seier K, Casablanca Y, et al
    Sexual harassment and gender discrimination in gynecologic oncology.
    Gynecol Oncol. 2020 Aug 21. pii: S0090-8258(20)33815.
    PubMed     Abstract available


  410. SHUSHKEVICH A, Thaker PH, Littell RD, Shah NA, et al
    State of the science: Uterine sarcomas: From pathology to practice.
    Gynecol Oncol. 2020 Aug 21. pii: S0090-8258(20)33764.
    PubMed    


  411. BETELLA I, Turbitt WJ, Szul T, BinghaoWu, et al
    Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774].
    Gynecol Oncol. 2020 Aug 21. pii: S0090-8258(20)33750.
    PubMed    


  412. OHNO A, Iwata T, Katoh Y, Taniguchi S, et al
    Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy.
    Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)33756.
    PubMed     Abstract available


  413. GURRAM L, Patil R, Chopra S, Maheshwari A, et al
    Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience.
    Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)33809.
    PubMed     Abstract available


  414. RICHARDSON MT, Mysona DP, Klein DA, Mann A, et al
    Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
    Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)32386.
    PubMed     Abstract available


  415. MAULARD A, Chargari C, Faron M, Alwohaibi A, et al
    A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer.
    Gynecol Oncol. 2020 Aug 19. pii: S0090-8258(20)33758.
    PubMed     Abstract available


  416. CHEN Y, Qian H, Wang H, Zhang X, et al
    Corrigendum to 'ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents' [gynecologic oncology 107 (2007) 505-512].
    Gynecol Oncol. 2020 Aug 19. pii: S0090-8258(20)33763.
    PubMed    


  417. AVIKI EM, Lavery JA, Roche KL, Cowan R, et al
    Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
    Gynecol Oncol. 2020 Aug 16. pii: S0090-8258(20)33754.
    PubMed     Abstract available


  418. SINHA S, Lazar A, Lam A, Anderson EM, et al
    Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.
    Gynecol Oncol. 2020 Aug 15. pii: S0090-8258(20)33748.
    PubMed     Abstract available


  419. WU J, Huang Y, Tergas AI, Melamed A, et al
    The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer.
    Gynecol Oncol. 2020 Aug 14. pii: S0090-8258(20)33762.
    PubMed     Abstract available


  420. KO EM, Brensinger CM, Cory L, Giuntoli RL 2nd, et al
    Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
    Gynecol Oncol. 2020 Aug 13. pii: S0090-8258(20)33755.
    PubMed     Abstract available


  421. HE D, Wang H, Dong Y, Zhang Y, et al
    POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    Gynecol Oncol. 2020 Aug 12. pii: S0090-8258(20)33752.
    PubMed     Abstract available


  422. KNOTH J, Potter R, Jurgenliemk-Schulz IM, Haie-Meder C, et al
    Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study.
    Gynecol Oncol. 2020 Aug 11. pii: S0090-8258(20)32382.
    PubMed     Abstract available


  423. BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
    Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
    Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
    PubMed     Abstract available


  424. POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
    Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
    PubMed     Abstract available


  425. POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
    Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
    PubMed     Abstract available


  426. BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
    When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
    Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
    PubMed     Abstract available


  427. PYRZAK A, Saiz A, Polan RM, Barber EL, et al
    Risk factors for potentially avoidable readmissions following gynecologic oncology surgery.
    Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33753.
    PubMed     Abstract available


  428. LEE EK, Xiong N, Cheng SC, Barry WT, et al
    Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
    PubMed     Abstract available


  429. REDONDO A, Colombo N, McCormack M, Dreosti L, et al
    Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
    Gynecol Oncol. 2020 Aug 4. pii: S0090-8258(20)33661.
    PubMed     Abstract available


  430. WEDIN M, Stalberg K, Marcickiewicz J, Ahlner E, et al
    Incidence of lymphedema in the lower limbs and lymphocyst formation within one year of surgery for endometrial cancer: A prospective longitudinal multicenter study.
    Gynecol Oncol. 2020 Aug 3. pii: S0090-8258(20)32389.
    PubMed     Abstract available


  431. NICA A, Covens A
    Cone biopsy (with pelvic lymphadenectomy) for fertility preservation in early stage cervical cancer: Ready for prime time?
    Gynecol Oncol. 2020;158:229-230.
    PubMed    


  432. ZIEBA S, Chechlinska M, Kowalik A, Kowalewska M, et al
    Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies.
    Gynecol Oncol. 2020;158:498-506.
    PubMed     Abstract available


    July 2020
  433. LEE JM, Annunziata CM, Hays JL, Cao L, et al
    Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)33677.
    PubMed     Abstract available


  434. COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
    The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
    PubMed     Abstract available


  435. PARK JY, Chong GO, Park JY, Chung D, et al
    Tumor budding in cervical cancer as a prognostic factor and its possible role as an additional intermediate-risk factor.
    Gynecol Oncol. 2020 Jul 30. pii: S0090-8258(20)33665.
    PubMed     Abstract available


  436. TEWARI KS, Sill MW, Coleman RL, Aghajanian C, et al
    Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32390.
    PubMed     Abstract available


  437. BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
    Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
    PubMed     Abstract available


  438. SCHWARTZ GG, Tretli S, Klug MG, Robsahm TE, et al
    Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32381.
    PubMed     Abstract available


  439. SIMMS KT, Yuill S, Killen J, Smith MA, et al
    Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)31099.
    PubMed     Abstract available


  440. OAKNIN A, Friedman CF, Roman LD, D'Souza A, et al
    Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33660.
    PubMed     Abstract available


  441. SHIGETA S, Shida M, Nagase S, Ikeda M, et al
    Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33658.
    PubMed     Abstract available


  442. ZIVANOVIC O, Chen LY, Vickers A, Straubhar A, et al
    Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study.
    Gynecol Oncol. 2020 Jul 24. pii: S0090-8258(20)32379.
    PubMed     Abstract available


  443. PIFER PM, Bhargava R, Patel AK, Ling DC, et al
    Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study.
    Gynecol Oncol. 2020 Jul 24. pii: S0090-8258(20)33659.
    PubMed     Abstract available


  444. ROBELIN P, Tod M, Colomban O, Lachuer J, et al
    Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)33656.
    PubMed     Abstract available


  445. FALCONER H, Joneborg U, Krawiec K, Palsdottir K, et al
    Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32384.
    PubMed     Abstract available


  446. COBB LP, Sun CC, Iyer R, Nick AM, et al
    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
    PubMed     Abstract available


  447. ANGELES MA, Rychlik A, Cabarrou B, Spagnolo E, et al
    A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32321.
    PubMed     Abstract available


  448. ERICKSON BK, Najjar O, Damast S, Blakaj A, et al
    Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32391.
    PubMed     Abstract available


  449. ZHOU JG, Zhao HT, Jin SH, Tian X, et al
    Corrigendum to 'Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma' [Gynecologic Oncology 155 (2019) 499-507].
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32339.
    PubMed    


  450. WEISS AS, Swisher E, Pennington KP, Radke M, et al
    Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
    PubMed     Abstract available


  451. LORUSSO D, Marchetti C, Conte C, Giudice E, et al
    Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    Gynecol Oncol. 2020 Jul 20. pii: S0090-8258(20)33657.
    PubMed     Abstract available


  452. TAYLAN E, Zayou F, Murali R, Karlan BY, et al
    Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
    Gynecol Oncol. 2020 Jul 19. pii: S0090-8258(20)32380.
    PubMed     Abstract available


  453. ROSA RCA, Santis JO, Teixeira LA, Molfetta GA, et al
    Lynch syndrome identification in a Brazilian cohort of endometrial cancer screened by a universal approach.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32388.
    PubMed     Abstract available


  454. JEGATHEESWARAN K, Cormier B, Dube S, Gotlieb WH, et al
    Evaluating the diagnostic performance of preoperative endometrial biopsies in patients diagnosed with high grade endometrial cancer: A study of the Society of Gynecologic Oncology (GOC) Community of Practice (CoP).
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32336.
    PubMed     Abstract available


  455. WU JL, Zhao J, Zhang HB, Zuo WW, et al
    Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32387.
    PubMed     Abstract available


  456. ESSELEN K, Sinno AK, Varughese J, Wethington SL, et al
    Social needs in gynecologic oncology: A Society of Gynecologic Oncology (SGO) clinical practice statement.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32323.
    PubMed    


  457. BUCHANAN TR, Johns EA, Massad LS, Dick R, et al
    A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)33653.
    PubMed     Abstract available


  458. MATSUO K, Nusbaum DJ, Matsuzaki S, Chang EJ, et al
    Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32385.
    PubMed     Abstract available


  459. ZHENG L, Cui C, Shi O, Lu X, et al
    Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32383.
    PubMed     Abstract available


  460. ARA R, Khatun S, Pervin S, Jahan M, et al
    Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening.
    Gynecol Oncol. 2020 Jul 14. pii: S0090-8258(20)32322.
    PubMed     Abstract available


  461. MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
    Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
    PubMed     Abstract available


  462. CASARIN J, Buda A, Bogani G, Fanfani F, et al
    Predictors of recurrence following laparoscopic radical hysterectomy for early-stage cervical cancer: A multi-institutional study.
    Gynecol Oncol. 2020 Jul 11. pii: S0090-8258(20)32334.
    PubMed     Abstract available


  463. BOUCHARD-FORTIER G, Ghorani E, Short D, Aguiar X, et al
    Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse?
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32298.
    PubMed     Abstract available


  464. PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
    Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
    PubMed     Abstract available


  465. ROSS TL, DeFazio A, Friedlander M, Grant P, et al
    Insomnia and its association with quality of life in women with ovarian cancer.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32326.
    PubMed     Abstract available


  466. MARTELL K, McIntyre JB, Kornaga EN, Chan AMY, et al
    PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32332.
    PubMed     Abstract available


  467. BERNARD L, Boucher J, Helpman L
    Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
    PubMed     Abstract available


  468. HUH WK, Brady WE, Fracasso PM, Dizon DS, et al
    Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32317.
    PubMed     Abstract available


  469. KURNIT KC, Reid P, Moroney JW, Fleming GF, et al
    Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32325.
    PubMed     Abstract available


  470. BRIEGER KK, Peterson S, Lee AW, Mukherjee B, et al
    Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32296.
    PubMed     Abstract available


  471. ROSS ME, Glickman A, Brennecke A, Tayebnejad A, et al
    Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: A subanalysis.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32331.
    PubMed     Abstract available


  472. DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
    Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
    Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
    PubMed     Abstract available


  473. CHAMBERS LM, Costales AB, Crean-Tate K, Kuznicki M, et al
    A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology.
    Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32302.
    PubMed     Abstract available


  474. SISODIA RC, Dewdney SB, Fader AN, Wethington SL, et al
    Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II.
    Gynecol Oncol. 2020;158:201-207.
    PubMed    


  475. SISODIA RC, Dewdney SB, Fader AN, Wethington SL, et al
    Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I.
    Gynecol Oncol. 2020;158:194-200.
    PubMed    


  476. BAE-JUMP V
    Unraveling the mystery of clear cell endometrial cancer.
    Gynecol Oncol. 2020;158:1-2.
    PubMed    


    June 2020
  477. ADJEI BOAKYE E, Grubb L, Peterson CE, Osazuwa-Peters N, et al
    Risk of second primary cancers among survivors of gynecological cancers.
    Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32316.
    PubMed     Abstract available


  478. JONES TL, Sandler CX, Spence RR, Hayes SC, et al
    Physical activity and exercise in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32300.
    PubMed     Abstract available


  479. BONAZZOLI E, Bellone S, Zammataro L, Gnutti B, et al
    Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
    Gynecol Oncol. 2020 Jun 26. pii: S0090-8258(20)32299.
    PubMed     Abstract available


  480. KOKTS-PORIETIS RL, McNeil J, Nelson G, Courneya KS, et al
    Prospective cohort study of metabolic syndrome and endometrial cancer survival.
    Gynecol Oncol. 2020 Jun 26. pii: S0090-8258(20)32303.
    PubMed     Abstract available


  481. BALAYA V, Guani B, Benoit L, Magaud L, et al
    Diagnostic value of frozen section examination of sentinel lymph nodes in early-stage cervical cancer at the time of ultrastaging.
    Gynecol Oncol. 2020 Jun 25. pii: S0090-8258(20)31128.
    PubMed     Abstract available


  482. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)31132.
    PubMed     Abstract available


  483. SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
    Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
    PubMed     Abstract available


  484. MARIA S, Faron M, Maulard A, Pautier P, et al
    Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
    PubMed     Abstract available


  485. DILLEY J, Burnell M, Gentry-Maharaj A, Ryan A, et al
    Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31029.
    PubMed     Abstract available


  486. NICA A, Covens A, Parra-Herran C, May T, et al
    Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)32293.
    PubMed     Abstract available


  487. PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
    Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
    PubMed     Abstract available


  488. ELLEDGE CR, Beriwal S, Chargari C, Chopra S, et al
    Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations.
    Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32301.
    PubMed     Abstract available


  489. MARCHETTI C, Minucci A, D'Indinosante M, Ergasti R, et al
    Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294.
    PubMed     Abstract available


  490. MOORE KN, Birrer MJ, Marsters J, Wang Y, et al
    Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jun 11. pii: S0090-8258(20)31124.
    PubMed     Abstract available


  491. SUTARIA T, Sparks AD, Rao YJ, Lopez-Acevedo M, et al
    Trends in guideline-adherent fertility-sparing surgery for early-stage cervical cancer before and after the Affordable Care Act.
    Gynecol Oncol. 2020 Jun 11. pii: S0090-8258(20)31096.
    PubMed     Abstract available


  492. LINDFORS A, Heshar H, Adok C, Sundfeldt K, et al
    Long-term survival in obese patients after robotic or open surgery for endometrial cancer.
    Gynecol Oncol. 2020 Jun 9. pii: S0090-8258(20)31928.
    PubMed     Abstract available


  493. BARRINGTON DA, Sinnott JA, Calo C, Cohn DE, et al
    Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes.
    Gynecol Oncol. 2020 Jun 9. pii: S0090-8258(20)31086.
    PubMed     Abstract available


  494. CARTER J, Goldfarb S, Baser RE, Goldfrank DJ, et al
    A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors.
    Gynecol Oncol. 2020 Jun 8. pii: S0090-8258(20)31094.
    PubMed     Abstract available


  495. NARASIMHULU DM, McGree ME, Weaver AL, Jatoi A, et al
    Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31131.
    PubMed     Abstract available


  496. BOGANI G, Lopez S, Mantiero M, Ducceschi M, et al
    Immunotherapy for platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31924.
    PubMed     Abstract available


  497. LI X, Xia L, Chen X, Fu Y, et al
    Simple conization and pelvic lymphadenectomy in early-stage cervical cancer: A retrospective analysis and review of the literature.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31120.
    PubMed     Abstract available


  498. STRAUBHAR AM, Filippova OT, Cowan RA, Lakhman Y, et al
    A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31126.
    PubMed     Abstract available


  499. FADER AN, Huh WK, Kesterson J, Pothuri B, et al
    When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31766.
    PubMed     Abstract available


  500. MORRISON A, Nasioudis D
    Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
    PubMed     Abstract available


  501. HAMILTON E, O'Malley DM, O'Cearbhaill R, Cristea M, et al
    Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31123.
    PubMed     Abstract available


  502. BOLZE PA, Lopez J, Allias F, Hajri T, et al
    Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31127.
    PubMed     Abstract available


  503. TU H, Gu HF, Huang H, Liu KJ, et al
    Sectioning protocol determines accuracy of intraoperative pathological examination of sentinel lymph node in cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31122.
    PubMed     Abstract available


  504. VENERIS JT, Mahajan P, Frazier AL
    Contemporary management of ovarian germ cell tumors and remaining controversies.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
    PubMed     Abstract available


  505. CHEN H, Wu Q, Zhang Y, Li Q, et al
    Nomograms based on the novel platelet index score predict postoperative prognosis in endometrial cancer.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31125.
    PubMed     Abstract available


  506. ELLIS PE, Barron GA, Bermano G
    Adipocytokines and their relationship to endometrial cancer risk: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31118.
    PubMed     Abstract available


  507. ARMEL SR, Volenik A, Demsky R, Malcolmson J, et al
    Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082.
    PubMed     Abstract available


  508. LIU P, Liang C, Lu A, Chen X, et al
    Risk factors and long-term impact of urologic complications during radical hysterectomy for cervical cancer in China, 2004-2016.
    Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31098.
    PubMed     Abstract available


  509. BOLAND JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, et al
    Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
    Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31073.
    PubMed     Abstract available


  510. ROCHE KL, Chi DS
    Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?
    Gynecol Oncol. 2020;157:561-562.
    PubMed    


  511. CHAMBERS LM, Pendlebury A, Rose PG, Yao M, et al
    Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31018.
    PubMed     Abstract available


  512. THOMAIER L, Jewett P, Brown K, Gotlieb R, et al
    The associations between physical activity, neuropathy symptoms and health-related quality of life among gynecologic cancer survivors.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31095.
    PubMed     Abstract available


  513. PIGOTT A, Obermair A, Janda M, Vagenas D, et al
    Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31012.
    PubMed     Abstract available


  514. VASSEUR D, Lopez J, Croce S, Tondeur G, et al
    Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression.
    Gynecol Oncol. 2020;157:775-782.
    PubMed     Abstract available


  515. MANCINI S, Bucchi L, Baldacchini F, Giuliani O, et al
    Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015.
    Gynecol Oncol. 2020;157:656-663.
    PubMed     Abstract available


  516. KILTS TP, Long B, Glasgow AE, Bakkum-Gamez JN, et al
    Invasive vulvar extramammary Paget's disease in the United States.
    Gynecol Oncol. 2020;157:649-655.
    PubMed     Abstract available


  517. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    PubMed     Abstract available


  518. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    PubMed     Abstract available


  519. SPEKREIJSE JJ, Streng BMM, Vermeulen RFM, Voss FO, et al
    The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: A systematic review.
    Gynecol Oncol. 2020;157:671-677.
    PubMed     Abstract available


    May 2020
  520. ESPENEL S, Kissel M, Garcia MA, Schernberg A, et al
    Implementation of image-guided brachytherapy as part of non-surgical treatment in inoperable endometrial cancer patients.
    Gynecol Oncol. 2020 May 29. pii: S0090-8258(20)31101.
    PubMed     Abstract available


  521. ELSHAIKH MA, Modh A, Jhingran A, Biagioli MC, et al
    Executive summary of the American Radium Society(R) Appropriate Use Criteria for management of uterine carcinosarcoma.
    Gynecol Oncol. 2020 May 29. pii: S0090-8258(20)30983.
    PubMed     Abstract available


  522. GRAUL A, Haggerty A, Stickley C, Kumar P, et al
    Corrigendum to "Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care services among gynecologic oncology patients: A randomized controlled trial" [Gynecol. Oncol. 156 (2020) 482-487].
    Gynecol Oncol. 2020 May 28. pii: S0090-8258(20)31083.
    PubMed    


  523. MATSUO K, Matsuzaki S, Mandelbaum RS, Chang EJ, et al
    Minimally invasive radical hysterectomy for early-stage cervical cancer: Volume-outcome relationship in the early experience period.
    Gynecol Oncol. 2020 May 27. pii: S0090-8258(20)31077.
    PubMed     Abstract available


  524. HE F, Li W, Liu P, Kang S, et al
    Influence of uterine corpus invasion on prognosis in stage IA2-IIB cervical cancer: A multicenter retrospective cohort study.
    Gynecol Oncol. 2020 May 26. pii: S0090-8258(20)31072.
    PubMed     Abstract available


  525. DIAZ-FEIJOO B, Franco S, Torne A, Benito V, et al
    Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study.
    Gynecol Oncol. 2020 May 26. pii: S0090-8258(20)31071.
    PubMed     Abstract available


  526. ZYLA RE, Gien LT, Vicus D, Olkhov-Mitsel E, et al
    The prognostic role of horizontal and circumferential tumor extent in cervical cancer: Implications for the 2019 FIGO staging system.
    Gynecol Oncol. 2020 May 26. pii: S0090-8258(20)31084.
    PubMed     Abstract available


  527. DI SPIEZIO SARDO A, De Angelis MC, Della Corte L, Carugno J, et al
    Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer?
    Gynecol Oncol. 2020 May 25. pii: S0090-8258(20)31080.
    PubMed     Abstract available


  528. NARDUCCI F, Bogart E, Hebert T, Gauthier T, et al
    Severe perioperative morbidity after robot-assisted versus conventional laparoscopy in gynecologic oncology: Results of the randomized ROBOGYN-1004 trial.
    Gynecol Oncol. 2020 May 25. pii: S0090-8258(20)31078.
    PubMed     Abstract available


  529. GADDUCCI A, Aletti GD
    Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists.
    Gynecol Oncol. 2020 May 25. pii: S0090-8258(20)31089.
    PubMed     Abstract available


  530. SCHINK JC, Filiaci V, Huang HQ, Tidy J, et al
    An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.
    Gynecol Oncol. 2020 May 24. pii: S0090-8258(20)31081.
    PubMed     Abstract available


  531. MOUKARZEL LA, Byrne ME, Leiva S, Wu M, et al
    The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies.
    Gynecol Oncol. 2020 May 24. pii: S0090-8258(20)31090.
    PubMed     Abstract available


  532. HOFFMAN MS, Chi DS, Clarke-Pearson DL, Cliby W, et al
    Surgical training in gynecologic oncology: Past, present, future.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31074.
    PubMed     Abstract available


  533. KNISELY A, Huang Y, Melamed A, Tergas AI, et al
    Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31085.
    PubMed     Abstract available


  534. SILVA SR, Gaskins JT, Nichols MR, Metzinger DS, et al
    Cervical cancer incidence and mortality rates in Kentucky.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31079.
    PubMed     Abstract available


  535. GLEESON M, Kentwell M, Meiser B, Do J, et al
    The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028.
    PubMed     Abstract available


  536. SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
    The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
    PubMed     Abstract available


  537. MATSUO K, Novatt H, Matsuzaki S, Hom MS, et al
    Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic.
    Gynecol Oncol. 2020 May 18. pii: S0090-8258(20)31087.
    PubMed     Abstract available


  538. NGUYEN JMV, Hogen L, Laframboise S, Bouchard-Fortier G, et al
    The use of indocyanine green fluorescence angiography to assess anastomotic perfusion following bowel resection in surgery for gynecologic malignancies - A report of 100 consecutive anastomoses.
    Gynecol Oncol. 2020 May 15. pii: S0090-8258(20)31076.
    PubMed     Abstract available


  539. STEENBEEK MP, Bulten J, Snijders MPLM, Lombaers M, et al
    Fallopian tube abnormalities in uterine serous carcinoma.
    Gynecol Oncol. 2020 May 11. pii: S0090-8258(20)31017.
    PubMed     Abstract available


  540. JAREEMIT N, Horowitz NS, Goldstein DP, Berkowitz RS, et al
    EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
    Gynecol Oncol. 2020 May 11. pii: S0090-8258(20)31009.
    PubMed     Abstract available


  541. MATSUO K, Chang EJ, Matsuzaki S, Mandelbaum RS, et al
    Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30304.
    PubMed     Abstract available


  542. WASHINGTON CR, Haggerty A, Ronner W, Neff PM, et al
    Knowledge of endometrial cancer risk factors in a general gynecologic population.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30257.
    PubMed     Abstract available


  543. FREITAS F, Braga A, Viggiano M, Velarde LGC, et al
    Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)31014.
    PubMed     Abstract available


  544. LUO S, Zhang Y, Yang Y, Zhu S, et al
    Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)30995.
    PubMed     Abstract available


  545. BOGANI G, Casarin J, Maggiore ULR, Ditto A, et al
    Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis.
    Gynecol Oncol. 2020 May 7. pii: S0090-8258(20)30991.
    PubMed    


  546. BOUCHARD-FORTIER G, Cusimano MC, Fazelzad R, Sajewycz K, et al
    Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30259.
    PubMed     Abstract available


  547. LENTZ SE, Salyer CV, Dontsi M, Armstrong MA, et al
    Comparison of two Lynch screening strategies in endometrial cancer in a California health system.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30992.
    PubMed     Abstract available


  548. WENZEL HHB, Van Kol KGG, Nijman HW, Lemmens VEPP, et al
    Cervical cancer with </=5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI?
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31015.
    PubMed     Abstract available


  549. SIVAKUMARAN T, Mileshkin L, Grant P, Na L, et al
    Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31016.
    PubMed     Abstract available


  550. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    PubMed     Abstract available


  551. SONG F, Li L, Zhang B, Zhao Y, et al
    Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Gynecol Oncol. 2020 May 1. pii: S0090-8258(20)30988.
    PubMed     Abstract available


  552. PATEL SN, Staples JN, Garcia C, Chatfield L, et al
    Are ethnic and racial minority women less likely to participate in clinical trials?
    Gynecol Oncol. 2020;157:323-328.
    PubMed     Abstract available


  553. STUEBS FA, Mehlhorn G, Gass P, Schulmeyer CE, et al
    Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia.
    Gynecol Oncol. 2020;157:463-468.
    PubMed     Abstract available


  554. POUNDS R, O'Neill D, Subba K, Garg A, et al
    The role of preoperative computerized tomography (CT) scan of the pelvis and groin in the management of clinically early staged vulva squamous cell carcinoma.
    Gynecol Oncol. 2020;157:444-449.
    PubMed     Abstract available


    April 2020
  555. PAIVA CE, Paiva BSR, Menezes D, Zanini LE, et al
    Development of a screening tool to improve the referral of patients with breast and gynecological cancer to outpatient palliative care.
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31011.
    PubMed     Abstract available


  556. STAPLES JN, Peres LC, Camacho F, Alberg AJ, et al
    Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31010.
    PubMed     Abstract available


  557. GULTEKIN M, Dundar S, Keskinkilic B, Turkyilmaz M, et al
    How to triage HPV positive cases: Results of four million females.
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31008.
    PubMed     Abstract available


  558. CHEN Y, Li G
    Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31019.
    PubMed    


  559. MONK BJ, Coleman RL, Moore KN, Herzog TJ, et al
    COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31013.
    PubMed    


  560. NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
    Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
    PubMed     Abstract available


  561. HELPMAN L, Pond GR, Elit L, Anderson LN, et al
    Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30993.
    PubMed     Abstract available


  562. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Effect of bilateral salpingo-oophorectomy on the overall survival of premenopausal patients with stage I low-grade endometrial stromal sarcoma; a National Cancer Database analysis.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30260.
    PubMed     Abstract available


  563. HWANG JH, Kim BW, Jeong H, Kim H, et al
    Comparison of urologic complications between laparoscopic radical hysterectomy and abdominal radical hysterectomy: A nationwide study from the National Health Insurance.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30986.
    PubMed     Abstract available


  564. KOGAN L, Matanes E, Wissing M, Mitric C, et al
    The added value of sentinel node mapping in endometrial cancer.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30987.
    PubMed     Abstract available


  565. REICH O, Regauer S, Kashofer K
    Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30985.
    PubMed     Abstract available


  566. SEARLE G, Pounds R, Phillips A, Kehoe S, et al
    Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
    Gynecol Oncol. 2020 Apr 25. pii: S0090-8258(20)30307.
    PubMed     Abstract available


  567. LIN H, Ye M, Chan SW, Zhu J, et al
    The effectiveness of online interventions for patients with gynecological cancer: An integrative review.
    Gynecol Oncol. 2020 Apr 24. pii: S0090-8258(20)30990.
    PubMed     Abstract available


  568. FREY MK, Blank SV
    Coronavirus concerns: What do women with gynecologic cancer need to know during the COVID-19 crisis?
    Gynecol Oncol. 2020 Apr 24. pii: S0090-8258(20)30997.
    PubMed    


  569. POTHURI B, Alvarez Secord A, Armstrong DK, Chan J, et al
    Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
    Gynecol Oncol. 2020 Apr 23. pii: S0090-8258(20)30994.
    PubMed     Abstract available


  570. KIM SR, Cloutier BT, Leung S, Cochrane D, et al
    Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Gynecol Oncol. 2020 Apr 21. pii: S0090-8258(20)30302.
    PubMed     Abstract available


  571. MAJIDI A, Na R, Dixon-Suen S, Jordan SJ, et al
    Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Apr 18. pii: S0090-8258(20)30253.
    PubMed     Abstract available


  572. YU YL, Yeo H, Kang S
    The impact of depressive symptoms on health value in patients with gynecologic cancer: A comparison with physical symptoms and performance status.
    Gynecol Oncol. 2020 Apr 16. pii: S0090-8258(20)30303.
    PubMed     Abstract available


  573. BRUEGL AS, Joshi S, Batman S, Weisenberger M, et al
    Gynecologic cancer incidence and mortality among American Indian/Alaska Native women in the Pacific Northwest, 1996-2016.
    Gynecol Oncol. 2020 Apr 15. pii: S0090-8258(20)30258.
    PubMed     Abstract available


  574. KALAMPOKAS E, Payne F, Nomikos A, Gurumurthy M, et al
    Corrigendum to "An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology" [Gynecol. Oncol. 150 (2018) 378-386].
    Gynecol Oncol. 2020 Apr 13. pii: S0090-8258(20)30230.
    PubMed    


  575. TEMKIN SM, Rubinsak L, Benoit MF, Hong L, et al
    Take me to your leader: Reporting structures and equity in academic gynecologic oncology.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30256.
    PubMed     Abstract available


  576. BATMAN S, Skeith A, Allen A, Munro E, et al
    Cost-effectiveness of second curettage for treatment of low-risk non-metastatic gestational trophoblastic neoplasia.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30254.
    PubMed     Abstract available


  577. RASMUSSEN CL, Thomsen LT, Aalborg GL, Kjaer SK, et al
    Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30255.
    PubMed     Abstract available


  578. HOOGSTAD-VAN EVERT JS, Bekkers R, Ottevanger N, Jansen JH, et al
    Harnessing natural killer cells for the treatment of ovarian cancer.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30236.
    PubMed     Abstract available


  579. KORENAGA TK, Tewari KS
    Gynecologic cancer in pregnancy.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30231.
    PubMed     Abstract available


  580. AREND RC, Beer HM, Cohen YC, Berlin S, et al
    Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30180.
    PubMed     Abstract available


  581. GRIGSBY PW, Massad LS, Mutch DG, Powell MA, et al
    FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.
    Gynecol Oncol. 2020 Apr 2. pii: S0090-8258(20)30252.
    PubMed     Abstract available


  582. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    PubMed     Abstract available


  583. GERSHENSON DM, Okamoto A, Ray-Coquard I
    Rare Gynecologic Tumors: Coming of Age.
    Gynecol Oncol. 2020;157:1-2.
    PubMed    


  584. MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
    Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
    PubMed     Abstract available


  585. NARASIMHULU DM, Kumar A, Weaver AL, Langstraat CL, et al
    Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30249.
    PubMed     Abstract available


  586. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    PubMed     Abstract available


  587. GAULIN NB, Lesnock JL, Tian C, Osei-Bonsu K, et al
    Survival disparities in vulvar cancer patients in Commission on Cancer(R)-accredited facilities.
    Gynecol Oncol. 2020;157:136-145.
    PubMed     Abstract available


  588. NASIOUDIS D, Bhadra M, Ko EM
    Extramammary Paget disease of the vulva: Management and prognosis.
    Gynecol Oncol. 2020;157:146-150.
    PubMed     Abstract available


    March 2020
  589. BENNETSEN AKK, Baandrup L, Aalborg GL, Kjaer SK, et al
    Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40years.
    Gynecol Oncol. 2020 Mar 26. pii: S0090-8258(20)30246.
    PubMed     Abstract available


  590. GONZALEZ R, Gockley AA, Melamed A, Sugrue R, et al
    Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gynecol Oncol. 2020 Mar 25. pii: S0090-8258(20)30228.
    PubMed     Abstract available


  591. TYMON-ROSARIO JR, Miller DT, Novetsky AP, Goldberg GL, et al
    Risk factors associated with delayed discharge following robotic assisted surgery for gynecologic malignancy.
    Gynecol Oncol. 2020 Mar 23. pii: S0090-8258(20)30235.
    PubMed     Abstract available


  592. DHOLAKIA J, Llamocca E, Quick A, Salani R, et al
    Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Mar 23. pii: S0090-8258(20)30232.
    PubMed     Abstract available


  593. RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
    Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
    PubMed     Abstract available


  594. WONG CHL, Sundberg T, Chung VCH, Voiss P, et al
    Prevalence and predictors of mind-body medicine use among women diagnosed with gynecological cancer: Findings from the 2017 US National Health Interview Survey.
    Gynecol Oncol. 2020 Mar 17. pii: S0090-8258(20)30227.
    PubMed     Abstract available


  595. BETELLA I, Turbitt WJ, Szul T, Wu B, et al
    Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
    Gynecol Oncol. 2020 Mar 16. pii: S0090-8258(20)30226.
    PubMed     Abstract available


  596. WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
    Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
    PubMed     Abstract available


  597. AWAD E, Paladugu R, Jones N, Pierce JY, et al
    Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30218.
    PubMed     Abstract available


  598. MIGNOT F, Gouy S, Schernberg A, Bockel S, et al
    Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30222.
    PubMed     Abstract available


  599. LIONTOS M, Sotiropoulou M, Kaparelou M, Tzannis K, et al
    Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224.
    PubMed     Abstract available


  600. SUN Z, Huang B, Liu C, Yang Y, et al
    Comparison of neoadjuvant treatments followed by radical surgery or chemoradiation on quality of life in patients with stage IB2-IIA cervical cancer.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30092.
    PubMed     Abstract available


  601. RAUH LA, Sullivan MW, Camacho F, Janke MJ, et al
    Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30223.
    PubMed     Abstract available


  602. ROZE JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, et al
    Prognostic value of radiological recurrence patterns in ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219.
    PubMed     Abstract available


  603. VAN WALREE IC, Bretveld R, van Huis-Tanja LH, Louwers JA, et al
    Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30221.
    PubMed     Abstract available


  604. LIN DI, Hemmerich A, Edgerly C, Duncan D, et al
    Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
    Gynecol Oncol. 2020 Mar 7. pii: S0090-8258(20)30160.
    PubMed     Abstract available


  605. LEVY T, Migdan Z, Aleohin N, Ben-Shem, et al
    Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Gynecol Oncol. 2020 Mar 6. pii: S0090-8258(20)30158.
    PubMed     Abstract available


  606. HAQUE R, Skates SJ, Armstrong MA, Lentz SE, et al
    Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164.
    PubMed     Abstract available


  607. HOSKINS PJ, Le N, Kumar A, Pina A, et al
    Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.
    Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30100.
    PubMed     Abstract available


  608. PIERSON WE, Peters PN, Chang MT, Chen LM, et al
    An integrated molecular profile of endometrioid ovarian cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30144.
    PubMed     Abstract available


  609. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    PubMed     Abstract available


  610. REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
    Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
    PubMed     Abstract available


  611. KIM H, Cho WK, Kim YJ, Kim YS, et al
    Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30177.
    PubMed     Abstract available


  612. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    PubMed     Abstract available


  613. MOORE KN, Zorn KK
    Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations.
    Gynecol Oncol. 2020;156:515-516.
    PubMed    


  614. PARACCHINI S, Chauvet P, Galczynski K, Boulay E, et al
    Surgical technique for the sentinel lymph node (SLN) mapping in 10 steps.
    Gynecol Oncol. 2020;156:746-747.
    PubMed    


  615. HU SY, Rezhake R, Chen F, Zhang X, et al
    Outcomes in women with biopsy-confirmed cervical intraepithelial neoplasia grade 1 or normal cervix and related cofactors: A 15-year population-based cohort study from China.
    Gynecol Oncol. 2020;156:616-623.
    PubMed     Abstract available


  616. HUISMAN BW, Burggraaf J, Vahrmeijer AL, Schoones JW, et al
    Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers.
    Gynecol Oncol. 2020;156:734-743.
    PubMed     Abstract available


  617. LEE H, Choi M, Jo M, Park EY, et al
    Assessment of clinical performance of an ultrasensitive nanowire assay for detecting human papillomavirus DNA in urine.
    Gynecol Oncol. 2020;156:641-646.
    PubMed     Abstract available


  618. POWELL CB, Littell RD, Landen CN Jr, Pramanik S, et al
    Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
    Gynecol Oncol. 2020;156:636-640.
    PubMed     Abstract available


  619. ZONG L, Zhang Q, Kong Y, Yang F, et al
    The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery.
    Gynecol Oncol. 2020;156:676-681.
    PubMed     Abstract available


    February 2020
  620. CHANG CP, Chen Y, Blackburn B, Abdelaziz S, et al
    Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30162.
    PubMed     Abstract available


  621. LI X, Xia L, Li J, Chen X, et al
    Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30152.
    PubMed     Abstract available


  622. PLETT H, Harter P, Ataseven B, Heitz F, et al
    Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
    Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
    PubMed     Abstract available


  623. KIM CH, Lefkowits C, Holschneider C, Bixel K, et al
    Managing opioid use in the acute surgical setting: A society of gynecologic oncology clinical practice statement.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30068.
    PubMed     Abstract available


  624. GLASER GE, Kalogera E, Kumar A, Yi J, et al
    Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
    PubMed     Abstract available


  625. CHOI CH, Chung JY, Kang JH, Paik ES, et al
    Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30153.
    PubMed     Abstract available


  626. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
    PubMed     Abstract available


  627. AVIKI EM, Chen L, Dessources K, Leitao MM Jr, et al
    Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30165.
    PubMed     Abstract available


  628. NASIOUDIS D, Sakamuri S, Ko EM, Haggerty AF, et al
    Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma.
    Gynecol Oncol. 2020 Feb 20. pii: S0090-8258(20)30098.
    PubMed     Abstract available


  629. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].
    Gynecol Oncol. 2020 Feb 20. pii: S0090-8258(20)30159.
    PubMed    


  630. ACOSTA-TORRES S, Murdock T, Matsuno R, Beavis AL, et al
    The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30103.
    PubMed     Abstract available


  631. O'MALLEY DM, Matulonis UA, Birrer MJ, Castro CM, et al
    Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090.
    PubMed     Abstract available


  632. CHARO LM, Vaida F, Eskander RN, Binder P, et al
    Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial.
    Gynecol Oncol. 2020 Feb 17. pii: S0090-8258(20)30154.
    PubMed     Abstract available


  633. SINNO AK, Pinkerton J, Febbraro T, Jones N, et al
    Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American
    Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30088.
    PubMed    


  634. CHEN B, Ji M, Li P, Liu P, et al
    Comparison between robot-assisted radical hysterectomy and abdominal radical hysterectomy for cervical cancer: A multicentre retrospective study.
    Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30155.
    PubMed     Abstract available


  635. TRAN LKH, Tran PMH, Mysona DP, Purohit SB, et al
    A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
    Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30151.
    PubMed     Abstract available


  636. UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
    Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
    Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
    PubMed     Abstract available


  637. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Erratum to "Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival" [Gynecol. Oncol. 155 (2019) 483-488].
    Gynecol Oncol. 2020 Feb 12. pii: S0090-8258(20)30146.
    PubMed    


  638. FREY MK, Lee SS, Gerber D, Schwartz ZP, et al
    Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007.
    PubMed     Abstract available


  639. WESTON E, Noel M, Douglas K, Terrones K, et al
    The impact of an enhanced recovery after minimally invasive surgery program on opioid use in gynecologic oncology patients undergoing hysterectomy.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30094.
    PubMed     Abstract available


  640. PETERSEN S, Wilson AJ, Hirst J, Roby KF, et al
    CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091.
    PubMed     Abstract available


  641. MAESTA I, Nitecki R, Desmarais CCF, Horowitz NS, et al
    Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30096.
    PubMed     Abstract available


  642. COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
    Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
    PubMed     Abstract available


  643. PIAO J, Lee EJ, Lee M
    Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30097.
    PubMed     Abstract available


  644. EVA LJ, Sadler L, Fong KL, Sahota S, et al
    Trends in HPV-dependent and HPV-independent vulvar cancers: The changing face of vulvar squamous cell carcinoma.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30083.
    PubMed     Abstract available


  645. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    PubMed     Abstract available


  646. SOLSKY I, Chen J, Rebbeck TR
    Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Gynecol Oncol. 2020;156:363-376.
    PubMed     Abstract available


  647. DOGAN NU, Dogan S, Erol M, Uzun BT, et al
    Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
    Gynecol Oncol. 2020;156:511.
    PubMed     Abstract available


  648. DILLEY S, Miller KM, Huh WK
    Human papillomavirus vaccination: Ongoing challenges and future directions.
    Gynecol Oncol. 2020;156:498-502.
    PubMed     Abstract available


  649. RISHI A, Rollins M, Ahmed KA, Hunt DC, et al
    High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity.
    Gynecol Oncol. 2020;156:349-356.
    PubMed     Abstract available


  650. VENERIS JT, Matulonis UA, Liu JF, Konstantinopoulos PA, et al
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    Gynecol Oncol. 2020;156:488-497.
    PubMed     Abstract available


    January 2020
  651. MILLER DS, Randall ME, Filiaci V
    Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group.
    Gynecol Oncol. 2020 Jan 31. pii: S0090-8258(20)30019.
    PubMed     Abstract available


  652. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    PubMed     Abstract available


  653. LONG B, Clarke MA, Morillo ADM, Wentzensen N, et al
    Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30085.
    PubMed     Abstract available


  654. MATERN T, Kang E, Lim PC
    Factors in the feasibility and safety of outpatient robotic-assisted hysterectomy for endometrial or cervical carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30081.
    PubMed     Abstract available


  655. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    PubMed     Abstract available


  656. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    PubMed     Abstract available


  657. BERTOLI HK, Thomsen LT, Iftner T, Dehlendorff C, et al
    Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30082.
    PubMed     Abstract available


  658. CABASAG CJ, Butler J, Arnold M, Rutherford M, et al
    Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877.
    PubMed     Abstract available


  659. TRIMBLE CL, Levinson K, Maldonado L, Donovan MJ, et al
    A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31865.
    PubMed     Abstract available


  660. MULLEN MM, Porcelli BP, Cripe J, Massad LS, et al
    Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision.
    Gynecol Oncol. 2020 Jan 27. pii: S0090-8258(19)31629.
    PubMed     Abstract available


  661. XUE C, Xu Y, Ye W, Xie Q, et al
    Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
    PubMed     Abstract available


  662. JORDAN SE, Schlumbrecht M, George S, Pearson JM, et al
    The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30001.
    PubMed     Abstract available


  663. STEWART LM, Stewart CJR, Spilsbury K, Cohen PA, et al
    Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30080.
    PubMed     Abstract available


  664. TAKEHARA K, Yamashita N, Watanabe R, Teramoto N, et al
    Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30064.
    PubMed     Abstract available


  665. MATSUO K, Matsuzaki S, Mandelbaum RS, Matsushima K, et al
    Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30021.
    PubMed     Abstract available


  666. HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
    Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
    PubMed     Abstract available


  667. MATSUO K, Mandelbaum RS, Adams CL, Roman LD, et al
    Corrigendum to "Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study" [Gynecol. Oncol. 153 (2019) 368-375].
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30069.
    PubMed    


  668. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    PubMed     Abstract available


  669. TIMMERMAN S, Van Rompuy AS, Van Gorp T, Vanden Bempt I, et al
    Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(20)30061.
    PubMed     Abstract available


  670. SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
    Low-grade serous ovarian cancer: State of the science.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
    PubMed     Abstract available


  671. LOOPIK DL, IntHout J, Ebisch RMF, Melchers WJG, et al
    The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: A population-based cohort study with 80,442 women.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30067.
    PubMed     Abstract available


  672. ENGERUD H, Berg HF, Myrvold M, Halle MK, et al
    High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30062.
    PubMed     Abstract available


  673. FEKETE JT, Osz A, Pete I, Nagy GR, et al
    Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
    PubMed     Abstract available


  674. LI T, Wu Z, Jiang M, Zhao Y, et al
    Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.
    Gynecol Oncol. 2020 Jan 18. pii: S0090-8258(20)30022.
    PubMed     Abstract available


  675. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    PubMed     Abstract available


  676. CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
    A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
    PubMed     Abstract available


  677. JUN F, Peng Z, Zhang Y, Shi D, et al
    Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(20)30020.
    PubMed     Abstract available


  678. PUROHIT S, Ferris DG, Alvarez M, Tran PMH, et al
    Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(20)30023.
    PubMed     Abstract available


  679. ACOSTA-TORRES S, Fader AN
    Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
    PubMed     Abstract available


  680. VERGOTE I, Powell MA, Teneriello MG, Miller DS, et al
    Second-line lenvatinib in patients with recurrent endometrial cancer.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31869.
    PubMed     Abstract available


  681. CHO HW, Ouh YT, Min KJ, Lee NW, et al
    The impact of previous cesarean section (C/S) on the risk for post-molar gestational trophoblastic neoplasia (GTN).
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31683.
    PubMed     Abstract available


  682. MERIDETH MA, Harney LA, Vyas N, Bachi A, et al
    Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31867.
    PubMed     Abstract available


  683. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    PubMed     Abstract available


  684. GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
    Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
    PubMed     Abstract available


  685. BEAVIS AL, Yen TT, Stone RL, Wethington SL, et al
    Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
    Gynecol Oncol. 2020 Jan 13. pii: S0090-8258(19)31849.
    PubMed     Abstract available


  686. BIXEL K, Vetter M, Davidson B, Berchuck A, et al
    Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
    PubMed     Abstract available


  687. MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
    Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
    PubMed     Abstract available


  688. WHITCOMB B, Lutman C, Pearl M, Medlin E, et al
    Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(19)31805.
    PubMed    


  689. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    PubMed     Abstract available


  690. STALEY SA, Tucker K, Newton M, Ertel M, et al
    Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
    PubMed     Abstract available


  691. IIHARA H, Shimokawa M, Hayasaki Y, Fujita Y, et al
    Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(20)30004.
    PubMed     Abstract available


  692. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    PubMed     Abstract available


  693. MONK BJ, Herzog TJ, Wang G, Triantos S, et al
    A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
    PubMed     Abstract available


  694. BRANDT B, Sioulas V, Basaran D, Kuhn T, et al
    Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31868.
    PubMed     Abstract available


  695. SIAMAKPOUR-REIHANI S, Cobb LP, Jiang C, Zhang D, et al
    Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31840.
    PubMed     Abstract available


  696. SANTIN AD, Deng W, Frumovitz M, Buza N, et al
    Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31864.
    PubMed     Abstract available


  697. SCHAD MD, Patel AK, Glaser SM, Balasubramani GK, et al
    Declining brachytherapy utilization for cervical cancer patients - Have we reversed the trend?
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31863.
    PubMed     Abstract available


  698. CHEN LM, Blank SV, Burton E, Glass K, et al
    Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 5
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31850.
    PubMed    


  699. FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
    High homogeneity of MMR deficiency in ovarian cancer.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
    PubMed     Abstract available


  700. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    PubMed     Abstract available


  701. LIANG MI, Aviki EM, Wright JD, Havrilesky LJ, et al
    Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31866.
    PubMed    


  702. BREWER M, Angioli R, Scambia G, Lorusso D, et al
    Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
    PubMed     Abstract available


  703. TURNER TB, Kushner DM, Winkel AF, Oldham J, et al
    The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training.
    Gynecol Oncol. 2020 Jan 3. pii: S0090-8258(19)31797.
    PubMed     Abstract available


  704. HERZOG TJ, Secord AA, Coleman RL, Naumann RW, et al
    European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.
    Gynecol Oncol. 2020 Jan 3. pii: S0090-8258(19)31639.
    PubMed     Abstract available


  705. MULTINU F, Chen J, Madison JD, Torres M, et al
    Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31844.
    PubMed     Abstract available


  706. GORRINGE KL, Cheasley D, Wakefield MJ, Ryland GL, et al
    Therapeutic options for mucinous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836.
    PubMed     Abstract available


  707. VARGHESE A, Shih IM
    Not All Peritoneal Implants Are Created Equal.
    Gynecol Oncol. 2020;156:1-2.
    PubMed    


  708. CHODAVADIA PA, Jacobs CD, Wang F, Havrilesky LJ, et al
    Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
    Gynecol Oncol. 2020;156:154-161.
    PubMed     Abstract available


  709. FROEDING LP, Hogdall C, Kristensen E, Zobbe V, et al
    Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study.
    Gynecol Oncol. 2020;156:124-130.
    PubMed     Abstract available


  710. MHAWECH-FAUCEGLIA P, Izevbaye I, Spindler T, Wang G, et al
    Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
    Gynecol Oncol. 2020;156:6-12.
    PubMed     Abstract available


    December 2019
  711. JORGE S, McFaddin AS, Doll KM, Pennington KP, et al
    Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802.
    PubMed     Abstract available


  712. SALMINEN L, Nadeem N, Jain S, Grenman S, et al
    A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
    PubMed     Abstract available


  713. WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
    The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
    PubMed     Abstract available


  714. JONES NL, Xiu J, Rocconi RP, Herzog TJ, et al
    Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31694.
    PubMed     Abstract available


  715. KAY AH, Venn M, Urban R, Gray HJ, et al
    Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
    PubMed     Abstract available


  716. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    PubMed     Abstract available


  717. AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
    EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
    PubMed     Abstract available


  718. CLARK KT, Trimble CL
    Current status of therapeutic HPV vaccines.
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31838.
    PubMed     Abstract available


  719. VAZ J, Tian C, Richardson MT, Chan JK, et al
    Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer(R)-accredited facilities.
    Gynecol Oncol. 2019 Dec 19. pii: S0090-8258(19)31800.
    PubMed     Abstract available


  720. VARELA CAGETTI L, Zemmour C, Minsat M, Lambaudie E, et al
    Lessons from radiochemotherapy and modern image-guided adaptive brachytherapy followed by hysterectomy.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31785.
    PubMed     Abstract available


  721. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    PubMed     Abstract available


  722. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
    PubMed    


  723. NASIOUDIS D, Latif NA, Simpkins F, Cory L, et al
    Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31784.
    PubMed     Abstract available


  724. KOHUT A, Earnhardt MC, Cuccolo NG, Kim CS, et al
    Evaluating unplanned readmission and prolonged length of stay following minimally invasive surgery for endometrial cancer.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31475.
    PubMed     Abstract available


  725. YANG J, Delara R, Magrina J, Magtibay P, et al
    Comparing survival outcomes between surgical and radiographic lymph node assessment in locally advanced cervical cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31801.
    PubMed     Abstract available


  726. KRILL L, Deng W, Eskander R, Mutch D, et al
    Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31795.
    PubMed     Abstract available


  727. ZHANG H, Wu X, Xu Z, Sun Z, et al
    Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31798.
    PubMed     Abstract available


  728. BALAYA V, Bresset A, Guani B, Magaud L, et al
    Risk factors for failure of bilateral sentinel lymph node mapping in early-stage cervical cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31614.
    PubMed     Abstract available


  729. PERES LC, Sinha S, Townsend MK, Fridley BL, et al
    Predictors of survival trajectories among women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803.
    PubMed     Abstract available


  730. ZHANG W, Tan C, Xu M, Wu X, et al
    Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31681.
    PubMed     Abstract available


  731. KRIMMEL-MORRISON JD, Ghezelayagh TS, Lian S, Zhang Y, et al
    Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31783.
    PubMed     Abstract available


  732. KIM S, Park J, Chen Y, Rowe K, et al
    Long-term diabetes risk among endometrial cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31598.
    PubMed     Abstract available


  733. CARLSON JW, Kauderer J, Hutson A, Carter J, et al
    GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.
    Gynecol Oncol. 2019 Dec 11. pii: S0090-8258(19)31566.
    PubMed     Abstract available


  734. RONCOLATO FT, O'Connell RL, Joly F, Lanceley A, et al
    Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom
    Gynecol Oncol. 2019 Dec 10. pii: S0090-8258(19)31558.
    PubMed     Abstract available


  735. GRAUL A, Haggerty A, Stickley C, Kumar P, et al
    Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care services among gynecologic oncology patients: A randomized controlled trial.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31674.
    PubMed     Abstract available


  736. VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
    A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
    PubMed     Abstract available


  737. VERGOTE IB, Lund B, Peen U, Umajuridze Z, et al
    Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
    Gynecol Oncol. 2019 Dec 7. pii: S0090-8258(19)31663.
    PubMed     Abstract available


  738. GITTO SB, Kim H, Rafail S, Omran DK, et al
    An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
    PubMed     Abstract available


  739. FORSSE D, Tangen IL, Fasmer KE, Halle MK, et al
    Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
    Gynecol Oncol. 2019 Dec 5. pii: S0090-8258(19)31782.
    PubMed     Abstract available


  740. PERKINS V, Moore K, Vesely S, Matsuo K, et al
    Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy.
    Gynecol Oncol. 2019 Dec 3. pii: S0090-8258(19)31620.
    PubMed     Abstract available


  741. KLAPHEKE AK, Keegan THM, Ruskin R, Cress RD, et al
    Changes in health-related quality of life in older women after diagnosis with gynecologic cancer.
    Gynecol Oncol. 2019 Dec 2. pii: S0090-8258(19)31684.
    PubMed     Abstract available


  742. LIANG C, Liu P, Cui Z, Liang Z, et al
    Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIB cervical cancer in China, 2004-2015.
    Gynecol Oncol. 2019 Dec 2. pii: S0090-8258(19)31619.
    PubMed     Abstract available


  743. HINCHCLIFF E, Jazaeri AA
    Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
    Gynecol Oncol. 2019;155:387-388.
    PubMed    


    November 2019
  744. MYSONA DP, Tran LKH, Tran PMH, Gehrig PA, et al
    Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers.
    Gynecol Oncol. 2019 Nov 30. pii: S0090-8258(19)31601.
    PubMed     Abstract available


  745. HAN C, Perrone E, Zeybek B, Bellone S, et al
    In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Gynecol Oncol. 2019 Nov 30. pii: S0090-8258(19)31669.
    PubMed     Abstract available


  746. VERGOTE I, Heitz F, Buderath P, Powell M, et al
    A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627.
    PubMed     Abstract available


  747. SANGTANI A, Wang C, Weaver A, Hoppman NL, et al
    Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection.
    Gynecol Oncol. 2019 Nov 28. pii: S0090-8258(19)31679.
    PubMed     Abstract available


  748. TAKAYA H, Nakai H, Sakai K, Nishio K, et al
    Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664.
    PubMed     Abstract available


  749. NARASIMHULU DM, Bews KA, Hanson KT, Chang YH, et al
    Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31628.
    PubMed     Abstract available


  750. KANAO H, Omi M, Takeshima N
    Step-by-step demonstration of laparoscopic laterally extended endopelvic resection for a recurrent endometrial cancerous tumor at a sciatic foramen, with a detailed explanation of the pelvic sidewall anatomy.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31666.
    PubMed     Abstract available


  751. MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
    Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
    PubMed     Abstract available


  752. LUHRS O, Ekdahl L, Lonnerfors C, Geppert B, et al
    Combining Indocyanine Green and Tc(99)-nanocolloid does not increase the detection rate of sentinel lymph nodes in early stage cervical cancer compared to Indocyanine Green alone.
    Gynecol Oncol. 2019 Nov 26. pii: S0090-8258(19)31677.
    PubMed     Abstract available


  753. LEITAO MM JR, Zhou QC, Gomez-Hidalgo NR, Iasonos A, et al
    Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.
    Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31624.
    PubMed     Abstract available


  754. CASARIN J, Song C, Multinu F, Cappuccio S, et al
    Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs.
    Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31667.
    PubMed     Abstract available


  755. GRIFFIN NE, Buchanan TR, Smith SH, Leon AA, et al
    Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
    Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31626.
    PubMed     Abstract available


  756. KIM J, Cho YJ, Ryu JY, Hwang I, et al
    CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625.
    PubMed     Abstract available


  757. NGUYEN JMV, Bouchard-Fortier G, Covens A
    Same-day discharge of Gynecologic Oncology patients following ileostomy closure is feasible and safe.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31665.
    PubMed     Abstract available


  758. GENTRY ZL, Boitano TKL, Smith HJ, Eads DK, et al
    The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31668.
    PubMed     Abstract available


  759. SCHLAPPE BA, Weaver AL, McGree ME, Ducie J, et al
    Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31623.
    PubMed     Abstract available


  760. LIANG MI, Pisu M, Summerlin SS, Boitano TKL, et al
    Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.
    Gynecol Oncol. 2019 Nov 23. pii: S0090-8258(19)31673.
    PubMed     Abstract available


  761. MACHIDA H, Iwata T, Okugawa K, Matsuo K, et al
    Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate.
    Gynecol Oncol. 2019 Nov 23. pii: S0090-8258(19)31672.
    PubMed     Abstract available


  762. OSTBY SA, Evans JG, Smith HJ, Boitano TKL, et al
    Reducing emergency department (ED) computed tomography (CT) utilization in women treated for gynecologic cancers.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31675.
    PubMed     Abstract available


  763. COLLINS A, Miles GJ, Wood J, MacFarlane M, et al
    Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31671.
    PubMed     Abstract available


  764. MAI PL, Huang HQ, Wenzel LB, Han PK, et al
    Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613.
    PubMed     Abstract available


  765. DONKERS H, Bekkers R, Massuger L, Galaal K, et al
    Socioeconomic deprivation and survival in endometrial cancer: The effect of BMI.
    Gynecol Oncol. 2019 Nov 20. pii: S0090-8258(19)31617.
    PubMed     Abstract available


  766. HIROSE S, Murakami N, Takahashi K, Kuno I, et al
    Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31606.
    PubMed     Abstract available


  767. STASENKO M, Tunnage I, Ashley CW, Rubinstein MM, et al
    Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31615.
    PubMed     Abstract available


  768. LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
    Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
    PubMed     Abstract available


  769. MCCOMAS KN, Torgeson AM, Ager BJ, Hellekson C, et al
    The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system.
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31609.
    PubMed     Abstract available


  770. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
    PubMed    


  771. BASARAN D, Bruce S, Aviki EM, Mueller JJ, et al
    Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31562.
    PubMed     Abstract available


  772. TAYLOR SE, Chu T, Elvin JA, Edwards RP, et al
    Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31616.
    PubMed     Abstract available


  773. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Learning curve of high-complexity surgery for advanced ovarian cancer.
    Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
    PubMed     Abstract available


  774. CLARKE MA, Long BJ, Sherman ME, Lemens MA, et al
    A prospective clinical cohort study of women at increased risk for endometrial cancer.
    Gynecol Oncol. 2019 Nov 9. pii: S0090-8258(19)31534.
    PubMed     Abstract available


  775. GAGNO S, Poletto E, Bartoletti M, Quartuccio L, et al
    A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603.
    PubMed     Abstract available


  776. MOORE KN, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569.
    PubMed     Abstract available


  777. ALIMUJIANG A, Khoja L, Wiensch A, Pike MC, et al
    "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival.
    Gynecol Oncol. 2019 Nov 6. pii: S0090-8258(19)31564.
    PubMed     Abstract available


  778. HARRIS KL, Maurer KA, Jarboe E, Werner TL, et al
    LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT?
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31537.
    PubMed     Abstract available


  779. FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
    Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
    PubMed     Abstract available


  780. CECERE SC, Giannone G, Salutari V, Arenare L, et al
    Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607.
    PubMed     Abstract available


  781. WORMALD BW, Doran SJ, Ind TE, D'Arcy J, et al
    Radiomic features of cervical cancer on T2-and diffusion-weighted MRI: Prognostic value in low-volume tumors suitable for trachelectomy.
    Gynecol Oncol. 2019 Nov 1. pii: S0090-8258(19)31567.
    PubMed     Abstract available


  782. FERRISS JS, Fader AN
    Enough already: Is this the end of comprehensive lymphadenectomy in endometrial cancer or are further trials needed?
    Gynecol Oncol. 2019;155:175-176.
    PubMed    


  783. MALAGON T, Louvanto K, Ramanakumar AV, Koushik A, et al
    Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age.
    Gynecol Oncol. 2019;155:245-253.
    PubMed     Abstract available


  784. WANG W, Liu X, Hou X, Lian X, et al
    Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
    Gynecol Oncol. 2019;155:224-228.
    PubMed     Abstract available


  785. BEIRNE JP, McArt DG, Roddy A, McDermott C, et al
    Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Gynecol Oncol. 2019;155:305-317.
    PubMed     Abstract available


  786. ONG PY, Poon SL, Tan KT, Putti TC, et al
    Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Gynecol Oncol. 2019;155:275-279.
    PubMed     Abstract available


  787. BI J, Areecheewakul S, Li Y, Yang S, et al
    MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.
    Gynecol Oncol. 2019;155:349-358.
    PubMed     Abstract available


  788. KHADRAOUI W, Zeybek B, Mutlu L, Menderes G, et al
    Robotic type II B posterior exenteration for recurrent vaginal cancer.
    Gynecol Oncol. 2019;155:384-385.
    PubMed     Abstract available


    October 2019
  789. CARTER J, Huang HQ, Armer J, Carlson JW, et al
    GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).
    Gynecol Oncol. 2019 Oct 31. pii: S0090-8258(19)31539.
    PubMed     Abstract available


  790. LORUSSO D, Ferrandina G, Colombo N, Pignata S, et al
    Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
    Gynecol Oncol. 2019 Oct 30. pii: S0090-8258(19)31596.
    PubMed     Abstract available


  791. ZHOU JG, Zhao HT, Jin SH, Tian X, et al
    Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma.
    Gynecol Oncol. 2019 Oct 26. pii: S0090-8258(19)31485.
    PubMed     Abstract available


  792. O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
    A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
    PubMed     Abstract available


  793. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
    PubMed    


  794. ISHIKAWA M, Kasamatsu T, Tsuda H, Fukunaga M, et al
    A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes.
    Gynecol Oncol. 2019 Oct 18. pii: S0090-8258(19)31540.
    PubMed     Abstract available


  795. WESTIN SN, Sill MW, Coleman RL, Waggoner S, et al
    Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Oct 15. pii: S0090-8258(19)31548.
    PubMed     Abstract available


  796. TATEBE K, Hasan Y, Son CH
    Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
    Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
    PubMed     Abstract available


  797. BAIOCCHI G, Salani R
    Meeting report from the 19th meeting of the International Gynecologic Cancer Society (IGCS) 2019: Summary of selected abstracts and meeting highlights.
    Gynecol Oncol. 2019 Oct 10. pii: S0090-8258(19)31563.
    PubMed    


  798. MARCHETTI C, Rosati A, Scaletta G, Pietragalla A, et al
    Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545.
    PubMed     Abstract available


  799. VAN KOL KGG, Vergeldt TFM, Bekkers RLM
    Abdominal radical trachelectomy versus chemotherapy followed by vaginal radical trachelectomy in stage 1B2 (FIGO 2018) cervical cancer. A systematic review on fertility and recurrence rates.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31546.
    PubMed     Abstract available


  800. MULTINU F, Ducie JA, Eriksson AGZ, Schlappe BA, et al
    Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31531.
    PubMed     Abstract available


  801. KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
    Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
    PubMed     Abstract available


  802. LABIDI-GALY SI, de La Motte Rouge T, Derbel O, Wolfer A, et al
    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528.
    PubMed     Abstract available


  803. BERG T, Nottrup TJ, Roed H
    Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31547.
    PubMed     Abstract available


  804. TAYLAN E, Oktay K
    Fertility preservation in gynecologic cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31532.
    PubMed     Abstract available


  805. WU P, Xiong H, Yang M, Li L, et al
    Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31560.
    PubMed     Abstract available


  806. CHO EJ, Chun SM, Park H, Sung CO, et al
    Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31542.
    PubMed     Abstract available


  807. RAKOWSKI JA, Holloway RW, Ahmad S, Jeppson CN, et al
    A prospective randomized trial of intravenous ketorolac vs. acetaminophen administered with opioid patient-controlled analgesia in gynecologic surgery.
    Gynecol Oncol. 2019 Oct 7. pii: S0090-8258(19)31543.
    PubMed     Abstract available


  808. NOMURA H, Aoki D, Susumu N, Mizuno M, et al
    Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
    Gynecol Oncol. 2019 Oct 7. pii: S0090-8258(19)31544.
    PubMed     Abstract available


  809. ELIAS KM, Berkowitz RS, Horowitz NS
    Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough?
    Gynecol Oncol. 2019;155:1-2.
    PubMed    


  810. NICA A, Covens A, Vicus D, Kupets R, et al
    Long term outcomes in patients with sentinel lymph nodes (SLNs) identified by injecting remaining scar after previously excised vulvar cancer.
    Gynecol Oncol. 2019;155:83-87.
    PubMed     Abstract available


  811. BUCHANAN TR, Zamorano AS, Massad LS, Liu J, et al
    Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6year follow-up study.
    Gynecol Oncol. 2019;155:88-92.
    PubMed     Abstract available


  812. GULERIA C, Suri V, Kapoor R, Minz RW, et al
    Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development.
    Gynecol Oncol. 2019;155:151-160.
    PubMed     Abstract available


    September 2019
  813. HOFFMAN MS, Xiong Y, Apte S, Roberts W, et al
    Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice.
    Gynecol Oncol. 2019 Sep 28. pii: S0090-8258(19)31533.
    PubMed     Abstract available


  814. DIOUN SM, Vilardo N, Goldberg GL, Gressel GM, et al
    Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
    Gynecol Oncol. 2019 Sep 28. pii: S0090-8258(19)31529.
    PubMed     Abstract available


  815. WONG JWH, Killeen JL, Carney ME
    Completeness of salpingectomy intended for ovarian cancer risk reduction.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31523.
    PubMed     Abstract available


  816. DOCKERY LE, Rubenstein AR, Ding K, Mashburn SG, et al
    Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31394.
    PubMed     Abstract available


  817. HIMOTO Y, Cybulska P, Shitano F, Sala E, et al
    Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?
    Gynecol Oncol. 2019 Sep 11. pii: S0090-8258(19)31462.
    PubMed     Abstract available


  818. VERGOTE I, du Bois A, Floquet A, Rau J, et al
    Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31476.
    PubMed     Abstract available


  819. SCHLECHTWEG K, Chen L, St Clair CM, Tergas AI, et al
    Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31522.
    PubMed     Abstract available


  820. SWAILES A, Gupta M, Chauhan SP, Kesterson J, et al
    Factors associated with the successful completion of randomized controlled trials in gynecological oncology.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31527.
    PubMed     Abstract available


  821. OLAWAIYE AB, Leath CA 3rd
    Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31483.
    PubMed     Abstract available


  822. SIMS TT, Colbert LE, Zheng J, Delgado Medrano AY, et al
    Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31489.
    PubMed     Abstract available


  823. GRONWALD J, Lubinski J, Huzarski T, Cybulski C, et al
    A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486.
    PubMed     Abstract available


  824. MICHELS KA, McNeel TS, Trabert B
    Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: An analysis of linked SEER-Medicare data.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31484.
    PubMed     Abstract available


  825. HOLLIS RL, Stanley B, Iida Y, Thomson J, et al
    Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487.
    PubMed     Abstract available


  826. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31469.
    PubMed     Abstract available


  827. MAKII C, Ikeda Y, Oda K, Uehara Y, et al
    Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31480.
    PubMed     Abstract available


  828. AHMAD TR, Chen LM, Chapman JS, Chen LL, et al
    Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology.
    Gynecol Oncol. 2019 Sep 3. pii: S0090-8258(19)31465.
    PubMed     Abstract available


  829. KAY AH, Urban RR, Gray HJ
    Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.
    Gynecol Oncol. 2019 Sep 3. pii: S0090-8258(19)31472.
    PubMed     Abstract available


  830. MCALPINE JN, Gilks CB
    Precision medicine in endometrial cancer.
    Gynecol Oncol. 2019;154:451-453.
    PubMed    


  831. WOELBER L, Eulenburg C, Kosse J, Neuser P, et al
    Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2019;154:571-576.
    PubMed     Abstract available


  832. CHAE SH, Shim SH, Chang M, Choi AY, et al
    Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
    Gynecol Oncol. 2019;154:638-650.
    PubMed     Abstract available


  833. PARRA SG, Rodriguez AM, Cherry KD, Schwarz RA, et al
    Low-cost, high-resolution imaging for detecting cervical precancer in medically-underserved areas of Texas.
    Gynecol Oncol. 2019;154:558-564.
    PubMed     Abstract available


  834. CAPOZZI VA, Ceni V, Sozzi G, Cianciolo A, et al
    Endoscopic near infrared and indocyanine green to verify the viability of the subcutaneous flap for vulvar cancer.
    Gynecol Oncol. 2019;154:653-654.
    PubMed     Abstract available


  835. KLAPDOR R, Wolber L, Hanker L, Schmalfeldt B, et al
    Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study.
    Gynecol Oncol. 2019;154:565-570.
    PubMed     Abstract available


    August 2019
  836. TOZZI R, Traill Z, Campanile RG, Kilic Y, et al
    Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: Can laparoscopy improve the accuracy of CT scan?
    Gynecol Oncol. 2019 Aug 31. pii: S0090-8258(19)31477.
    PubMed     Abstract available


  837. BJURBERG M, Holmberg E, Borgfeldt C, Floter-Radestad A, et al
    Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31474.
    PubMed     Abstract available


  838. ELZAKKERS JCJ, van der Aa MA, van Altena AM, de Hullu JA, et al
    Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31470.
    PubMed     Abstract available


  839. RADER JS, Pan A, Corbin B, Iden M, et al
    Identification and validation of a prognostic proteomic signature for cervical cancer.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31473.
    PubMed     Abstract available


  840. HIRAO N, Iwata T, Tanaka K, Nishio H, et al
    Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31478.
    PubMed     Abstract available


  841. RAFFONE A, Travaglino A, Mascolo M, Carbone L, et al
    TCGA molecular groups of endometrial cancer: Pooled data about prognosis.
    Gynecol Oncol. 2019 Aug 29. pii: S0090-8258(19)31471.
    PubMed     Abstract available


  842. LONG ROCHE K, Gardner GJ
    State of the science: Evolving role of surgery for the treatment of ovarian cancer.
    Gynecol Oncol. 2019 Aug 28. pii: S0090-8258(19)31468.
    PubMed    


  843. CHEN LM, Blank SV, Burton E, Glass K, et al
    Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
    Gynecol Oncol. 2019 Aug 22. pii: S0090-8258(19)31333.
    PubMed     Abstract available


  844. SHUKLA V, Varghese VK, Kabekkodu SP, Mallya S, et al
    Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer.
    Gynecol Oncol. 2019 Aug 18. pii: S0090-8258(19)31463.
    PubMed     Abstract available


  845. BIANCHI A, Lopez S, Altwerger G, Bellone S, et al
    PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Gynecol Oncol. 2019 Aug 18. pii: S0090-8258(19)31461.
    PubMed     Abstract available


  846. MATSUO K, Cripe JC, Kurnit KC, Kaneda M, et al
    Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31458.
    PubMed     Abstract available


  847. LITTELL RD, Kumar A, Einstein MH, Karam A, et al
    Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guide.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31450.
    PubMed     Abstract available


  848. LIU YL, Zhou Q, Iasonos A, Emengo VN, et al
    Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
    Gynecol Oncol. 2019 Aug 14. pii: S0090-8258(19)31457.
    PubMed     Abstract available


  849. WEBBER K, Carolus E, Mileshkin L, Sommeijer D, et al
    OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.
    Gynecol Oncol. 2019 Aug 12. pii: S0090-8258(19)31460.
    PubMed     Abstract available


  850. KILTS TP, Glaser GE, Langstraat CL, Kumar A, et al
    Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31456.
    PubMed     Abstract available


  851. WADE KNS, Brady MF, Thai T, Wang Y, et al
    Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31409.
    PubMed     Abstract available


  852. WESTON E, Raker C, Huang D, Parker A, et al
    Opioid use after minimally invasive hysterectomy in gynecologic oncology patients.
    Gynecol Oncol. 2019 Aug 9. pii: S0090-8258(19)31453.
    PubMed     Abstract available


  853. TORTORELLA L, Casarin J, Multinu F, Cappuccio S, et al
    Sentinel lymph node biopsy with cervical injection of indocyanine green in apparent early-stage endometrial cancer: predictors of unsuccessful mapping.
    Gynecol Oncol. 2019 Aug 8. pii: S0090-8258(19)31459.
    PubMed     Abstract available


  854. NARASIMHULU DM, Kumar A, Weaver AL, McGree ME, et al
    Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 8. pii: S0090-8258(19)31455.
    PubMed     Abstract available


  855. LATHAM AH, Chen L, Hou JY, Tergas AI, et al
    Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation.
    Gynecol Oncol. 2019 Aug 6. pii: S0090-8258(19)31410.
    PubMed     Abstract available


  856. ZAMORANO AS, Hagemann AR, Morrison L, Lee JA, et al
    Pre-diagnosis body mass index, physical activity and ovarian cancer mortality.
    Gynecol Oncol. 2019 Aug 2. pii: S0090-8258(19)31449.
    PubMed     Abstract available


  857. KIM SI, Lee M, Lee S, Suh DH, et al
    Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea.
    Gynecol Oncol. 2019 Aug 2. pii: S0090-8258(19)31408.
    PubMed     Abstract available


  858. PUECHL AM, Chino F, Havrilesky LJ, Davidson BA, et al
    Place of death by region and urbanization among gynecologic cancer patients: 2006-2016.
    Gynecol Oncol. 2019 Aug 1. pii: S0090-8258(19)31402.
    PubMed     Abstract available


  859. KAHR HS, Christiansen OB, Hogdall C, Grove A, et al
    Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. A Danish National Cohort Study.
    Gynecol Oncol. 2019 Aug 1. pii: S0090-8258(19)31411.
    PubMed     Abstract available


  860. DUDLEY S, Viswanathan A
    Margins in vulvar cancer: challenges to classical clinicopathologic vulvar recurrence risk factors.
    Gynecol Oncol. 2019;154:253-254.
    PubMed    


  861. BEDELL SM, Hedberg C, Griffin A, Pearson H, et al
    Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins.
    Gynecol Oncol. 2019;154:276-279.
    PubMed     Abstract available


  862. SALYER C, Kobelka C, Barrie A, Weintraub MR, et al
    Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2019;154:374-378.
    PubMed     Abstract available


  863. TE GROOTENHUIS NC, Pouwer AW, de Bock GH, Hollema H, et al
    Margin status revisited in vulvar squamous cell carcinoma.
    Gynecol Oncol. 2019;154:266-275.
    PubMed     Abstract available


    July 2019
  864. BALACHANDRAN K, Salawu A, Ghorani E, Kaur B, et al
    When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients.
    Gynecol Oncol. 2019 Jul 30. pii: S0090-8258(19)31448.
    PubMed     Abstract available


  865. RANDALL LM, Wenham RM, Low PS, Dowdy SC, et al
    A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.
    Gynecol Oncol. 2019 Jul 27. pii: S0090-8258(19)31396.
    PubMed     Abstract available


  866. RAMONDETTA LM, Hu W, Thaker PH, Urbauer DL, et al
    Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
    Gynecol Oncol. 2019 Jul 25. pii: S0090-8258(19)31353.
    PubMed     Abstract available


  867. KATO K, Omi M, Fusegi A, Takeshima N, et al
    Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer.
    Gynecol Oncol. 2019 Jul 24. pii: S0090-8258(19)31404.
    PubMed     Abstract available


  868. WISSING M, Mitric C, Amajoud Z, Abitbol J, et al
    Risk factors for lymph nodes involvement in obese women with endometrial carcinomas.
    Gynecol Oncol. 2019 Jul 24. pii: S0090-8258(19)31405.
    PubMed     Abstract available


  869. BARTELS HC, Rogers AC, McSharry V, McVey R, et al
    A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
    Gynecol Oncol. 2019 Jul 23. pii: S0090-8258(19)31397.
    PubMed     Abstract available


  870. IGNATOV A, Lebius C, Ignatov T, Ivros S, et al
    Lymph node micrometastases and outcome of endometrial cancer.
    Gynecol Oncol. 2019 Jul 22. pii: S0090-8258(19)31407.
    PubMed     Abstract available


  871. CYBULSKA P, Paula ADC, Tseng J, Leitao MM Jr, et al
    Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Gynecol Oncol. 2019 Jul 21. pii: S0090-8258(19)31398.
    PubMed     Abstract available


  872. XIANG L, Ye S, Yang H
    Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity.
    Gynecol Oncol. 2019 Jul 17. pii: S0090-8258(19)31352.
    PubMed     Abstract available


  873. GADDUCCI A, Zannoni GF
    Uterine smooth muscle tumors of unknown malignant potential: A challenging question.
    Gynecol Oncol. 2019 Jul 17. pii: S0090-8258(19)31351.
    PubMed     Abstract available


  874. ZANFAGNIN V, Huang Y, Mc Gree ME, Weaver AL, et al
    Predictors of extensive lymphatic dissemination and recurrences in node-positive endometrial cancer.
    Gynecol Oncol. 2019 Jul 16. pii: S0090-8258(19)31391.
    PubMed     Abstract available


  875. SAMUEL D, Vilardo N, Isani SS, Kuo DYS, et al
    Readability assessment of online gynecologic oncology patient education materials from major governmental, non-profit and pharmaceutical organizations.
    Gynecol Oncol. 2019 Jul 16. pii: S0090-8258(19)31347.
    PubMed     Abstract available


  876. LIU B, Li L, Wang M, Wei L, et al
    Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.
    Gynecol Oncol. 2019 Jul 12. pii: S0090-8258(19)31354.
    PubMed     Abstract available


  877. LIM SL, Puechl AM, Broadwater G, Ehrisman JA, et al
    Gender variation in Medicare utilization and payments in gynecologic oncology.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31318.
    PubMed     Abstract available


  878. HUBBARD AK, Poynter JN
    Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31348.
    PubMed     Abstract available


  879. ALIMENA S, Yang DD, Melamed A, Mahal BA, et al
    Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer.
    Gynecol Oncol. 2019 Jul 7. pii: S0090-8258(19)31338.
    PubMed     Abstract available


  880. KUMAR A, Martin DP, Dhanorker SR, Brandt SR, et al
    Improving the rate of surgical normothermia in gynecologic surgery.
    Gynecol Oncol. 2019 Jul 5. pii: S0090-8258(19)31349.
    PubMed     Abstract available


  881. SUZUKI K, Nagao S, Shibutani T, Yamamoto K, et al
    Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
    Gynecol Oncol. 2019 Jul 5. pii: S0090-8258(19)31262.
    PubMed     Abstract available


  882. MATSUO K, Huang Y, Zivanovic O, Shimada M, et al
    Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
    Gynecol Oncol. 2019 Jul 3. pii: S0090-8258(19)31337.
    PubMed     Abstract available


  883. PAIK ES, Lim MC, Kim MH, Kim YH, et al
    Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028).
    Gynecol Oncol. 2019 Jul 1. pii: S0090-8258(19)31339.
    PubMed     Abstract available


  884. KUMAR A, Sheedy S, Kim B, Suidan R, et al
    Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
    Gynecol Oncol. 2019;154:72-76.
    PubMed     Abstract available


    June 2019
  885. XIANG M, English DP, Kidd EA
    Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31336.
    PubMed     Abstract available


  886. PRENDERGAST EN, Holman LL, Liu AY, Lai TS, et al
    Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31332.
    PubMed     Abstract available


  887. ABDULFATAH E, Wakeling E, Sakr S, Al-Obaidy K, et al
    Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
    Gynecol Oncol. 2019 Jun 24. pii: S0090-8258(19)31323.
    PubMed     Abstract available


  888. LI W, Meng Y, Wang Y, Cheng X, et al
    Association of age and viral factors with high-risk HPV persistence: A retrospective follow-up study.
    Gynecol Oncol. 2019 Jun 24. pii: S0090-8258(19)31270.
    PubMed     Abstract available


  889. KRANAWETTER M, Ataseven B, Grimm C, Schneider S, et al
    Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
    Gynecol Oncol. 2019 Jun 21. pii: S0090-8258(19)31331.
    PubMed     Abstract available


  890. CANAZ E, Grabowski JP, Richter R, Braicu EI, et al
    Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31327.
    PubMed     Abstract available


  891. HENGEVELD EM, Zusterzeel PLM, Lajer H, Hogdall CK, et al
    The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31317.
    PubMed     Abstract available


  892. FUH KC, Java JJ, Chan JK, Kapp DS, et al
    Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
    Gynecol Oncol. 2019 Jun 19. pii: S0090-8258(19)31257.
    PubMed     Abstract available


  893. ARMBRUSTER SD, Previs R, Soliman PT, Westin SN, et al
    Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31278.
    PubMed     Abstract available


  894. TANG M, O'Connell RL, Amant F, Beale P, et al
    PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322.
    PubMed     Abstract available


  895. DOTTINO JA, He W, Sun CC, Zhao H, et al
    Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31280.
    PubMed     Abstract available


  896. MARIANI A, Wang C, Oberg AL, Riska SM, et al
    Genes associated with bowel metastases in ovarian cancer.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31321.
    PubMed     Abstract available


  897. LIU JF, Gordon M, Veneris J, Braiteh F, et al
    Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31265.
    PubMed     Abstract available


  898. PACHE B, Joliat GR, Hubner M, Grass F, et al
    Cost-analysis of Enhanced Recovery After Surgery (ERAS) program in gynecologic surgery.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31281.
    PubMed     Abstract available


  899. CYBULSKA P, Sioulas V, Orfanelli T, Zivanovic O, et al
    Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
    Gynecol Oncol. 2019 Jun 12. pii: S0090-8258(19)31259.
    PubMed     Abstract available


  900. HORNER W, Peng K, Pleasant V, Brackmann M, et al
    Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jun 11. pii: S0090-8258(19)31267.
    PubMed     Abstract available


  901. BOITANO TKL, Barrington DA, Batra S, McGwin G Jr, et al
    Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275.
    PubMed     Abstract available


  902. BERGAMINI A, Cormio G, Ferrandina G, Lorusso D, et al
    Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31273.
    PubMed     Abstract available


  903. DICK S, Kremer WW, De Strooper LMA, Lissenberg-Witte BI, et al
    Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
    Gynecol Oncol. 2019 Jun 7. pii: S0090-8258(19)31279.
    PubMed     Abstract available


  904. HARDING BN, Delaney JA, Urban RR, Weiss NS, et al
    Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
    Gynecol Oncol. 2019 Jun 6. pii: S0090-8258(19)31274.
    PubMed     Abstract available


  905. KIM JS, Turbov J, Rosales R, Thaete LG, et al
    Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
    Gynecol Oncol. 2019 Jun 6. pii: S0090-8258(19)31266.
    PubMed     Abstract available


  906. FRAZER JL, Hook CE, Addley HC, Jackson CR, et al
    Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31277.
    PubMed     Abstract available


  907. KORSHOLM M, Gyrd-Hansen D, Mogensen O, Moller S, et al
    Long term resource consequences of a nationwide introduction of robotic surgery for women with early stage endometrial cancer.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31271.
    PubMed     Abstract available


  908. ARO K, Nieminen P, Louvanto K, Jakobsson M, et al
    Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31268.
    PubMed     Abstract available


  909. MOORE KN, Gunderson CC, Sabbatini P, McMeekin DS, et al
    A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Jun 4. pii: S0090-8258(19)30496.
    PubMed     Abstract available


  910. WRIGHT JD, Chen L, Buskwofie A, Tergas AI, et al
    Regionalization of care for women with ovarian cancer.
    Gynecol Oncol. 2019 Jun 3. pii: S0090-8258(19)31269.
    PubMed     Abstract available


  911. WILLOWS K, Kupets R, Diong C, Vicus D, et al
    Rates over time and regional variation of radical minimally invasive surgery for cervical cancer: A population based study.
    Gynecol Oncol. 2019 Jun 3. pii: S0090-8258(19)31263.
    PubMed     Abstract available


  912. WETHINGTON SL, Fader AN
    ProMisE on the horizon: molecular classification of endometrial cancer in young women.
    Gynecol Oncol. 2019;153:465-466.
    PubMed    


  913. BACKES FJ, Cohen D, Salani R, Cohn DE, et al
    Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739).
    Gynecol Oncol. 2019;153:496-499.
    PubMed     Abstract available


  914. GUAN Y, Luan Y, Xie Y, Zhou H, et al
    Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma.
    Gynecol Oncol. 2019;153:661-669.
    PubMed     Abstract available


  915. SHERMAN-SAMIS M, Onallah H, Holth A, Reich R, et al
    SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Gynecol Oncol. 2019;153:651-660.
    PubMed     Abstract available


  916. ZIGRAS T, Kupets R, Barbera L, Covens A, et al
    Uptake of sentinel lymph node procedures in women with vulvar cancer over time in a population based study.
    Gynecol Oncol. 2019;153:574-579.
    PubMed     Abstract available


    May 2019
  917. NASIOUDIS D, Kahn R, Chapman-Davis E, Frey MK, et al
    Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31260.
    PubMed     Abstract available


  918. GRETTE K, Long B, Finan MA, Rocconi RP, et al
    Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31236.
    PubMed     Abstract available


  919. WRIGHT TC JR, Stoler MH, Parvu V, Yanson K, et al
    Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, >/=21years of age, with ASC-US or LSIL cytology.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31256.
    PubMed     Abstract available


  920. NASIOUDIS D, Haggerty AF, Giuntoli RL 2nd, Burger RA, et al
    Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
    Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233.
    PubMed     Abstract available


  921. MILESHKIN L, Edmondson R, O'Connell RL, Sjoquist KM, et al
    Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
    Gynecol Oncol. 2019 May 23. pii: S0090-8258(19)31232.
    PubMed     Abstract available


  922. GUDGEON JM, Varner MW, Hashibe M, Williams MS, et al
    Is immunohistochemistry-based screening for Lynch syndrome in endometrial cancer effective? The consent's the thing.
    Gynecol Oncol. 2019 May 23. pii: S0090-8258(19)31231.
    PubMed     Abstract available


  923. MATSUO K, Mandelbaum RS, Machida H, Yoshihara K, et al
    Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis.
    Gynecol Oncol. 2019 May 23. pii: S0090-8258(19)31258.
    PubMed     Abstract available


  924. MULTINU F, Casarin J, Cappuccio S, Keeney GL, et al
    Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 May 22. pii: S0090-8258(19)31234.
    PubMed     Abstract available


  925. LIU JF, Gray KP, Wright AA, Campos S, et al
    Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
    Gynecol Oncol. 2019 May 20. pii: S0090-8258(19)31228.
    PubMed     Abstract available


  926. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181.
    PubMed     Abstract available


  927. STASENKO M, Cybulska P, Feit N, Makker V, et al
    Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31229.
    PubMed     Abstract available


  928. BROWN CL
    50th Annual Meeting of the Society of Gynecologic Oncology.
    Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31148.
    PubMed    


  929. CHAPMAN BV, Swanick CW, Ning MS, Allen PK, et al
    Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Gynecol Oncol. 2019 May 17. pii: S0090-8258(19)31227.
    PubMed     Abstract available


  930. GIL KM, Pugh SL, Klopp AH, Yeung AR, et al
    Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.
    Gynecol Oncol. 2019 May 16. pii: S0090-8258(19)31184.
    PubMed     Abstract available


  931. GRANDI G, Perrone AM, Chiossi G, Friso S, et al
    Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
    Gynecol Oncol. 2019 May 16. pii: S0090-8258(19)31186.
    PubMed     Abstract available


  932. MARU Y, Tanaka N, Itami M, Hippo Y, et al
    Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Gynecol Oncol. 2019 May 14. pii: S0090-8258(19)31230.
    PubMed     Abstract available


  933. ANDERSEN B, Christensen BS, Christensen J, Ejersbo D, et al
    HPV-prevalence in elderly women in Denmark.
    Gynecol Oncol. 2019 May 11. pii: S0090-8258(19)31182.
    PubMed     Abstract available


  934. TOMAO F, Musacchio L, Di Mauro F, Boccia SM, et al
    Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504.
    PubMed     Abstract available


  935. FILIPPOVA OT, Chi DS, Long Roche K, Sonoda Y, et al
    Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Gynecol Oncol. 2019 May 8. pii: S0090-8258(19)31185.
    PubMed     Abstract available


  936. VAN ARSDALE A, Miller DT, Kuo DY, Isani S, et al
    Association of obesity with survival in patients with endometrial cancer.
    Gynecol Oncol. 2019 May 3. pii: S0090-8258(19)30493.
    PubMed     Abstract available


  937. HOPPENOT C, Peters P, Cowan M, Moore ED, et al
    Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
    Gynecol Oncol. 2019 May 2. pii: S0090-8258(19)31183.
    PubMed     Abstract available


  938. LEDERMANN JA
    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
    Gynecol Oncol. 2019;153:213-214.
    PubMed    


  939. BLOK F, Dasgupta S, Dinjens WNM, Roes EM, et al
    Retrospective study of a 16year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Gynecol Oncol. 2019;153:326-334.
    PubMed     Abstract available


  940. AVIKI EM, Abu-Rustum NR
    When surgical innovation and payment systems collide: The sentinel lymph node story.
    Gynecol Oncol. 2019;153:215-216.
    PubMed    


  941. FOKOM DOMGUE J, Messick C, Milbourne A, Guo M, et al
    Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study.
    Gynecol Oncol. 2019;153:266-270.
    PubMed     Abstract available


  942. SYKES P, Eva L, van der Griend R, McNally O, et al
    Pathological process has a crucial role in sentinel node biopsy for vulvar cancer.
    Gynecol Oncol. 2019;153:292-296.
    PubMed     Abstract available


  943. KRASNER CN, Castro C, Penson RT, Roche M, et al
    Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin.
    Gynecol Oncol. 2019;153:223-229.
    PubMed     Abstract available


  944. POLTERAUER S, Schwameis R, Grimm C, Hillemanns P, et al
    Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.
    Gynecol Oncol. 2019;153:286-291.
    PubMed     Abstract available


    April 2019
  945. SPIRTOS NM, Enserro D, Homesley HD, Gibbons SK, et al
    The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncolo
    Gynecol Oncol. 2019 Apr 30. pii: S0090-8258(19)30433.
    PubMed     Abstract available


  946. BOUBERHAN S, Shea M, Kennedy A, Erlinger A, et al
    Financial toxicity in gynecologic oncology.
    Gynecol Oncol. 2019 Apr 30. pii: S0090-8258(19)30498.
    PubMed     Abstract available


  947. MOHANKUMAR K, Li X, Sridharan S, Karki K, et al
    Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.
    Gynecol Oncol. 2019 Apr 30. pii: S0090-8258(19)31180.
    PubMed     Abstract available


  948. ANGIOLO G, Silvestro C, Guerrieri ME, Damiano AG, et al
    Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy.
    Gynecol Oncol. 2019 Apr 29. pii: S0090-8258(19)30184.
    PubMed     Abstract available


  949. MANDELBAUM RS, Chen L, Shoupe D, Paulson RJ, et al
    Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer.
    Gynecol Oncol. 2019 Apr 26. pii: S0090-8258(19)31151.
    PubMed     Abstract available


  950. DANIELE G, Arenare L, Scambia G, Pisano C, et al
    Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507.
    PubMed     Abstract available


  951. FRANCIS SR, Ager BJ, Do OA, Huang YJ, et al
    Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)31174.
    PubMed     Abstract available


  952. POLCHER M, Rottmann M, Brugger S, Mahner S, et al
    Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients.
    Gynecol Oncol. 2019 Apr 23. pii: S0090-8258(19)30497.
    PubMed     Abstract available


  953. KENNARD JA, Stephens AJ, Ahmad S, Zhu X, et al
    Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis.
    Gynecol Oncol. 2019 Apr 23. pii: S0090-8258(19)31152.
    PubMed     Abstract available


  954. ENGLISH DP, Huang M
    Highlights from the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2019 Apr 22. pii: S0090-8258(19)31150.
    PubMed    


  955. MA S, Wang J, Han Y, Guo F, et al
    Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2019 Apr 18. pii: S0090-8258(19)30508.
    PubMed     Abstract available


  956. GORE M, Hackshaw A, Brady WE, Penson RT, et al
    An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gynecol Oncol. 2019 Apr 17. pii: S0090-8258(19)30491.
    PubMed     Abstract available


  957. BOGANI G, Chiappa V, Vinti D, Somigliana E, et al
    Long-term results of fertility-sparing treatment for early-stage cervical cancer.
    Gynecol Oncol. 2019 Apr 16. pii: S0090-8258(19)30502.
    PubMed     Abstract available


  958. LUCIDO CT, Wynja E, Madeo M, Williamson CS, et al
    Innervation of cervical carcinoma is mediated by cancer-derived exosomes.
    Gynecol Oncol. 2019 Apr 16. pii: S0090-8258(19)31149.
    PubMed     Abstract available


  959. BALAYA V, Mathevet P, Magaud L, Bonsang-Kitzis H, et al
    Predictive factors of unexpected lymphatic drainage pathways in early-stage cervical cancer.
    Gynecol Oncol. 2019 Apr 16. pii: S0090-8258(19)30503.
    PubMed     Abstract available


  960. ALHILLI MM, Elson P, Rybicki L, Khorana AA, et al
    Delay in time to surgery and impact on survival in patients with endometrial cancer: A National Cancer Database Analysis.
    Gynecol Oncol. 2019 Apr 15. pii: S0090-8258(19)30437.
    PubMed     Abstract available


  961. SWAILES AL, Hossler CE, Kesterson JP
    Pathway to the Papanicolaou smear: The development of cervical cytology in twentieth-century America and implications in the present day.
    Gynecol Oncol. 2019 Apr 14. pii: S0090-8258(19)30499.
    PubMed     Abstract available


  962. LEE L, Matulonis U
    Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
    Gynecol Oncol. 2019 Apr 14. pii: S0090-8258(19)30490.
    PubMed     Abstract available


  963. MOORE RG, Blackman A, Miller MC, Robison K, et al
    Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Gynecol Oncol. 2019 Apr 13. pii: S0090-8258(19)30501.
    PubMed     Abstract available


  964. GAILLARD SL, Andreano KJ, Gay LM, Steiner M, et al
    Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
    Gynecol Oncol. 2019 Apr 13. pii: S0090-8258(19)30505.
    PubMed     Abstract available


  965. GIULIANO AR, Joura EA, Garland SM, Huh WK, et al
    Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
    Gynecol Oncol. 2019 Apr 11. pii: S0090-8258(19)30488.
    PubMed     Abstract available


  966. LEFKOWITS C, Bevis K, Carey EC, Sheeder J, et al
    Gynecologic oncology providers endorse practice-changing impact of communication skills training.
    Gynecol Oncol. 2019 Apr 9. pii: S0090-8258(19)30435.
    PubMed     Abstract available


  967. PIGNATA S, Scambia G, Lorusso D, De Giorgi U, et al
    The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
    Gynecol Oncol. 2019 Apr 9. pii: S0090-8258(19)30495.
    PubMed     Abstract available


  968. XU X, Kong X, Liu T, Zhou L, et al
    Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.
    Gynecol Oncol. 2019 Apr 9. pii: S0090-8258(19)30500.
    PubMed     Abstract available


  969. HORSBOEL TA, Kjaer SK, Johansen C, Suppli NP, et al
    Increased risk for depression persists for years among women treated for gynecological cancers - a register-based cohort study with up to 19years of follow-up.
    Gynecol Oncol. 2019 Apr 8. pii: S0090-8258(19)30494.
    PubMed     Abstract available


  970. REIJNEN C, Kusters-Vandevelde HVN, Prinsen CF, Massuger LFAG, et al
    Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
    Gynecol Oncol. 2019 Apr 3. pii: S0090-8258(19)30270.
    PubMed     Abstract available


  971. BOGANI G, Murgia F, Ditto A, Raspagliesi F, et al
    Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30489.
    PubMed     Abstract available


  972. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30434.
    PubMed     Abstract available


  973. HARPER DM, Nieminen P, Donders G, Einstein MH, et al
    The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5years of follow-up.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30484.
    PubMed     Abstract available


  974. LEITAO MM JR
    The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery.
    Gynecol Oncol. 2019;153:1-2.
    PubMed    


  975. VAN BAAL JOAM, Van de Vijver KK, Algera MD, van der A MA, et al
    The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    Gynecol Oncol. 2019 Apr 1. pii: S0090-8258(19)30492.
    PubMed     Abstract available


  976. PUECHL AM, Edwards J, Suri A, Nakayama J, et al
    The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
    Gynecol Oncol. 2019;153:74-79.
    PubMed     Abstract available


  977. MANNING-GEIST BL, Alimena S, Del Carmen MG, Goodman A, et al
    Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
    Gynecol Oncol. 2019;153:63-67.
    PubMed     Abstract available


    March 2019
  978. COSGROVE CM, Cohn DE, Rhoades J, Felix AS, et al
    The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
    Gynecol Oncol. 2019 Mar 30. pii: S0090-8258(19)30486.
    PubMed     Abstract available


  979. VENERIS JT, Lee EK, Goebel EA, Nucci MR, et al
    Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30482.
    PubMed     Abstract available


  980. DE ARRUDA FN, Oonk MHM, Mourits MJE, de Graeff P, et al
    Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30485.
    PubMed     Abstract available


  981. LAAKSONEN MA, Arriaga ME, Canfell K, MacInnis RJ, et al
    The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30275.
    PubMed     Abstract available


  982. LEE EK, Liu JF
    Antibody-drug conjugates in gynecologic malignancies.
    Gynecol Oncol. 2019 Mar 28. pii: S0090-8258(19)30438.
    PubMed     Abstract available


  983. SECORD AA, McCollum M, Davidson BA, Broadwater G, et al
    Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Gynecol Oncol. 2019 Mar 28. pii: S0090-8258(19)30441.
    PubMed     Abstract available


  984. GUO Y, Cui W, Pei Y, Xu D, et al
    Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway.
    Gynecol Oncol. 2019 Mar 27. pii: S0090-8258(19)30136.
    PubMed     Abstract available


  985. BRITTON H, Huang L, Lum A, Leung S, et al
    Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Gynecol Oncol. 2019 Mar 25. pii: S0090-8258(19)30271.
    PubMed     Abstract available


  986. MORONEY MR, Davies KD, Wilberger AC, Sheeder J, et al
    Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30273.
    PubMed     Abstract available


  987. DISILVESTRO PA
    Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30130.
    PubMed     Abstract available


  988. MACHIDA H, Matsuo K, Yamagami W, Ebina Y, et al
    Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30436.
    PubMed     Abstract available


  989. LIN AJ, Ma S, Markovina S, Schwarz J, et al
    Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30297.
    PubMed     Abstract available


  990. HEILMANN T, Pfisterer J, Hempel AM, Sass S, et al
    Early treatment modifications improve chemotherapy adherence in ovarian cancer patients >/=70years.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30125.
    PubMed     Abstract available


  991. LAWRENSON K, Song F, Hazelett DJ, Kar SP, et al
    Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30133.
    PubMed     Abstract available


  992. HILLMAN RT, Sanchez-Migallon A, Meyer LA, Iniesta MD, et al
    Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30274.
    PubMed     Abstract available


  993. ROZENHOLC A, Samouelian V, Warkus T, Gauthier P, et al
    Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30296.
    PubMed     Abstract available


  994. HUANG M, Kamath P, Schlumbrecht M, Miao F, et al
    Identifying disparities in germline and somatic testing for ovarian cancer.
    Gynecol Oncol. 2019 Mar 16. pii: S0090-8258(19)30155.
    PubMed     Abstract available


  995. WATSON CH, Lopez-Acevedo M, Broadwater G, Kim AH, et al
    A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery.
    Gynecol Oncol. 2019 Mar 15. pii: S0090-8258(19)30131.
    PubMed     Abstract available


  996. RATNER E, Bala M, Louie-Gao M, Aydin E, et al
    Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152.
    PubMed     Abstract available


  997. LAVIE O, Chetrit A, Novikov I, Sadetzki S, et al
    Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30132.
    PubMed     Abstract available


  998. PRESCOTT LS, Taylor JS, Enbaya A, Marten CA, et al
    Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30156.
    PubMed     Abstract available


  999. RUENGKHACHORN I, Phithakwatchara N, Viriyapak B, Sangkarat S, et al
    Comparison of oncologic outcomes of unanticipated cervical carcinoma in women undergoing inadvertent simple hysterectomy and those undergoing surgical treatment after preoperative diagnosis.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30135.
    PubMed     Abstract available


  1000. MORA PAR, Sun SY, Velarde GC, Filho JR, et al
    Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Gynecol Oncol. 2019 Mar 8. pii: S0090-8258(19)30153.
    PubMed     Abstract available


  1001. MURAKAMI R, Matsumura N, Michimae H, Tanabe H, et al
    The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology G
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30120.
    PubMed     Abstract available


  1002. FELIP I, Moiola CP, Megino-Luque C, Lopez-Gil C, et al
    Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30150.
    PubMed     Abstract available


  1003. WRIGHT TC JR, Parvu V, Stoler MH, Kodsi S, et al
    HPV infections and cytologic abnormalities in vaccinated women 21-34years of age: Results from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30126.
    PubMed     Abstract available


  1004. DOO DW, Kirkland CT, Griswold LH, McGwin G, et al
    Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.
    Gynecol Oncol. 2019 Mar 6. pii: S0090-8258(19)30149.
    PubMed     Abstract available


  1005. SON JH, Kim J, Shim J, Kong TW, et al
    Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision.
    Gynecol Oncol. 2019 Mar 4. pii: S0090-8258(19)30139.
    PubMed     Abstract available


  1006. MERT I, Kumar A, Torres D, Huang Y, et al
    Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Gynecol Oncol. 2019 Mar 2. pii: S0090-8258(19)30128.
    PubMed     Abstract available


  1007. BOGANI G, Mariani A, Paolini B, Ditto A, et al
    Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
    Gynecol Oncol. 2019 Mar 1. pii: S0090-8258(19)30137.
    PubMed     Abstract available


  1008. MOSS HA, Melamed A, Wright JD
    Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research.
    Gynecol Oncol. 2019;152:533-539.
    PubMed     Abstract available


  1009. CALO C, Elliott JO, Clements A, Reid G, et al
    Cervical cancer radiation therapy compliance rates based on location of radiation therapy.
    Gynecol Oncol. 2019;152:528-532.
    PubMed     Abstract available


  1010. ZAKEM SJ, Robin TP, Smith DE, Amini A, et al
    Evolving trends in the management of high-intermediate risk endometrial cancer in the United States.
    Gynecol Oncol. 2019;152:522-527.
    PubMed     Abstract available


  1011. GRESSEL GM, Dioun SM, Richley M, Lounsbury DW, et al
    Utilizing the Patient Reported Outcomes Measurement Information System (PROMIS(R)) to increase referral to ancillary support services for severely symptomatic patients with gynecologic cancer.
    Gynecol Oncol. 2019;152:509-513.
    PubMed     Abstract available


  1012. MEYER LA, Shi Q, Lasala J, Iniesta MD, et al
    Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
    Gynecol Oncol. 2019;152:501-508.
    PubMed     Abstract available


  1013. WANG XS, Shi Q, Williams LA, Cleeland CS, et al
    Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
    Gynecol Oncol. 2019;152:492-500.
    PubMed     Abstract available


  1014. KUMAR A, Nesbitt KM, Bakkum-Gamez JN
    Quality improvement in gynecologic oncology: Current successes and future promise.
    Gynecol Oncol. 2019;152:486-491.
    PubMed     Abstract available


  1015. NGUYEN JMV, Sadeghi M, Gien LT, Covens A, et al
    Impact of a preventive bundle to reduce surgical site infections in gynecologic oncology.
    Gynecol Oncol. 2019;152:480-485.
    PubMed     Abstract available


  1016. VELENTZIS LS, Smith MA, Simms KT, Lew JB, et al
    Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.
    Gynecol Oncol. 2019;152:465-471.
    PubMed     Abstract available


  1017. KWON JS, Tinker AV, Hanley GE, Pansegrau G, et al
    BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2019;152:459-464.
    PubMed     Abstract available


  1018. TAYLOR JS, Zhang N, Rajan SS, Chavez-MacGregor M, et al
    How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
    Gynecol Oncol. 2019;152:452-458.
    PubMed     Abstract available


  1019. FOOTE JR, Secord AA, Liang MI, Ehrisman JA, et al
    Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2019;152:445-451.
    PubMed     Abstract available


  1020. SUIDAN RS, He W, Sun CC, Zhao H, et al
    National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2019;152:439-444.
    PubMed     Abstract available


  1021. HALL MT, Smith MA, Lew JB, O'Hallahan J, et al
    The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Gynecol Oncol. 2019;152:472-479.
    PubMed     Abstract available


  1022. FELDER M, Kapur A, Rakhmilevich AL, Qu X, et al
    MUC16 suppresses human and murine innate immune responses.
    Gynecol Oncol. 2019;152:618-628.
    PubMed     Abstract available


  1023. SHEU J, Palileo A, Chen MY, Hoepner L, et al
    Hospice utilization in advanced cervical malignancies: An analysis of the National Inpatient Sample.
    Gynecol Oncol. 2019;152:594-598.
    PubMed     Abstract available


    February 2019
  1024. BROOKS RA, Tritchler DS, Darcy KM, Lankes HA, et al
    GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2019 Feb 28. pii: S0090-8258(19)30138.
    PubMed     Abstract available


  1025. TIMMERMANS M, van der Hel O, Sonke GS, Van de Vijver KK, et al
    The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30129.
    PubMed     Abstract available


  1026. ARQUIETTE JM, Moss HA, Truong T, Pieper CF, et al
    Impact of a documentation intervention on health-assessment metrics on an inpatient gynecologic oncology service.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30119.
    PubMed     Abstract available


  1027. BARRINGTON DA, Dilley SE, Smith HJ, Straughn JM Jr, et al
    Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2019 Feb 24. pii: S0090-8258(19)30123.
    PubMed     Abstract available


  1028. JORGENSEN SL, Mogensen O, Petersen MA, Wu CS, et al
    New insights into early recovery after robotic surgery for endometrial cancer.
    Gynecol Oncol. 2019 Feb 23. pii: S0090-8258(19)30111.
    PubMed     Abstract available


  1029. MORSE CB, Toukatly MN, Kilgore MR, Agnew KJ, et al
    Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    Gynecol Oncol. 2019 Feb 22. pii: S0090-8258(19)30121.
    PubMed     Abstract available


  1030. HUEPENBECKER SP, Cusworth SE, Kuroki LM, Lu P, et al
    Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use.
    Gynecol Oncol. 2019 Feb 21. pii: S0090-8258(19)30127.
    PubMed     Abstract available


  1031. MCGUIRE S, Kara B, Hart PC, Montag A, et al
    Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30059.
    PubMed     Abstract available


  1032. MESQUITA KA, Alabdullah M, Griffin M, Toss MS, et al
    ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30124.
    PubMed     Abstract available


  1033. MATSUO K, Machida H, Mandelbaum RS, Grubbs BH, et al
    Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30106.
    PubMed     Abstract available


  1034. MATSUO K, Mandelbaum RS, Adams CL, Roman LD, et al
    Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
    Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30105.
    PubMed     Abstract available


  1035. RODRIGUEZ-FREIXINOS V, Lheureux S, Mandilaras V, Clarke B, et al
    Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
    Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30108.
    PubMed     Abstract available


  1036. EINSTEIN MH, Ndlovu N, Lee J, Stier EA, et al
    Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.
    Gynecol Oncol. 2019 Feb 15. pii: S0090-8258(19)30065.
    PubMed     Abstract available


  1037. VAN WALREE IC, Hamaker ME, van de Poll-Franse LV, Vos MC, et al
    Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.
    Gynecol Oncol. 2019 Feb 13. pii: S0090-8258(19)30104.
    PubMed     Abstract available


  1038. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    Gynecol Oncol. 2019 Feb 12. pii: S0090-8258(19)30113.
    PubMed     Abstract available


  1039. LIANG J, Wolsiefer K, Zestcott CA, Chase D, et al
    Implicit bias toward cervical cancer: Provider and training differences.
    Gynecol Oncol. 2019 Feb 7. pii: S0090-8258(19)30055.
    PubMed     Abstract available


  1040. SUSZYNSKA M, Klonowska K, Jasinska AJ, Kozlowski P, et al
    Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecol Oncol. 2019 Feb 4. pii: S0090-8258(19)30069.
    PubMed     Abstract available


  1041. HUTCHCRAFT ML, Smith B, McLaughlin EM, Hade EM, et al
    Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.
    Gynecol Oncol. 2019 Feb 2. pii: S0090-8258(19)30068.
    PubMed     Abstract available


  1042. LIM SL, Havrilesky LJ, Habib AS, Secord AA, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30067.
    PubMed     Abstract available


  1043. VOGEL RI, Niendorf K, Petzel S, Lee H, et al
    A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062.
    PubMed     Abstract available


  1044. VASSILAKOS P, Poncet A, Catarino R, Viviano M, et al
    Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30064.
    PubMed     Abstract available


  1045. ORSULIC S, Karlan BY
    Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?
    Gynecol Oncol. 2019;152:221-222.
    PubMed    


  1046. SOONG TR, Howitt BE, Horowitz N, Nucci MR, et al
    The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
    Gynecol Oncol. 2019;152:426-433.
    PubMed     Abstract available


  1047. XIN W, Hua K, Ding J
    The way to display the chylous tubes and to prevent chylous leakage in laparoscopic para-aortic lymphadenectomy.
    Gynecol Oncol. 2019;152:434-435.
    PubMed    


  1048. SMITH JA, Le T, Martin GA, Gaikwad A, et al
    Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Gynecol Oncol. 2019;152:265-269.
    PubMed     Abstract available


  1049. FLEM KARLSEN K, McFadden E, Florenes VA, Davidson B, et al
    Soluble AXL is ubiquitously present in malignant serous effusions.
    Gynecol Oncol. 2019;152:408-415.
    PubMed     Abstract available


  1050. XIA P, Huang M, Zhang Y, Xiong X, et al
    NCK1 promotes the angiogenesis of cervical squamous carcinoma via Rac1/PAK1/MMP2 signal pathway.
    Gynecol Oncol. 2019;152:387-395.
    PubMed     Abstract available


    January 2019
  1051. HINCHCLIFF EM, Bednar EM, Lu KH, Rauh-Hain JA, et al
    Disparities in gynecologic cancer genetics evaluation.
    Gynecol Oncol. 2019 Jan 30. pii: S0090-8258(19)30066.
    PubMed     Abstract available


  1052. NISHIO S, Mikami Y, Tokunaga H, Yaegashi N, et al
    Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.
    Gynecol Oncol. 2019 Jan 29. pii: S0090-8258(19)30063.
    PubMed     Abstract available


  1053. HOSKINS P, Eccleston A, Hurry M, Dyer M, et al
    Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061.
    PubMed     Abstract available


  1054. MODUGNO F, Goughnour SL, Wallack D, Edwards RP, et al
    Breastfeeding factors and risk of epithelial ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060.
    PubMed     Abstract available


  1055. CHOI HJ, Heo JH, Park JY, Jeong JY, et al
    A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30045.
    PubMed     Abstract available


  1056. HURLEY RM, Wahner Hendrickson AE, Visscher DW, Ansell P, et al
    53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Gynecol Oncol. 2019 Jan 24. pii: S0090-8258(19)30058.
    PubMed     Abstract available


  1057. YANG B, Xu Y, Zhu Q, Xie L, et al
    Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Gynecol Oncol. 2019 Jan 21. pii: S0090-8258(19)30056.
    PubMed     Abstract available


  1058. HOLSCHNEIDER CH, Petereit DG, Chu C, Hsu IC, et al
    Brachytherapy: A critical component of primary radiation therapy for cervical cancer: For the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).
    Gynecol Oncol. 2019 Jan 17. pii: S0090-8258(18)31297.
    PubMed     Abstract available


  1059. GOODMAN CR, Hatoum S, Seagle BL, Donnelly ED, et al
    Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer.
    Gynecol Oncol. 2019 Jan 16. pii: S0090-8258(19)30040.
    PubMed     Abstract available


  1060. PRODROMIDOU A, Iavazzo C, Fotiou A, Psomiadou V, et al
    The application of fibrin sealant for the prevention of lymphocele after lymphadenectomy in patients with gynecological malignancies: A systematic review and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2019 Jan 16. pii: S0090-8258(19)30044.
    PubMed     Abstract available


  1061. UPPENDAHL LD, Felices M, Bendzick L, Ryan C, et al
    Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039.
    PubMed     Abstract available


  1062. DING J, Cheng XY, Liu S, Ji HY, et al
    Apatinib exerts anti-tumour effects on ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30043.
    PubMed     Abstract available


  1063. CRIPE JC, Buchanan TR Jr, Kuroki LM, Wan L, et al
    Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30042.
    PubMed     Abstract available


  1064. BREGAR A, Mojtahed A, Kilcoyne A, Kurra V, et al
    CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(18)31476.
    PubMed     Abstract available


  1065. KIM SI, Cho JH, Seol A, Kim YI, et al
    Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(19)30041.
    PubMed     Abstract available


  1066. OH SH, Park SJ, Lee EJ, Yim GW, et al
    Pelvic lymphadenectomy by vaginal natural orifice transluminal endoscopic surgery (vNOTES) for early-stage endometrial cancer.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(19)30002.
    PubMed    


  1067. MCCUAIG JM, Tone AA, Maganti M, Romagnuolo T, et al
    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(18)31541.
    PubMed     Abstract available


  1068. FABBRO M, Moore KN, Dorum A, Tinker AV, et al
    Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31473.
    PubMed     Abstract available


  1069. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, >/=25years of age, with NILM cytology.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31538.
    PubMed     Abstract available


  1070. WAGNER P, Kommoss FKF, Kommoss S, Hartkopf AD, et al
    Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease.
    Gynecol Oncol. 2019 Jan 8. pii: S0090-8258(18)31540.
    PubMed     Abstract available


  1071. BONAZZOLI E, Cocco E, Lopez S, Bellone S, et al
    PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(19)30004.
    PubMed     Abstract available


  1072. WANG J, Du Y, Dong J, Zhou Y, et al
    Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
    Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(18)31542.
    PubMed     Abstract available


  1073. MATSUO K, Hom MS, Yabuno A, Shida M, et al
    Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31534.
    PubMed     Abstract available


  1074. JERZAK KJ, Duska L, MacKay HJ
    Endocrine therapy in endometrial cancer: An old dog with new tricks.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31518.
    PubMed     Abstract available


  1075. YAO T, DeJong SR, McGree ME, Weaver AL, et al
    Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31539.
    PubMed     Abstract available


  1076. FULK K, Milam MR, Li S, Yussuf A, et al
    Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31535.
    PubMed     Abstract available


  1077. LONG B, Lilyquist J, Weaver A, Hu C, et al
    Cancer susceptibility gene mutations in type I and II endometrial cancer.
    Gynecol Oncol. 2019;152:20-25.
    PubMed     Abstract available


  1078. RUSH CM, Goodfellow PJ
    Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution.
    Gynecol Oncol. 2019;152:1-2.
    PubMed    


  1079. PARK SJ, Kim HS
    Laterally extended endopelvic resection with nephrectomy for vaginal cancer.
    Gynecol Oncol. 2019;152:218-219.
    PubMed    


  1080. NICA A, Covens A, Vicus D, Kupets R, et al
    Sentinel lymph nodes in vulvar cancer: Management dilemmas in patients with positive nodes and larger tumors.
    Gynecol Oncol. 2019;152:94-100.
    PubMed     Abstract available


  1081. SAND FL, Nielsen DMB, Frederiksen MH, Rasmussen CL, et al
    The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2019;152:208-217.
    PubMed     Abstract available


  1082. LOOPIK DL, Bekkers RLM, Massuger LFAG, Melchers WJG, et al
    Justifying conservative management of CIN2 in women younger than 25years - A population-based study.
    Gynecol Oncol. 2019;152:82-86.
    PubMed     Abstract available


  1083. SALCEDO MP, Sood AK, Dos Reis R, Ramalingam P, et al
    Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.
    Gynecol Oncol. 2019;152:101-105.
    PubMed     Abstract available


  1084. SULLIVAN MW, Camacho FT, Mills AM, Modesitt SC, et al
    Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
    Gynecol Oncol. 2019;152:119-126.
    PubMed     Abstract available


    December 2018
  1085. LING DC, Vargo JA, Glaser SM, Kim H, et al
    Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.
    Gynecol Oncol. 2018 Dec 29. pii: S0090-8258(18)31536.
    PubMed     Abstract available


  1086. MATULONIS UA, Sill MW, Makker V, Mutch DG, et al
    A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Dec 23. pii: S0090-8258(18)31460.
    PubMed     Abstract available


  1087. ZHANG L, Jiang Y, Lu X, Zhao H, et al
    Genomic characterization of cervical cancer based on human papillomavirus status.
    Gynecol Oncol. 2018 Dec 20. pii: S0090-8258(18)31516.
    PubMed     Abstract available


  1088. ROSS JGC, Escamilla V, Lee NK, Diane Yamada S, et al
    Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.
    Gynecol Oncol. 2018 Dec 20. pii: S0090-8258(18)31470.
    PubMed     Abstract available


  1089. RAUH-HAIN JA, Hidrue MK, Gaccione P, Melamed A, et al
    Variation in resource utilization associated with the surgical management of ovarian cancer.
    Gynecol Oncol. 2018 Dec 19. pii: S0090-8258(18)31513.
    PubMed     Abstract available


  1090. MYSONA D, Pyrzak A, Purohit S, Zhi W, et al
    A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31515.
    PubMed     Abstract available


  1091. CEPPI L, Galli F, Lamanna M, Magni S, et al
    Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31452.
    PubMed     Abstract available


  1092. BULLS HW, Hoogland AI, Kennedy B, James BW, et al
    A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31458.
    PubMed     Abstract available


  1093. NIE D, Gong H, Mao X, Li Z, et al
    Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31454.
    PubMed     Abstract available


  1094. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31471.
    PubMed    


  1095. DAVIDSON BA, Broadwater G, Crim A, Boccacio R, et al
    Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31475.
    PubMed     Abstract available


  1096. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31456.
    PubMed     Abstract available


  1097. XIANG M, English DP, Kidd EA
    National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31472.
    PubMed     Abstract available


  1098. NORQUIST BM
    Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31459.
    PubMed    


  1099. BEDNAR EM, Sun CC, Camacho B, Terrell J, et al
    Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31457.
    PubMed     Abstract available


  1100. LAW KE, Hildebrand EA, Hawthorne HJ, Hallbeck MS, et al
    A pilot study of non-routine events in gynecological surgery: Type, impact, and effect.
    Gynecol Oncol. 2018 Dec 6. pii: S0090-8258(18)31455.
    PubMed     Abstract available


  1101. VARGA A, Piha-Paul S, Ott PA, Mehnert JM, et al
    Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
    Gynecol Oncol. 2018 Dec 3. pii: S0090-8258(18)31418.
    PubMed     Abstract available


  1102. DUSKA LR
    Evolving times and paradigms in endometrial cancer: Incorporating and interpreting new data and technologic advances.
    Gynecol Oncol. 2018;151:393-394.
    PubMed    


  1103. GAFFNEY DK, Hashibe M, Kepka D, Maurer KA, et al
    Too many women are dying from cervix cancer: Problems and solutions.
    Gynecol Oncol. 2018;151:547-554.
    PubMed     Abstract available


  1104. VAN DER LINDEN M, van Esch E, Bulten J, Dreef E, et al
    The immune cell infiltrate in the microenvironment of vulvar Paget disease.
    Gynecol Oncol. 2018;151:453-459.
    PubMed     Abstract available


    November 2018
  1105. TORRES D, Kumar A, Bakkum-Gamez JN, Weaver AL, et al
    Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31420.
    PubMed     Abstract available


  1106. HAY CM, Donovan HS, Campbell GB, Taylor SE, et al
    Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31451.
    PubMed     Abstract available


  1107. STANLEY B, Hollis RL, Nunes H, Towler JD, et al
    Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
    Gynecol Oncol. 2018 Nov 27. pii: S0090-8258(18)31450.
    PubMed     Abstract available


  1108. PENN CA, Kamdar NS, Morgan DM, Spencer RJ, et al
    Preoperatively predicting non-home discharge after surgery for gynecologic malignancy.
    Gynecol Oncol. 2018 Nov 26. pii: S0090-8258(18)31449.
    PubMed     Abstract available


  1109. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    PubMed     Abstract available


  1110. ALBEESH R, Turgeon GA, Alfieri J, Mansure JJ, et al
    Adjuvant therapy in stage III endometrial cancer confined to the pelvis.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31364.
    PubMed     Abstract available


  1111. FRIJSTEIN MM, Lok CAR, van Trommel NE, Ten Kate-Booij MJ, et al
    Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31416.
    PubMed     Abstract available


  1112. WISWELL S, Bell JG, McHale J, Elliott JO, et al
    The effect of art therapy on the quality of life in patients with a gynecologic cancer receiving chemotherapy.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31446.
    PubMed     Abstract available


  1113. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    PubMed     Abstract available


  1114. JAVELLANA M, Hoppenot C, Lengyel E
    The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
    PubMed     Abstract available


  1115. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
    Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
    Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
    PubMed     Abstract available


  1116. SANJIDA S, Janda M, McPhail SM, Kissane D, et al
    How many patients enter endometrial cancer surgery with psychotropic medication prescriptions, and how many receive a new prescription perioperatively?
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31419.
    PubMed     Abstract available


  1117. ZHU B, Pan Y, Zheng X, Zhang Q, et al
    A clinical, biologic and mechanistic analysis of the role of ZNF692 in cervical cancer.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31423.
    PubMed     Abstract available


  1118. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
    Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
    PubMed     Abstract available


  1119. PRADER S, Vollmar N, du Bois A, Heitz F, et al
    Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2018 Nov 18. pii: S0090-8258(18)31363.
    PubMed     Abstract available


  1120. GONZALEZ MARTIN A, Oza AM, Embleton AC, Pfisterer J, et al
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31166.
    PubMed     Abstract available


  1121. ZHANG Q, Wang C, Cliby WA
    Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415.
    PubMed     Abstract available


  1122. ROMEO C, Joly F, Ray-Coquard I, El Kouri C, et al
    Non-pegylated liposomal doxorubicin (NPLD, Myocet(R))+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358.
    PubMed     Abstract available


  1123. KOTOULA V, Lakis S, Tikas I, Giannoulatou E, et al
    Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417.
    PubMed     Abstract available


  1124. SIN STK, Li Y, Liu M, Ma S, et al
    TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling.
    Gynecol Oncol. 2018 Nov 12. pii: S0090-8258(18)31354.
    PubMed     Abstract available


  1125. SPEES LP, Wheeler SB, Varia M, Weinberger M, et al
    Evaluating the urban-rural paradox: The complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients.
    Gynecol Oncol. 2018 Nov 12. pii: S0090-8258(18)31407.
    PubMed     Abstract available


  1126. UPPAL S, Rebecca Liu J, Kevin Reynolds R, Rice LW, et al
    Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012-2015).
    Gynecol Oncol. 2018 Nov 10. pii: S0090-8258(18)31246.
    PubMed     Abstract available


  1127. BUCKINGHAM L, Haggerty A, Graul A, Morgan M, et al
    Sexual function following hysterectomy for endometrial cancer: A five-year follow up investigation.
    Gynecol Oncol. 2018 Nov 9. pii: S0090-8258(18)31308.
    PubMed     Abstract available


  1128. TORTORELLA L, Casarin J, Mara KC, Weaver AL, et al
    Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31350.
    PubMed     Abstract available


  1129. KURNIT KC, Previs RA, Soliman PT, Westin SN, et al
    Prognostic factors impacting survival in early stage uterine carcinosarcoma.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31317.
    PubMed     Abstract available


  1130. ASHLEY CW, Da Cruz Paula A, Kumar R, Mandelker D, et al
    Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31316.
    PubMed     Abstract available


  1131. HALL E, Finch A, Jacobson M, Rosen B, et al
    Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31355.
    PubMed     Abstract available


  1132. ZHONG Q, Hu Z, Li Q, Yi T, et al
    Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31310.
    PubMed     Abstract available


  1133. TURASHVILI G, Gomez-Hidalgo NR, Flynn J, Gonen M, et al
    Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
    Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315.
    PubMed     Abstract available


  1134. LEE JY, Park JY, Park SY, Lee JW, et al
    Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31314.
    PubMed     Abstract available


  1135. MULLEN MM, Kuroki LM, Thaker PH
    Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306.
    PubMed     Abstract available


  1136. SPENCER RJ, Rice LW, Ye C, Woo K, et al
    Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores.
    Gynecol Oncol. 2018 Nov 4. pii: S0090-8258(18)31302.
    PubMed     Abstract available


  1137. SELLA T, Stone RM
    The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.
    Gynecol Oncol. 2018;151:187-189.
    PubMed    


  1138. LEEMAN A, Ebisch RMF, Kasius A, Bosgraaf RP, et al
    Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
    Gynecol Oncol. 2018;151:311-318.
    PubMed     Abstract available


  1139. FIANO V, Trevisan M, Fasanelli F, Grasso C, et al
    Methylation in host and viral genes as marker of aggressiveness in cervical lesions: Analysis in 543 unscreened women.
    Gynecol Oncol. 2018;151:319-326.
    PubMed     Abstract available


  1140. SPAANS VM, Scheunhage DA, Barzaghi B, de Kroon CD, et al
    Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.
    Gynecol Oncol. 2018;151:196-201.
    PubMed     Abstract available


    October 2018
  1141. MATSUO K, Machida H, Mandelbaum RS, Konishi I, et al
    Validation of the 2018 FIGO cervical cancer staging system.
    Gynecol Oncol. 2018 Oct 30. pii: S0090-8258(18)31309.
    PubMed     Abstract available


  1142. WANG Y, Jiang J, He L, Gong G, et al
    Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
    Gynecol Oncol. 2018 Oct 29. pii: S0090-8258(18)31313.
    PubMed     Abstract available


  1143. DUSKA LR, Suh DH, Wilson M, Diane Yamada S, et al
    International Gynecologic Cancer Society (IGCS) 2018: Meeting report.
    Gynecol Oncol. 2018 Oct 27. pii: S0090-8258(18)31301.
    PubMed    


  1144. TANGEN IL, Fasmer KE, Konings GF, Jochems A, et al
    Blood steroids are associated with prognosis and fat distribution in endometrial cancer.
    Gynecol Oncol. 2018 Oct 26. pii: S0090-8258(18)31307.
    PubMed     Abstract available


  1145. DING L, Ding Y, Kong X, Wu J, et al
    Dysregulation of Kruppel-like factor 12 in the development of endometrial cancer.
    Gynecol Oncol. 2018 Oct 25. pii: S0090-8258(18)31311.
    PubMed     Abstract available


  1146. HANSEN JM, Sood AK, Coleman RL, Westin SN, et al
    Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31299.
    PubMed     Abstract available


  1147. HINCHCLIFF E, Hong D, Le H, Chisholm G, et al
    Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31287.
    PubMed     Abstract available


  1148. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303.
    PubMed    


  1149. CIBULA D, Abu-Rustum NR, Fischerova D, Pather S, et al
    Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.
    Gynecol Oncol. 2018 Oct 20. pii: S0090-8258(18)31298.
    PubMed     Abstract available


  1150. TA RM, Hecht JL, Lin DI
    Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Gynecol Oncol. 2018 Oct 16. pii: S0090-8258(18)31291.
    PubMed     Abstract available


  1151. HUANG C, Lu H, Li J, Xie X, et al
    SOX2 regulates radioresistance in cervical cancer via the hedgehog signaling pathway.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31284.
    PubMed     Abstract available


  1152. TANNER EJ, Filippova OT, Gardner GJ, Long Roche KC, et al
    A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31285.
    PubMed     Abstract available


  1153. SAPIENZA LG, Jhingran A, Kollmeier MA, Lin LL, et al
    Decrease in uterine perforations with ultrasound image-guided applicator insertion in intracavitary brachytherapy for cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2018 Oct 14. pii: S0090-8258(18)31290.
    PubMed     Abstract available


  1154. CARTER NJ, Marshall ML, Susswein LR, Zorn KK, et al
    Germline pathogenic variants identified in women with ovarian tumors.
    Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249.
    PubMed     Abstract available


  1155. CIBULA D, McCluggage WG
    Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions.
    Gynecol Oncol. 2018 Oct 11. pii: S0090-8258(18)31286.
    PubMed     Abstract available


  1156. SALINARO JR, Puechl AM, Havrilesky LJ, Davidson BA, et al
    Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31288.
    PubMed     Abstract available


  1157. KIM HS, Kim JY, Lee YJ, Kim SH, et al
    Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31153.
    PubMed     Abstract available


  1158. NAUMANN RW, Morris JC, Tait DL, Higgins RV, et al
    Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31282.
    PubMed     Abstract available


  1159. MONK BJ, Kauderer JT, Moxley KM, Bonebrake AJ, et al
    A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31281.
    PubMed     Abstract available


  1160. BELUR NAGARAJ A, Joseph P, Kovalenko O, Wang Q, et al
    Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
    Gynecol Oncol. 2018 Oct 6. pii: S0090-8258(18)31238.
    PubMed     Abstract available


  1161. WANG J, Dean DC, Hornicek FJ, Shi H, et al
    RNA sequencing (RNA-Seq) and its application in ovarian cancer.
    Gynecol Oncol. 2018 Oct 5. pii: S0090-8258(18)31283.
    PubMed     Abstract available


  1162. RASH JK, Lyle KD, Jairam-Thodla A, Ioffe Y, et al
    Delivery of gynecologic oncology care: Optimizing scope of advanced practice providers to enhance patient care: A Society of Gynecologic Oncology Position Paper.
    Gynecol Oncol. 2018 Oct 4. pii: S0090-8258(18)31237.
    PubMed    


  1163. WANG W, Zou W, Liu JR
    Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Gynecol Oncol. 2018;151:1-3.
    PubMed    


  1164. ALOISI A, Casanova JM, Tseng JH, Seader KA, et al
    Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.
    Gynecol Oncol. 2018 Oct 1. pii: S0090-8258(18)31240.
    PubMed     Abstract available


  1165. MARTINEZ-GOMEZ C, Angeles MA, Martinez A, Ferron G, et al
    Creation of a Miami Pouch in 10 logical steps.
    Gynecol Oncol. 2018;151:178-179.
    PubMed    


  1166. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
    Gynecol Oncol. 2018;151:180-181.
    PubMed    


  1167. RODRIGUES LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, et al
    Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajos region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.
    Gynecol Oncol. 2018;151:102-110.
    PubMed     Abstract available


  1168. HORNE ZD, Dohopolski MJ, Pradhan D, Bhargava R, et al
    Human papillomavirus infection mediates response and outcome of vulvar squamous cell carcinomas treated with radiation therapy.
    Gynecol Oncol. 2018;151:96-101.
    PubMed     Abstract available


    September 2018
  1169. ELNAGGAR AC, Hade EM, O'Malley DM, Liang MI, et al
    Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2018 Sep 30. pii: S0090-8258(18)31233.
    PubMed     Abstract available


  1170. NASSER S, Lathouras K, Nixon K, Campbell J, et al
    Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 29. pii: S0090-8258(18)31247.
    PubMed     Abstract available


  1171. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31241.
    PubMed    


  1172. ZHANG L, Xu XQ, Hu SY, Chen F, et al
    Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31231.
    PubMed     Abstract available


  1173. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
    Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
    PubMed     Abstract available


  1174. MANGILI G, Cioffi R, Danese S, Frigerio L, et al
    Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31244.
    PubMed     Abstract available


  1175. WANG W, Zhang F, Hu K, Hou X, et al
    Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer.
    Gynecol Oncol. 2018 Sep 25. pii: S0090-8258(18)31243.
    PubMed     Abstract available


  1176. LIM SL, Moss HA, Secord AA, Lee PS, et al
    Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31239.
    PubMed     Abstract available


  1177. NIEMI RJ, Roine AN, Eraviita E, Kumpulainen PS, et al
    FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31235.
    PubMed     Abstract available


  1178. TAYLOR JS, He W, Harrison R, Zhao H, et al
    Disparities in treatment and survival among elderly ovarian cancer patients.
    Gynecol Oncol. 2018 Sep 22. pii: S0090-8258(18)31171.
    PubMed     Abstract available


  1179. HANNIBAL CG, Dehlendorff C, Kjaer SK
    Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31242.
    PubMed     Abstract available


  1180. ZIVANOVIC O, Chi DS, Filippova O, Randall LM, et al
    It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31218.
    PubMed     Abstract available


  1181. HUA W, Zhao Y, Jin X, Yu D, et al
    METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31234.
    PubMed     Abstract available


  1182. BOITANO TKL, Smith HJ, Rushton T, Johnston MC, et al
    Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.
    Gynecol Oncol. 2018 Sep 20. pii: S0090-8258(18)31220.
    PubMed     Abstract available


  1183. ROBERTS ME, Aynardi JT, Chu CS
    Uterine leiomyosarcoma: A review of the literature and update on management options.
    Gynecol Oncol. 2018 Sep 20. pii: S0090-8258(18)31221.
    PubMed     Abstract available


  1184. DOWDY SC, Cliby WA, Famuyide AO
    Quality indicators in gynecologic oncology.
    Gynecol Oncol. 2018 Sep 13. pii: S0090-8258(18)31175.
    PubMed    


  1185. WANG D, Cao D, Jia C, Huang H, et al
    Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
    Gynecol Oncol. 2018 Sep 12. pii: S0090-8258(18)31214.
    PubMed     Abstract available


  1186. ODA K, Hamanishi J, Matsuo K, Hasegawa K, et al
    Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Gynecol Oncol. 2018 Sep 11. pii: S0090-8258(18)31174.
    PubMed     Abstract available


  1187. JAZAERI A, Coleman RL, Sood AK, Frumovitz MM, et al
    A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Gynecol Oncol. 2018 Sep 10. pii: S0090-8258(18)31167.
    PubMed     Abstract available


  1188. AZIZ D, Etemadmoghadam D, Caldon CE, Au-Yeung G, et al
    19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Gynecol Oncol. 2018 Sep 9. pii: S0090-8258(18)31169.
    PubMed     Abstract available


  1189. ZHAO H, Yu H, Zheng J, Ning N, et al
    Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31162.
    PubMed     Abstract available


  1190. CONNOR JP, O'Shea A, McCool K, Sampene E, et al
    Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31170.
    PubMed     Abstract available


  1191. MATSUO K, Machida H, Mandelbaum RS, Ragab OM, et al
    Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31165.
    PubMed     Abstract available


  1192. RAJKUMAR S, Polson A, Nath R, Lane G, et al
    Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31172.
    PubMed     Abstract available


  1193. GHELARDI A, Parazzini F, Martella F, Pieralli A, et al
    SPERANZA project: HPV vaccination after treatment for CIN2.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31163.
    PubMed    


  1194. KIM HJ, Chang JS, Koom WS, Lee KC, et al
    Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer.
    Gynecol Oncol. 2018 Sep 5. pii: S0090-8258(18)31158.
    PubMed     Abstract available


  1195. SCURRY J, van Zyl B, Gulliver D, Otton G, et al
    Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31160.
    PubMed     Abstract available


  1196. SIMONDS HM, Botha MH, Neugut AI, Van Der Merwe FH, et al
    Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31168.
    PubMed     Abstract available


  1197. LIU Y, Weber Z, San Lucas FA, Deshpande A, et al
    Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31173.
    PubMed     Abstract available


  1198. MILLS KA, Roach ST, Quinn JM, Guo L, et al
    SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecol Oncol. 2018 Sep 3. pii: S0090-8258(18)31097.
    PubMed     Abstract available


  1199. TSENG JH, Cowan RA, Afonso AM, Zhou Q, et al
    Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154.
    PubMed     Abstract available


  1200. YEN TT, Miyamoto T, Asaka S, Chui MH, et al
    Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
    Gynecol Oncol. 2018;150:426-431.
    PubMed     Abstract available


  1201. DE VINCENZO R, Tortorella L, Ricci C, Cavaliere AF, et al
    Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome.
    Gynecol Oncol. 2018;150:398-405.
    PubMed     Abstract available


  1202. DEL CARMEN MG, Pareja R, Melamed A, Rodriguez J, et al
    Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.
    Gynecol Oncol. 2018;150:406-411.
    PubMed     Abstract available


  1203. ZIEBA S, Kowalik A, Zalewski K, Rusetska N, et al
    Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Gynecol Oncol. 2018;150:552-561.
    PubMed     Abstract available


    August 2018
  1204. TEW WP, Sill MW, Walker JL, Secord AA, et al
    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31157.
    PubMed     Abstract available


  1205. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
    Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
    PubMed     Abstract available


  1206. BOARDMAN CH, Brady WE, Dizon DS, Kunos CA, et al
    A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologi
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31095.
    PubMed     Abstract available


  1207. KIM SR, Pina A, Albert A, McAlpine J, et al
    Does MMR status in endometrial cancer influence response to adjuvant therapy?
    Gynecol Oncol. 2018 Aug 29. pii: S0090-8258(18)31151.
    PubMed     Abstract available


  1208. SHINDE A, Li R, Amini A, Chen YJ, et al
    Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31159.
    PubMed     Abstract available


  1209. VAN NIEUWENHUYSEN E, Busschaert P, Neven P, Han SN, et al
    The genetic landscape of 87 ovarian germ cell tumors.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31130.
    PubMed     Abstract available


  1210. LYCKE M, Kristjansdottir B, Sundfeldt K
    A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31155.
    PubMed     Abstract available


  1211. DIOUN S, Jorgensen JR, Miller EM, Tymon-Rosario J, et al
    Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31150.
    PubMed     Abstract available


  1212. YUK JS, Lee JH
    Six-year survival of patients with unsuspected uterine malignancy after laparoscopic versus laparotomic myomectomy: An 11-year national retrospective cohort study.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31156.
    PubMed     Abstract available


  1213. RAUH-HAIN JA, Brewster WR, Behbakht K
    Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31149.
    PubMed    


  1214. CHANG JS, Kim SW, Kim YJ, Kim JY, et al
    Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31129.
    PubMed     Abstract available


  1215. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver.
    Gynecol Oncol. 2018 Aug 20. pii: S0090-8258(18)31134.
    PubMed     Abstract available


  1216. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Aug 19. pii: S0090-8258(18)31085.
    PubMed     Abstract available


  1217. TSENG JH, Cowan RA, Zhou Q, Iasonos A, et al
    Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Gynecol Oncol. 2018 Aug 17. pii: S0090-8258(18)31131.
    PubMed     Abstract available


  1218. SON JH, Lee JH, Jung JA, Kong TW, et al
    Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2018 Aug 16. pii: S0090-8258(18)31098.
    PubMed     Abstract available


  1219. BARBER EL, Rossi EC, Alexander A, Bilimoria K, et al
    Benign hysterectomy performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31127.
    PubMed     Abstract available


  1220. PERES LC, Cushing-Haugen KL, Anglesio M, Wicklund K, et al
    Histotype classification of ovarian carcinoma: A comparison of approaches.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31133.
    PubMed     Abstract available


  1221. ULM MA, ElNaggar AC, Tillmanns TD
    Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31132.
    PubMed     Abstract available


  1222. CONNOR EV, Newlin EM, Jelovsek JE, AlHilli MM, et al
    Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Gynecol Oncol. 2018 Aug 11. pii: S0090-8258(18)31128.
    PubMed     Abstract available


  1223. BISCH SP, Wells T, Gramlich L, Faris P, et al
    Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes.
    Gynecol Oncol. 2018 Aug 9. pii: S0090-8258(18)31096.
    PubMed     Abstract available


  1224. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].
    Gynecol Oncol. 2018 Aug 7. pii: S0090-8258(18)31079.
    PubMed    


  1225. MOORE KN, O'Malley DM, Vergote I, Martin LP, et al
    Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2018 Aug 6. pii: S0090-8258(18)31081.
    PubMed     Abstract available


  1226. MALLEN A, Soong TR, Townsend MK, Wenham RM, et al
    Surgical prevention strategies in ovarian cancer.
    Gynecol Oncol. 2018 Aug 4. pii: S0090-8258(18)31094.
    PubMed     Abstract available


  1227. LI A, Xie R, Zhi Q, Deng Y, et al
    BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31088.
    PubMed     Abstract available


  1228. WORTMAN BG, Bosse T, Nout RA, Lutgens LCHW, et al
    Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31084.
    PubMed     Abstract available


  1229. PINTO MP, Balmaceda C, Bravo ML, Kato S, et al
    Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31089.
    PubMed     Abstract available


  1230. WILFORD J, Osann K, Hsieh S, Monk B, et al
    Validation of PROMIS emotional distress short form scales for cervical cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31086.
    PubMed     Abstract available


  1231. LEE J, Gubernick LR, Brodsky AL, Fehniger JE, et al
    Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.
    Gynecol Oncol. 2018 Aug 1. pii: S0090-8258(18)31087.
    PubMed     Abstract available


  1232. LEVINE DA
    The limits of aggressive surgical cytoreduction.
    Gynecol Oncol. 2018;150:205-206.
    PubMed    


  1233. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    Laparoscopic hand-assisted Miami Pouch after pelvic exenteration in 10 steps.
    Gynecol Oncol. 2018;150:389-390.
    PubMed     Abstract available


  1234. MANNING-GEIST BL, Hicks-Courant K, Gockley AA, Clark RM, et al
    Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Gynecol Oncol. 2018;150:233-238.
    PubMed     Abstract available


  1235. SHAH R, Xia C, Krailo M, Amatruda JF, et al
    Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
    Gynecol Oncol. 2018;150:253-260.
    PubMed     Abstract available


    July 2018
  1236. BEHBAKHT K, Cohn DE, Straughn JM Jr
    Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Gynecol Oncol. 2018 Jul 30. pii: S0090-8258(18)31083.
    PubMed    


  1237. SONG M, Kumaran MN, Gounder M, Gibbon DG, et al
    Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecol Oncol. 2018 Jul 29. pii: S0090-8258(18)31014.
    PubMed     Abstract available


  1238. VERGOTE I, von Moos R, Manso L, Van Nieuwenhuysen E, et al
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
    Gynecol Oncol. 2018 Jul 27. pii: S0090-8258(18)31082.
    PubMed     Abstract available


  1239. MATSUO K, Blake EA, Machida H, Mandelbaum RS, et al
    Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31080.
    PubMed     Abstract available


  1240. MEAGHER NS, Schuster K, Voss A, Budden T, et al
    Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31077.
    PubMed     Abstract available


  1241. WEBSTER EM, Burke WM, Ware HM, Jones BA, et al
    Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31064.
    PubMed     Abstract available


  1242. NISHIO S, Shimokawa M, Tasaki K, Nasu H, et al
    A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31078.
    PubMed     Abstract available


  1243. CHAN JK, Gardner AB, Mann AK, Kapp DS, et al
    Hospital-acquired conditions after surgery for gynecologic cancer - An analysis of 82,304 patients.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31065.
    PubMed     Abstract available


  1244. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma.
    Gynecol Oncol. 2018 Jul 19. pii: S0090-8258(18)31067.
    PubMed     Abstract available


  1245. GREEN RW, Valentin L, Alcazar JL, Chiappa V, et al
    Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy.
    Gynecol Oncol. 2018 Jul 17. pii: S0090-8258(18)31009.
    PubMed     Abstract available


  1246. BI Y, Verginadis II, Dey S, Lin L, et al
    Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Gynecol Oncol. 2018 Jul 16. pii: S0090-8258(18)31015.
    PubMed     Abstract available


  1247. TIWARI R, Narayanan GS, Jayakumar V, Narayanan S, et al
    The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario.
    Gynecol Oncol. 2018 Jul 14. pii: S0090-8258(18)31068.
    PubMed     Abstract available


  1248. GALINDO LJ, Hernandez-Beeftink T, Salas A, Jung Y, et al
    HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
    Gynecol Oncol. 2018 Jul 12. pii: S0090-8258(18)31063.
    PubMed     Abstract available


  1249. BARNARD ME, Pyden A, Rice MS, Linares M, et al
    Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31016.
    PubMed     Abstract available


  1250. TIMMERMANS M, van der Aa MA, Lalisang RI, Witteveen PO, et al
    Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31017.
    PubMed     Abstract available


  1251. DENG K, Yang C, Tan Q, Song W, et al
    Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31004.
    PubMed     Abstract available


  1252. XUE R, Cai X, Xu H, Wu S, et al
    The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis.
    Gynecol Oncol. 2018 Jul 8. pii: S0090-8258(18)31018.
    PubMed     Abstract available


  1253. BURGER RA, Deng W, Makker V, Collins Y, et al
    Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Jul 2. pii: S0090-8258(18)30999.
    PubMed     Abstract available


  1254. SECORD AA, Previs RA, Nixon AB
    Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Gynecol Oncol. 2018;150:1-2.
    PubMed    


  1255. CIUCCI A, Ferrandina G, Mascilini F, Filippetti F, et al
    Estrogen receptor beta: Potential target for therapy in adult granulosa cell tumors?
    Gynecol Oncol. 2018;150:158-165.
    PubMed     Abstract available


  1256. NALDINI A, Vizzielli G, Perrone E, Gallotta V, et al
    Robotic video endoscopic inguinal lymphadenectomy (R-VEIL) for vulvar cancer with sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology.
    Gynecol Oncol. 2018;150:203-204.
    PubMed     Abstract available


  1257. MARTINEZ-GOMEZ C, Angeles MA, Martinez A, Ferron G, et al
    Laparoscopic anterior pelvic exenteration in 10 steps.
    Gynecol Oncol. 2018;150:201-202.
    PubMed    


  1258. LEES BF, Stewart TP, Rash JK, Baron SR, et al
    Abuse, cancer and sexual dysfunction in women: A potentially vicious cycle.
    Gynecol Oncol. 2018;150:166-172.
    PubMed     Abstract available


  1259. CHARAKORN C, Thadanipon K, Chaijindaratana S, Rattanasiri S, et al
    The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2018;150:190-200.
    PubMed     Abstract available


    June 2018
  1260. MEYER LA, He W, Sun CC, Zhao H, et al
    Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Gynecol Oncol. 2018 Jun 29. pii: S0090-8258(18)31002.
    PubMed     Abstract available


  1261. ROGERI CD, Silveira HCS, Causin RL, Villa LL, et al
    Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30990.
    PubMed     Abstract available


  1262. ZHANG XS, Zhang YM, Li B, Fan B, et al
    Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30988.
    PubMed     Abstract available


  1263. VERDOODT F, Dehlendorff C, Friis S, Kjaer SK, et al
    Non-aspirin NSAID use and ovarian cancer mortality.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)31000.
    PubMed     Abstract available


  1264. LEATH CA 3RD, Monk BJ
    Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.
    Gynecol Oncol. 2018 Jun 26. pii: S0090-8258(18)31005.
    PubMed     Abstract available


  1265. GOCKLEY AA, Kolin DL, Awtrey CS, Lindeman NI, et al
    Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    Gynecol Oncol. 2018 Jun 21. pii: S0090-8258(18)30937.
    PubMed     Abstract available


  1266. RAUH LA, Saks EJ, Nakad-Rodriguez D, Showalter TN, et al
    Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers.
    Gynecol Oncol. 2018 Jun 20. pii: S0090-8258(18)31001.
    PubMed     Abstract available


  1267. NIEVES-NEIRA W, Kim JJ, Matei D
    Hormonal strategies in gynecologic cancer: Bridging biology and therapy.
    Gynecol Oncol. 2018 Jun 20. pii: S0090-8258(18)30947.
    PubMed    


  1268. GEBHARDT BJ, Vargo JA, Kim H, Houser CJ, et al
    Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30987.
    PubMed     Abstract available


  1269. ROSS MS, Burriss ME, Winger DG, Edwards RP, et al
    Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30984.
    PubMed     Abstract available


  1270. CLARK RM, Rice LW, Del Carmen MG
    Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30985.
    PubMed     Abstract available


  1271. URBAN RR, Pappas TC, Bullock RG, Munroe DG, et al
    Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30946.
    PubMed     Abstract available


  1272. TORRES D, Wang C, Kumar A, Bakkum-Gamez JN, et al
    Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
    Gynecol Oncol. 2018 Jun 17. pii: S0090-8258(18)30944.
    PubMed     Abstract available


  1273. CHAN JK, Brady W, Monk BJ, Brown J, et al
    A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30941.
    PubMed     Abstract available


  1274. LI N, Zhan X, Zhan X
    The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30989.
    PubMed     Abstract available


  1275. BODY N, Gregoire J, Renaud MC, Sebastianelli A, et al
    Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer.
    Gynecol Oncol. 2018 Jun 14. pii: S0090-8258(18)30943.
    PubMed     Abstract available


  1276. GRAETZ I, Anderson JN, McKillop CN, Stepanski EJ, et al
    Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.
    Gynecol Oncol. 2018 Jun 11. pii: S0090-8258(18)30983.
    PubMed     Abstract available


  1277. BOLZE PA, Mathe M, Hajri T, You B, et al
    First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive.
    Gynecol Oncol. 2018 Jun 8. pii: S0090-8258(18)30942.
    PubMed     Abstract available


  1278. MICHAEL STRAUGHN J JR, Boitano T, Smith HJ, Dilley SE, et al
    Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.
    Gynecol Oncol. 2018 Jun 7. pii: S0090-8258(18)30923.
    PubMed     Abstract available


  1279. BUDA A, Gasparri ML, Puppo A, Mereu L, et al
    Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy.
    Gynecol Oncol. 2018 Jun 7. pii: S0090-8258(18)30945.
    PubMed     Abstract available


  1280. WOOLDERINK JM, De Bock GH, de Hullu JA, Hollema H, et al
    Characteristics of Lynch syndrome associated ovarian cancer.
    Gynecol Oncol. 2018 Jun 4. pii: S0090-8258(18)30240.
    PubMed     Abstract available


  1281. STOLER MH, Wright TC Jr, Parvu V, Vaughan L, et al
    The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Gynecol Oncol. 2018;149:498-505.
    PubMed     Abstract available


    May 2018
  1282. STOLNICU S, Barsan I, Hoang L, Patel P, et al
    Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.
    Gynecol Oncol. 2018 May 30. pii: S0090-8258(18)30848.
    PubMed     Abstract available


  1283. AREND RC, Jones BA, Martinez A, Goodfellow P, et al
    Endometrial cancer: Molecular markers and management of advanced stage disease.
    Gynecol Oncol. 2018 May 27. pii: S0090-8258(18)30902.
    PubMed     Abstract available


  1284. LINDEMANN K, Gao B, Mapagu C, Fereday S, et al
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30907.
    PubMed     Abstract available


  1285. GIANNOPOULOU L, Mastoraki S, Buderath P, Strati A, et al
    ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30922.
    PubMed     Abstract available


  1286. YAGUR Y, Weitzner O, Gemer O, Lavie O, et al
    Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group Study.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30903.
    PubMed     Abstract available


  1287. AHMED A, Deng W, Tew W, Bender D, et al
    Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30909.
    PubMed     Abstract available


  1288. SALVO G, Frumovitz M, Pareja R, Lee J, et al
    Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (>/=2cm) cervical cancer: Bridging the gap to fetal viability.
    Gynecol Oncol. 2018 May 24. pii: S0090-8258(18)30908.
    PubMed     Abstract available


  1289. AGHAJANIAN C, Filiaci V, Dizon DS, Carlson JW, et al
    A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2018 May 24. pii: S0090-8258(18)30905.
    PubMed     Abstract available


  1290. BAIOCCHI G, Mantoan H, Chen MJ, Faloppa CC, et al
    Uterine transposition after radical trachelectomy.
    Gynecol Oncol. 2018 May 23. pii: S0090-8258(18)30896.
    PubMed    


  1291. MAYOR P, Starbuck K, Zsiros E
    Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
    Gynecol Oncol. 2018 May 23. pii: S0090-8258(18)30920.
    PubMed     Abstract available


  1292. KALAMPOKAS E, Payne F, Gurumurthy M
    An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30910.
    PubMed     Abstract available


  1293. MUELLER JJ, Schlappe BA, Kumar R, Olvera N, et al
    Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30895.
    PubMed     Abstract available


  1294. KOTSOPOULOS J, Gronwald J, Karlan B, Rosen B, et al
    Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30898.
    PubMed     Abstract available


  1295. VON GRUENIGEN VE, Huang HQ, Cella D, Zevon M, et al
    Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 May 17. pii: S0090-8258(18)30904.
    PubMed     Abstract available


  1296. ROLSTON A, Spencer RJ, Kevin Reynolds R, Rice LW, et al
    Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy - implications for bundled care payments.
    Gynecol Oncol. 2018 May 16. pii: S0090-8258(18)30897.
    PubMed     Abstract available


  1297. PHILP L, Jembere N, Wang L, Gao J, et al
    Pap tests in the diagnosis of cervical cancer: Help or hinder?
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30906.
    PubMed     Abstract available


  1298. O'SHEA A, McCool K, Harrison R, Sampene E, et al
    Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30901.
    PubMed     Abstract available


  1299. TSENG JH, Aloisi A, Sonoda Y, Gardner GJ, et al
    Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30849.
    PubMed     Abstract available


  1300. FELIX AS, Sinnott JA, Vetter MH, Rhoades J, et al
    Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30893.
    PubMed     Abstract available


  1301. RUSCITO I, Darb-Esfahani S, Kulbe H, Bellati F, et al
    The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30892.
    PubMed     Abstract available


  1302. NASIOUDIS D, Mastroyannis SA, Albright BB, Haggerty AF, et al
    Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30845.
    PubMed     Abstract available


  1303. DAVIS M, Strickland K, Easter SR, Worley M Jr, et al
    The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30887.
    PubMed     Abstract available


  1304. BAERT T, Van Camp J, Vanbrabant L, Busschaert P, et al
    Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30891.
    PubMed     Abstract available


  1305. YI Y, Bryce CL, Adambekov S, Edwards RP, et al
    Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage.
    Gynecol Oncol. 2018 May 7. pii: S0090-8258(18)30843.
    PubMed     Abstract available


  1306. TEMPFER CB, Giger-Pabst U, Seebacher V, Petersen M, et al
    A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
    Gynecol Oncol. 2018 May 6. pii: S0090-8258(18)30851.
    PubMed     Abstract available


  1307. KONSTANTINOPOULOS PA, Brady WE, Farley J, Armstrong A, et al
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
    Gynecol Oncol. 2018 May 5. pii: S0090-8258(18)30850.
    PubMed     Abstract available


  1308. NEBGEN DR, Hurteau J, Holman LL, Bradford A, et al
    Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Gynecol Oncol. 2018 May 4. pii: S0090-8258(18)30842.
    PubMed     Abstract available


  1309. RICE LW
    Expanding the pipeline. The 2018 Society of Gynecologic Oncology presidential address. Sunday, March 25, 2018. By Laurel W. Rice, MD. 2017-2018 SGO president.
    Gynecol Oncol. 2018 May 2. pii: S0090-8258(18)30837.
    PubMed    


  1310. TRIMBLE CL
    Towards identifying new therapeutic targets in cancers attributable to HPV.
    Gynecol Oncol. 2018;149:225-226.
    PubMed    


  1311. HINTEN F, Molijn A, Eckhardt L, Massuger LFAG, et al
    Vulvar cancer: Two pathways with different localization and prognosis.
    Gynecol Oncol. 2018;149:310-317.
    PubMed     Abstract available


    April 2018
  1312. NISKAKOSKI A, Pasanen A, Porkka N, Eldfors S, et al
    Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
    Gynecol Oncol. 2018 Apr 28. pii: S0090-8258(18)30844.
    PubMed     Abstract available


  1313. MAYADEV J, Klapheke A, Yashar C, Hsu IC, et al
    Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.
    Gynecol Oncol. 2018 Apr 27. pii: S0090-8258(18)30841.
    PubMed     Abstract available


  1314. NAGLE CM, Crosbie EJ, Brand A, Obermair A, et al
    The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer.
    Gynecol Oncol. 2018 Apr 26. pii: S0090-8258(18)30283.
    PubMed     Abstract available


  1315. BROWN J, Naumann RW, Brady WE, Coleman RL, et al
    Clinical trial methodology in rare gynecologic tumor research: Strategies for success.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30285.
    PubMed     Abstract available


  1316. WANG J, Garbutt C, Ma H, Gao P, et al
    Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30835.
    PubMed     Abstract available


  1317. ROSSI A, Frechette L, Miller D, Miller E, et al
    Acceptability and feasibility of a Fitbit physical activity monitor for endometrial cancer survivors.
    Gynecol Oncol. 2018 Apr 21. pii: S0090-8258(18)30838.
    PubMed     Abstract available


  1318. FERGUSON SE, Panzarella T, Lau S, Gien LT, et al
    Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer.
    Gynecol Oncol. 2018 Apr 19. pii: S0090-8258(18)30836.
    PubMed     Abstract available


  1319. EL-ZEIN M, Bouten S, Louvanto K, Gilbert L, et al
    Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
    Gynecol Oncol. 2018 Apr 17. pii: S0090-8258(18)30274.
    PubMed     Abstract available


  1320. MATODA M, Takeshima N, Michimae H, Iwata T, et al
    Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30286.
    PubMed     Abstract available


  1321. BERGSTROM JE, Scott ME, Alimi Y, Yen TT, et al
    Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30273.
    PubMed     Abstract available


  1322. CHAPEL DB, Yamada SD, Cowan M, Lastra RR, et al
    Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30282.
    PubMed     Abstract available


  1323. JIANG F, Wan XR, Xu T, Feng FZ, et al
    Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30271.
    PubMed     Abstract available


  1324. UYAR D, Neary J, Monroe A, Nugent M, et al
    Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30239.
    PubMed     Abstract available


  1325. LIU J, Nicum S, Reichardt P, Croitoru K, et al
    Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Gynecol Oncol. 2018 Apr 4. pii: S0090-8258(18)30238.
    PubMed     Abstract available


  1326. ARMBRUSTER SD, Sun CC, Westin SN, Bodurka DC, et al
    Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration.
    Gynecol Oncol. 2018 Apr 2. pii: S0090-8258(18)30234.
    PubMed     Abstract available


  1327. DOCKERY LE, Motwani A, Ding K, Doescher M, et al
    Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.
    Gynecol Oncol. 2018;149:89-92.
    PubMed     Abstract available


  1328. MANRRIQUEZ E, Chapman JS, Mak J, Blanco AM, et al
    Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Gynecol Oncol. 2018;149:84-88.
    PubMed     Abstract available


  1329. DOLL KM
    Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications.
    Gynecol Oncol. 2018;149:78-83.
    PubMed     Abstract available


  1330. TEMKIN SM, Rimel BJ, Bruegl AS, Gunderson CC, et al
    A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review.
    Gynecol Oncol. 2018;149:70-77.
    PubMed     Abstract available


  1331. HAGOPIAN GS, Lieber M, Dottino PR, Margaret Kemeny M, et al
    The impact of nativity on cervical cancer survival in the public hospital system of Queens, New York.
    Gynecol Oncol. 2018;149:63-69.
    PubMed     Abstract available


  1332. RAMEY SJ, Asher D, Kwon D, Ahmed AA, et al
    Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact.
    Gynecol Oncol. 2018;149:53-62.
    PubMed     Abstract available


  1333. DILLEY S, Erickson BK, Phillips CE, Kennemer CR, et al
    Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
    Gynecol Oncol. 2018;149:49-52.
    PubMed     Abstract available


  1334. COWAN RA, Tseng J, Ali N, Dearie H, et al
    Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Gynecol Oncol. 2018;149:43-48.
    PubMed     Abstract available


  1335. RAUH-HAIN JA, Melamed A, Schaps D, Bregar AJ, et al
    Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.
    Gynecol Oncol. 2018;149:4-11.
    PubMed     Abstract available


  1336. LEE J, Gerber D, Aphinyanaphongs Y, Curtin JP, et al
    Laparoscopy decreases the disparity in postoperative complications between black and white women after hysterectomy for endometrial cancer.
    Gynecol Oncol. 2018;149:22-27.
    PubMed     Abstract available


  1337. DUBIL EA, Tian C, Wang G, Tarney CM, et al
    Racial disparities in molecular subtypes of endometrial cancer.
    Gynecol Oncol. 2018;149:106-116.
    PubMed     Abstract available


  1338. STAPLES JN, Wong MS, Rimel BJ
    An educational intervention to improve human papilloma virus (HPV) and cervical cancer knowledge among African American college students.
    Gynecol Oncol. 2018;149:101-105.
    PubMed     Abstract available


  1339. DEL CARMEN MG, Rice LW
    Towards the elimination of health care disparities in gynecologic oncology: Call to action.
    Gynecol Oncol. 2018;149:1-3.
    PubMed    


  1340. MAO X, Qin X, Li L, Zhou J, et al
    A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma.
    Gynecol Oncol. 2018;149:181-187.
    PubMed     Abstract available


  1341. MOORE KN, Mirza MR, Matulonis UA
    The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Gynecol Oncol. 2018;149:214-220.
    PubMed     Abstract available


    March 2018
  1342. BONHOF CS, Mols F, Vos MC, Pijnenborg JMA, et al
    Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30232.
    PubMed     Abstract available


  1343. WU H, Zhang J
    Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30237.
    PubMed     Abstract available


  1344. CUNNINGHAM-ERVES J, Forbes L, Ivankova N, Mayo-Gamble T, et al
    Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.
    Gynecol Oncol. 2018 Mar 24. pii: S0090-8258(18)30219.
    PubMed     Abstract available


  1345. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
    Gynecol Oncol. 2018 Mar 21. pii: S0090-8258(18)30231.
    PubMed    


  1346. LONG J, Zhu JY, Liu YB, Fu K, et al
    Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30176.
    PubMed     Abstract available


  1347. CHEN L, Luan S, Xia B, Liu Y, et al
    Integrated analysis of HPV-mediated immune alterations in cervical cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30070.
    PubMed     Abstract available


  1348. KIM J, Kim S, Lee HS, Yang W, et al
    Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30132.
    PubMed     Abstract available


  1349. MCDONALD JF
    Back to the future - The integration of big data with machine learning is re-establishing the importance of predictive correlations in ovarian cancer diagnostics and therapeutics.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30233.
    PubMed    


  1350. HAN C, Bellone S, Siegel ER, Altwerger G, et al
    A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30230.
    PubMed     Abstract available


  1351. WILSON AJ, Stubbs M, Liu P, Ruggeri B, et al
    The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30229.
    PubMed     Abstract available


  1352. AGRAWAL S, Chen L, Tergas AI, Hou JY, et al
    Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30220.
    PubMed     Abstract available


  1353. VENIGALLA S, Chowdhry AK, Shalowitz DI
    Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30218.
    PubMed     Abstract available


  1354. IDAHL A, Hermansson A, Lalos A
    Social support and ovarian cancer incidence - A Swedish prospective population-based study.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30214.
    PubMed     Abstract available


  1355. CARLTON AL, Illendula A, Gao Y, Llaneza DC, et al
    Small molecule inhibition of the CBFbeta/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.
    Gynecol Oncol. 2018 Mar 15. pii: S0090-8258(18)30174.
    PubMed     Abstract available


  1356. ESKANDER RN, Kauderer J, Tewari KS, Mannel RS, et al
    Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30216.
    PubMed     Abstract available


  1357. TORTORELLA L, Langstraat CL, Weaver AL, McGree ME, et al
    Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30141.
    PubMed     Abstract available


  1358. UCCELLA S, Mele MC, Quagliozzi L, Rinninella E, et al
    Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30215.
    PubMed     Abstract available


  1359. BRUCE SF, Carr DN, Burton ER, Sorosky JI, et al
    Implementation of an abdominal closure bundle to reduce surgical site infection in patients on a gynecologic oncology service undergoing exploratory laparotomy.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30217.
    PubMed     Abstract available


  1360. KO EM, Havrilesky LJ, Alvarez RD, Zivanovic O, et al
    Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP).
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30130.
    PubMed     Abstract available


  1361. RAMZAN AA, Fischer S, Buss MK, Urban RR, et al
    Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30127.
    PubMed     Abstract available


  1362. QU XM, Velker VM, Leung E, Kwon JS, et al
    The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30172.
    PubMed     Abstract available


  1363. PRZYBYL J, Kidzinski L, Hastie T, Debiec-Rychter M, et al
    Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30177.
    PubMed     Abstract available


  1364. MATSUO K, Yabuno A, Hom MS, Shida M, et al
    Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30131.
    PubMed     Abstract available


  1365. STEWART LE, Beck TL, Giannakopoulos NV, Rendi MH, et al
    Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: A multicenter review.
    Gynecol Oncol. 2018 Mar 11. pii: S0090-8258(18)30180.
    PubMed     Abstract available


  1366. YI L, Zhang H, Zou J, Luo P, et al
    Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30175.
    PubMed     Abstract available


  1367. GOSTNER JM, Obermayr E, Braicu IE, Concin N, et al
    Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30139.
    PubMed     Abstract available


  1368. VON GRUENIGEN VE, Karlan BY
    Sexual harassment in the work place: Its impact on gynecologic oncology and women's health.
    Gynecol Oncol. 2018 Mar 8. pii: S0090-8258(18)30137.
    PubMed     Abstract available


  1369. SCHORGE JO, Bregar AJ, Durfee J, Berkowitz RS, et al
    Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer.
    Gynecol Oncol. 2018 Mar 7. pii: S0090-8258(18)30142.
    PubMed     Abstract available


  1370. SCHUURMAN MS, Kruitwagen RFPM, Portielje JEA, Roes EM, et al
    Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30136.
    PubMed     Abstract available


  1371. LIAO CI, Chow S, Chen LM, Kapp DS, et al
    Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30069.
    PubMed     Abstract available


  1372. KANAO H, Aoki Y, Hisa T, Takeshima N, et al
    Laparoscopic laterally extended endopelvic resection (LEER) for cervical carcinoma recurring at the pelvic sidewall after concurrent chemoradiotherapy: Our experience in three cases.
    Gynecol Oncol. 2018 Mar 3. pii: S0090-8258(18)30112.
    PubMed     Abstract available


  1373. BUSKWOFIE A, Huang Y, Tergas AI, Hou JY, et al
    Impact of hospital volume on racial disparities and outcomes for endometrial cancer.
    Gynecol Oncol. 2018 Mar 2. pii: S0090-8258(18)30138.
    PubMed     Abstract available


  1374. HARKENRIDER MM, Altoos B, Small W Jr.
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018;148:437-438.
    PubMed    


  1375. MINION LE, Tewari KS
    Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Gynecol Oncol. 2018;148:609-621.
    PubMed     Abstract available


  1376. POWELL CB, Alabaster A, Stoller N, Armstrong MA, et al
    Bone loss in women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2018;148:535-539.
    PubMed     Abstract available


  1377. STECKLEIN SR, Frumovitz M, Klopp AH, Gunther JR, et al
    Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy.
    Gynecol Oncol. 2018;148:474-479.
    PubMed     Abstract available


  1378. FILIPPOV-LEVY N, Cohen-Schussheim H, Trope CG, Hetland Falkenthal TE, et al
    Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Gynecol Oncol. 2018;148:559-566.
    PubMed     Abstract available


  1379. TE GROOTENHUIS NC, Pouwer AW, de Bock GH, Hollema H, et al
    Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review.
    Gynecol Oncol. 2018;148:622-631.
    PubMed     Abstract available


    February 2018
  1380. XIAO X, Dong D, He W, Song L, et al
    Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30128.
    PubMed     Abstract available


  1381. WRIGHT JD, Havrilesky LJ, Cohn DE, Huang Y, et al
    Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30129.
    PubMed     Abstract available


  1382. WEAVER DT, Raphel TJ, Melamed A, Rauh-Hain JA, et al
    Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30126.
    PubMed     Abstract available


  1383. HUVILA J, Laajala TD, Edqvist PH, Mardinoglu A, et al
    Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30135.
    PubMed     Abstract available


  1384. BARRINGTON DA, Champion ML, Boitano TKL, Walters-Haygood CL, et al
    Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30133.
    PubMed     Abstract available


  1385. JAREID M, Thalabard JC, Aarflot M, Bovelstad HM, et al
    Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30125.
    PubMed     Abstract available


  1386. PAREJA R, Echeverri L, Rendon G, Munsell M, et al
    Radical parametrectomy after 'cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30134.
    PubMed     Abstract available


  1387. LHEUREUX S, McCourt C, Rimel BJ, Duska L, et al
    Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.
    Gynecol Oncol. 2018 Feb 21. pii: S0090-8258(18)30124.
    PubMed     Abstract available


  1388. LEFKOWITS C, Buss MK, Ramzan AA, Fischer S, et al
    Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review.
    Gynecol Oncol. 2018 Feb 20. pii: S0090-8258(18)30066.
    PubMed     Abstract available


  1389. KELLENBERGER LD, Petrik J
    Hyperglycemia promotes insulin-independent ovarian tumor growth.
    Gynecol Oncol. 2018 Feb 17. pii: S0090-8258(18)30122.
    PubMed     Abstract available


  1390. OZA A, Kaye S, Van Tornout J, Sessa C, et al
    Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecol Oncol. 2018 Feb 14. pii: S0090-8258(18)30058.
    PubMed     Abstract available


  1391. LI Y, Wu T, Wang Y, Yang L, et al
    gamma-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30062.
    PubMed     Abstract available


  1392. CRANE EK, Brown J
    Early stage mucinous ovarian cancer: A review.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30074.
    PubMed     Abstract available


  1393. DESAI P, Wallace R, Anderson ML, Howard BV, et al
    An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
    Gynecol Oncol. 2018 Feb 5. pii: S0090-8258(18)30038.
    PubMed     Abstract available


  1394. HACKER KE, Reynolds RK, Uppal S
    Ongoing strategies and updates on pain management in gynecologic oncology patients.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30073.
    PubMed     Abstract available


  1395. SWANSON CL, Kumar A, Maharaj JM, Kemppainen JL, et al
    Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30072.
    PubMed     Abstract available


  1396. MILLER KR, Patel JN, Zhang Q, Norris EJ, et al
    HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30061.
    PubMed     Abstract available


  1397. THARAVICHITKUL E, Chakrabandhu S, Klunklin P, Onchan W, et al
    Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30047.
    PubMed     Abstract available


  1398. STROHL AE, Lurain JR
    Nonmetastatic Excised Gestational Choriocarcinoma: To Treat or Not to Treat.
    Gynecol Oncol. 2018;148:237-238.
    PubMed    


  1399. NAUMANN RW, Brown J
    Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Gynecol Oncol. 2018 Feb 1. pii: S0090-8258(18)30068.
    PubMed     Abstract available


  1400. KIM SI, Lee S, Jeong CW, Kim HS, et al
    Robot-assisted anterior pelvic exenteration in vulvovaginal malignant melanoma.
    Gynecol Oncol. 2018;148:430-431.
    PubMed     Abstract available


  1401. FU S, Lairson DR, Chan W, Wu CF, et al
    Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
    Gynecol Oncol. 2018;148:342-348.
    PubMed     Abstract available


  1402. KANG WD, Ju UC, Kim SM
    Is human papillomavirus genotype important in predicting disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US) cytology?
    Gynecol Oncol. 2018;148:305-310.
    PubMed     Abstract available


    January 2018
  1403. ARMBRUSTER SD, Song J, Gatus L, Lu KH, et al
    Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30067.
    PubMed     Abstract available


  1404. DEWDNEY SB, Dancisak AC, Lachance JA, Grendys EC Jr, et al
    Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30060.
    PubMed     Abstract available


  1405. GRIMM C, Polterauer S, Helmy-Bader S, Zikan M, et al
    A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30044.
    PubMed     Abstract available


  1406. GUNDERSON CC, Matulonis U, Moore KN
    Management of the toxicities of common targeted therapeutics for gynecologic cancers.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30042.
    PubMed     Abstract available


  1407. KESSOUS R, Octeau D, Klein K, Tonin PN, et al
    Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30055.
    PubMed     Abstract available


  1408. HENRY CE, Llamosas E, Daniels B, Coopes A, et al
    ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30064.
    PubMed     Abstract available


  1409. NITECKI R, Diver EJ, Kamdar MM, Boruta DM 2nd, et al
    Patterns of palliative care referral in ovarian cancer: A single institution 5year retrospective analysis.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30056.
    PubMed     Abstract available


  1410. ZHANG HR, Lai SY, Huang LJ, Zhang ZF, et al
    Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30065.
    PubMed     Abstract available


  1411. PENNINGTON KP, McTiernan A
    The role of physical activity in breast and gynecologic cancer survivorship.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30059.
    PubMed     Abstract available


  1412. KATO K, Okamoto S, Ota E, Takeshima N, et al
    Secondary debulking surgery for para-aortic nodal recurrence in endometrial cancer requiring circumferential resection of the inferior vena cava.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30063.
    PubMed    


  1413. SAMIMI G, Trabert B, Duggan MA, Robinson JL, et al
    Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    Gynecol Oncol. 2018 Jan 25. pii: S0090-8258(18)30048.
    PubMed     Abstract available


  1414. KRISHNAN V, Schaar B, Tallapragada S, Dorigo O, et al
    Tumor associated macrophages in gynecologic cancers.
    Gynecol Oncol. 2018 Jan 22. pii: S0090-8258(18)30046.
    PubMed     Abstract available


  1415. DOSTALEK L, Zikan M, Fischerova D, Kocian R, et al
    SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.
    Gynecol Oncol. 2018 Jan 21. pii: S0090-8258(18)30001.
    PubMed     Abstract available


  1416. BARROILHET L, Matulonis U
    The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Gynecol Oncol. 2018 Jan 20. pii: S0090-8258(18)30040.
    PubMed     Abstract available


  1417. GRAY HJ, Bell-McGuinn K, Fleming GF, Cristea M, et al
    Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620.
    PubMed     Abstract available


  1418. BERGSTROM J, Aloisi A, Armbruster S, Yen TT, et al
    Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.
    Gynecol Oncol. 2018 Jan 12. pii: S0090-8258(18)30002.
    PubMed     Abstract available


  1419. SHALOWITZ DI, Cohn DE
    Cancer care delivery research in gynecologic oncology.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31618.
    PubMed    


  1420. TRABERT B, Aarestrup J, Ulrich LG, Wentzensen N, et al
    Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31622.
    PubMed     Abstract available


  1421. PARK SH, Cheon H, Chong GO, Jeong SY, et al
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(18)30037.
    PubMed     Abstract available


  1422. HAGEMANN AR, McCourt CK, Varaday SS, Moore KN, et al
    Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31608.
    PubMed     Abstract available


  1423. SAED GM, Fletcher NM, Diamond MP, Morris RT, et al
    Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31606.
    PubMed     Abstract available


  1424. BACORRO W, Dumas I, Escande A, Gouy S, et al
    Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.
    Gynecol Oncol. 2018 Jan 8. pii: S0090-8258(17)31621.
    PubMed     Abstract available


  1425. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
    Gynecol Oncol. 2018 Jan 5. pii: S0090-8258(17)31619.
    PubMed    


  1426. MUKERJI B, Baptiste C, Chen L, Tergas AI, et al
    Racial disparities in young women with endometrial cancer.
    Gynecol Oncol. 2018 Jan 4. pii: S0090-8258(17)31623.
    PubMed     Abstract available


  1427. DONG L, Wang MZ, Zhao XL, Feng RM, et al
    Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
    Gynecol Oncol. 2018;148:103-110.
    PubMed     Abstract available


  1428. GOROSTIDI M, Villalain C, Ruiz R, Jaunarena I, et al
    Technique for precaval and laterocaval nodes excision at extraperitoneal paraaortic lymphadenectomy.
    Gynecol Oncol. 2018;148:233-234.
    PubMed     Abstract available


  1429. SATMARY W, Holschneider CH, Brunette LL, Natarajan S, et al
    Vulvar intraepithelial neoplasia: Risk factors for recurrence.
    Gynecol Oncol. 2018;148:126-131.
    PubMed     Abstract available


    December 2017
  1430. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Gynecol Oncol. 2017 Dec 28. pii: S0090-8258(17)31617.
    PubMed     Abstract available


  1431. SOISSON S, Ganz PA, Gaffney D, Rowe K, et al
    Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
    Gynecol Oncol. 2017 Dec 27. pii: S0090-8258(17)31616.
    PubMed     Abstract available


  1432. XIANG L, Jiang W, Ye S, He T, et al
    ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Gynecol Oncol. 2017 Dec 23. pii: S0090-8258(17)31614.
    PubMed     Abstract available


  1433. SUD S, Holmes J, Eblan M, Chen R, et al
    Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31607.
    PubMed     Abstract available


  1434. MONTEALEGRE JR, Peckham-Gregory EC, Marquez-Do D, Dillon L, et al
    Racial/ethnic differences in HPV 16/18 genotypes and integration status among women with a history of cytological abnormalities.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31597.
    PubMed     Abstract available


  1435. GEPPERT B, Lonnerfors C, Bollino M, Persson J, et al
    Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
    Gynecol Oncol. 2017 Dec 20. pii: S0090-8258(17)31602.
    PubMed     Abstract available


  1436. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    PubMed     Abstract available


  1437. FORNALIK H, Fornalik N
    Robotic hysterectomy and pelvic lymphadenectomy without Trendelenburg position (BMI 36).
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31549.
    PubMed    


  1438. LEE J, Lin JB, Chang CL, Sun FJ, et al
    Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
    Gynecol Oncol. 2017 Dec 18. pii: S0090-8258(17)31550.
    PubMed     Abstract available


  1439. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    PubMed     Abstract available


  1440. MATSUO K, Ross MS, Im DD, Klobocista MM, et al
    Significance of venous thromboembolism in women with uterine carcinosarcoma.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31546.
    PubMed     Abstract available


  1441. BRAGA A, Campos V, Filho JR, Lin LH, et al
    Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31554.
    PubMed     Abstract available


  1442. CASTLE PE, Pierz A, Stoler MH
    A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31548.
    PubMed     Abstract available


  1443. DILLEY S, Miller K, Huh W
    HPV vaccination.
    Gynecol Oncol. 2017 Dec 12. pii: S0090-8258(17)31547.
    PubMed    


  1444. BERNARDS SS, Pennington KP, Harrell MI, Agnew KJ, et al
    Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31551.
    PubMed     Abstract available


  1445. KIM SI, Lee JW, Lee M, Kim HS, et al
    Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552.
    PubMed     Abstract available


  1446. COYLE C, Short D, Jackson L, Sebire NJ, et al
    What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31555.
    PubMed     Abstract available


  1447. BIZZARRI N, Ghirardi V, Kucukmetin A
    Indocyanine green-assisted parametrial dissection during type C1 radical hysterectomy after sentinel lymph node biopsy in early stage cervical cancer.
    Gynecol Oncol. 2017 Dec 6. pii: S0090-8258(17)31496.
    PubMed